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1. Abstract 
 
While the global cancer burden is still high with 10 million people being diagnosed with cancer and 6 million 
cancer-related deaths yearly, academia and industry are developing more and more sophisticated therapies to 
combat cancer. One recent development are antibody-drug conjugates (ADCs) which consist of an antibody 
portion that mediates tumor selectivity and a highly cytotoxic drug designed to efficiently kill cancer cells. The 
majority of ADCs in clinical trials today carries payloads targeting the cytoskeleton. However, microtubule-
targeting agents often lack clinical efficacy and thus, drugs with other mode of actions are in focus of current 
ADC research. With Mylotarg and Besponsa for example two ADCs carrying DNA damaging agents are already 
approved and SYD985 an ADC carrying the DNA-alkylating agent duocarmycin is currently showing promising 
results in a clinical phase III study. Although ADCs have shown promising anticancer effects and often come 
along with a broadened therapeutic window compared to conventional chemotherapy, there is still room for 
improvement regarding e.g. saftey aspects. Establishment of combination therapy for ADCs might pose a 
strategy for increasing efficacy, diminish side-effects and slow down resistance development especially because 
single agent therapy has seldom been curative. This work aimed at the discovery of a synergistic drug 
combination that might enhance the efficacy of duocarmycin-based ADCs like the clinically evaluated ADC 
SYD985. Therefore, 17 DNA-damage response inhibitors (DDRis), potentially involved in the repair of 
duocarmycin-induced lesions, were selected based on literature and tested in in vitro models. HCC-1954 and 
MDA-MB-468 cancer cells were treated with a combination of the selected DDRis and duocarmycin and the 
antiproliferative effects of the combination treatment were compared to the effects of the single agents alone. 
These experiments clearly demonstrated that inhibitors of the kinase ATR, which plays a central role in the 
response to replication stress, synergistically enhanced the cytotoxic effects of duocarmycin. This observation 
was additionally confirmed by treatment of ATR Knock-down cells with duocarmycin. Further drug combination 
experiments revealed the impact of structural features of different duocarmycins and ATR inhibtors on the 
synergism level. Besides studying the combinatorial effects of the small molecules alone, it was demonstrated 
that this combination effect could be translated to a targeted therapy approach like antibody-drug conjugates. 
Several duocarmycin based ADCs showed strong synergistic effects in combination with different ATR inhibitors 
in vitro as well as in vivo. rag2 mice bearing a HER2-expressing NCI-N87 tumor were treated with HER2-targeting 
duocarmycin-ADC and two different ATR inhibitors. The ATR inhibitors monotreatment showed very mild tumor 
growth inhibition while the treatment with the ADC at concentrations below the maximum effective dose led to 
a partial tumor response. The combination treatment, however, resulted in very strong anti-tumor effects while 
being well tolerated. The present study demonstrates the superiority of combining the targeted delivery of 
duocarmycin to the tumor using an anti-HER2-duocarmycin ADC with systemic application of ATR inhibitors over 
the treatment with the drugs as single agents. This might support endeavors of evaluating such combinations in 
a clinical setting. 
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2. Zusammenfassung 
 
Jährlich werden 10 Millionen neue Fälle von Krebs diagnostiziert und gleichzeitig sterben 6 Million Menschen an 
der Krankheit. Deshalb werden durch akademische und industrielle Forschung immer ausgeklügeltere Therapien 
entwickelt um Krebs zu bekämpfen. Eine neue Entwicklung stellen Antikörper-Wirkstoff Konjugate (AWK) dar, 
die aus einem tumor-selektiven Antikörper und einem hochpotenten Toxin bestehen um zielgerecht und 
effizient Krebszellen zu töten. Die meisten AWKs in klinischer Erprobung nutzen dabei Wirkstoffe, die das 
Zellskelett angreifen. Problematisch ist jedoch, dass es diesen Molekülklassen oft an klinischer Wirksamkeit 
magelt, wodurch neue Wirkmechanismen gesucht werden. Die beiden bereits zugelassenen AWKs Mylotarg und 
Besponsa zum Beispiel nutzen DNA-schädigende Wirkstoffe und der in Phase III klinischer Erprobung befindliche 
AWK SYD985 ist der am weitesten fortgeschrittene AWK mit dem DNA-Alkylator Duocarmycin als Wirkstoff. 
Obwohl AWKs bereits vielversprechende Wirksamkeit gegen Krebs zeigen konnten und auch ein im Vergleich zu 
konventioneller Chemotherapie großes therapeutisches Fenster besitzen, gibt es dennoch viel 
Optimierungsbedarf. Die Etablierung einer Kombinationstherapie für AWKs könnte eine Strategie darstellen um 
die Wirksamkeit zu erhöhen, Nebeneffekte und auch Resistenzbildung zu verlangsamen, besonders da die 
Monotherapie zur Behandlung von Krebs bisher selten zur Heilung geführt hat. Die vorliegende Arbeit hat es 
sich deshalb zum Ziel gemacht, einen Kombinationspartner für Duocarmycin-basierte AWKs wie z.B. SYD985 zu 
finden, der die Wirksamkeit von Duocarmycin-AWKs synergistisch verstärken kann. Deshalb wurden 17 
Inhibitoren der DNA-Schadensantwort selektiert und in in vitro Modellen getestet, die basierend auf 
Literaturdaten möglicherweise bei der Reparatur von Duocarmycin-induzierten DNA-Schäden beteiligt sind. 
HCC-1954 und MDA-MB-468 Krebszellen wurden mit einer Kombination von Inhibitoren der DNA-
Schadensantwort und Duocarmycin behandelt und die zytostatischen Effekte der Kombination wurden mit 
denen der individuellen Wirkstoffe verglichen. Diese Experimente demonstrierten, dass Inhibitoren der ATR 
Kinase, die eine zentrale Rolle in der Reaktion auf Replikationsstress spielt, die zytotoxischen Effekte von 
Duocarmycin synergistisch verstärken können. Diese Beobachtung wurde durch das Herunterregulieren von ATR 
und anschließender Behandlung mit Duocarmycin bestätigt. Weitere Kombinationseffekte offenbarten den 
Einfluss der Struktur der Duocarmycine sowie der ATR Inhibitoren auf die synergistischen Effekte. Neben den 
Untersuchungen der Kombinationseffekte der kleinen Moleküle, konnten die Kombinationseffekte auch auf 
Kombinationen mit Molekülen der gerichteten Therapie übertragen werden wie z.B. AWKs. Dafür wurden 
mehrere Duocarmycin-AWKs hergestellt, die in Kombination mit ATR Inhibitoren synergistische 
Kombinationseffekte in vitro und in vivo zeigten. Rag2 Mäuse, die einen HER2-exprimierenden NCI-N87 Tumor 
trugen, wurden mit einem gegen HER2-gerichteten duocarmycin-AWK und zwei verschiedenen ATR Inhibitoren 
behandelt. Während die ATR Inhibitoren nahezu keinen Effekt auf das Tumorwachstum hatten, konnte der AWK 
unterhalb der maximalen effektiven Dosis bereits teilweise das Tumorwachstum inhibieren. Die 
Kombinationsbehandlung jedoch reduzierte stark die Tumorgröße und wurde gleichzeitig gut toleriert. Die 
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vorliegende Arbeit demonstriert die Überlegenheit der Kombination aus zielgerechter Abgabe des Toxins 
Duocarmycin an den Tumor mittels anti-HER2-Duocarmycin AWK und systemischer Gabe von ATR Inhibitoren 
gegenüber der Behandlung mit den Molekülen als Monotherapie. Die Ergebnisse könnten Bestrebungen 
unterstützen, diese Kombination im klinischen Kontext zu untersuchen. 
  
   4 
3. Introduction 
 
3.1. Cancer Prevalence 
 
Cell division is a natural process that assures the replacement of old or damaged cells by new ones. If this process 
is disturbed, cancer may arise. Cancer is an umbrella term for related diseases that are generally characterized 
by the uncontrolled division of cells. Most cancers form tissue masses, so called tumors which can be classified 
as malignant or benign. While malignant tumors can invade and spread into nearby tissue, benign tumors 
cannot.1 In 2012, the age-standardized global incidence of cancer was 182 per 100 thousand people with a 
mortality rate of 56%.2 This adds up to a global cancer burden of 10 million people being diagnosed with cancer 
and 6 million cancer-related deaths yearly.2 The reasons for falling ill with cancer are numerous and the cancer 
risk is influenced by genetic predispositions and additionally by life-style factors.2 In the United States of America 
cancer is caused in approximately 60% of cases by preventable life-style risk factors.3 
For instance, it was shown that the western life is generally accompanied with a higher risk for lung, colorectum, 
breast and prostate cancer. A typical risk factor is frequent smoking of tobacco. The risk of developing lung 
cancer for example increases with the amount of tobacco consumption and it is 20 times higher for smokers 
than for non-smokers. Another life-style risk factor is the diet. While the consumption of red meat correlates 
with an increased risk for the development of colon cancer, a diet rich in vegetables and fruits decreases the 
risk. Furthermore, environmental factors play a major role in the prevalence of cancer. Indoor pollution caused 
by, as already mentioned, smoking but also cooking and building materials like asbestos increase the cancer risk. 
Additionally, occupational risks like chemicals encountered at work, or outdoor air pollution caused by traffic 
and industry play a significant role in the development of cancer. Chronic infections with hepatitis B virus, 
papillomaviruses or heliobacter pylori are leading to higher incidence of liver, cervix or stomach cancer, 
respectively.4 A summary of the contribution of preventable life-style factors on cancer incidence is given in 
figure 1. 
 
 
Figure 1: Contribution of live style factors to preventable cancer incidence in the United States of America adapted from Colditz and 
Wei3. 
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An increased cancer risk caused by life-style factors is reflected by an altered physiology on the molecular and 
cellular level. Given the high incidence and mortality of cancer, extensive research on tumor biology was 
performed that led to the identification of two major factors that enable tumor growth: genomic instability and 
tumor-promoting inflammation. Furthermore, tumors exhibit several common characteristics. The following 
chapter is dedicated to enabling characteristics of tumor growth as well as hallmarks of cancer, because 
understanding of molecular background of cancer might leverage efforts for the development of a successful 
anti-cancer therapy. 
  
3.2. Enabling Characteristics of Tumor Development and Hallmarks of Cancer 
 
This chapter shall shed light on the tumorigenesis and the characteristics of cancer. Hanahan and Weinberg 
postulated two distinct mechnisms – genomic instability and tumor-promoting inflammation – that enable 
tumor growth in the first place. Although the reasons that lead to genomic instability and tumor-promoting 
inflammation and subsequently tumor development are numerous as described in the previous chapter, cancer 
has distinct characteristics in common. Tumor biology research has led to the postulation of eight hallmarks of 
cancer according to Hanahan and Weinberg: (1) sustained proliferative signaling, (2) deregulated cellular 
energetics, (3) resistant against cell death, (4) angiogenesis, (5) avoiding immune destruction, (6) replicative 
immortality, (7) evading growth suppression, (8) invasion and metastasis (Figure 2).5  
The previously described life-style factors largely influence the development of cancer through genetic 
alterations, or epigentic factors so called epimutations that regulate gene expression.5,6 These alterations 
include mutations like nucleotide changes, chromosomal aberations of structural nature but also the number of 
chromosomes might be changed leading to loss of heterozygosity and DNA segments be amplified at high 
frequencies.6 Genetic predispositions are another aspect that might lead to a cancer vulnerability through 
genomic instability. However, cells have developed a sophisticated machinery that recognizes DNA damage, 
directly repairs DNA lesions or inactivates mutagenic molecules before they reach the DNA to prevent 
mutations. If the repair machinery is impaired in one of these factors, the sensitivity of the cell towards 
mutagenic molecules but also endogenous stress like replication stress increases.5 The Li-Fraumeni syndrome 
for example is characterized by an inactivating germline mutation of either p53 or CHK2 kinase genes. The latter 
activates p53 in response to DNA-damage. The impaired p53 function leads to escape of cancer cells from 
apoptosis. The consequense is a high incidence of characteristic tumors such as osteosarcomas, soft tissue 
sarcomas, leukemias, adrenocortical and breast carcinomas as well as brain tumors. Members of families with 
Li-Fraumeni syndrome have a 50% cancer risk by the age of 40 and 90% cancer risk by the age of 60.7 
Mutations might arise that confer evolutionary benefits for the mutated cell leading to dominance in the 
surrounding tissue. So far, alterations of the genome that might eventually lead to genomic instability have been 
described.  
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In addition, the preventable cancer risk factors can trigger the acute activation of immune effector programs8 
leading to “tumor-promoting inflammation”.5 As a result, immune cells invade damaged tissues where a chronic 
inflammation might arise.8 In this contex, senescent cells secret inflammatory mediators that should inhibit 
tumor growth by sustained growth arrest and clearance of senescent cells by the immune cells. In contrast to 
the intended effect, tumor-supporting inflammatory cells such as macrophages and fibroblasts might be 
recruited that promote tumor growth9 by supplying the cancer cells with growth signals, survival factors, matrix-
modifying enzmes etc.10 They also produce reactive oxygen species to kill cancerous cells, which in contrast 
might damage the DNA of the cancer cell and thus promote mutation of the genome which closes the loop to 
genomic instability.  
The eight hallmarks of cancer will be discussed in detail in the following. Sustained proliferative signaling helps 
cancer cells to divide uncontrollably. Cancer cells are capable of producing growth-stimulating signals 
themselves, leading to so called autocrine proliferative stimulation. Besides, surrounding stroma can be 
stimulated to produce growth stimuli that again lead to the proliferation of the cancer cells. In addition to that, 
elevated levels of receptors, structural changes of the receptor and mutations of proteins in the downstream 
signaling have been identified to render the signaling pathway constitutively activated. 
Another hallmark of cancer is the evasion of tumor suppression. A prominent example of a tumor suppressor 
protein is p53, which is mutated in 50% of all human cancers.7 It is activated in the presence of cellular stress 
and can stop cell-cycle progression in order to gain time for stress reduction. However, if alarm signals indicate 
overwhelming or unrepairable damage, the cell might undergo p53-induced cell death by apoptosis. The 
inactivation of tumor suppressor proteins leads to cell proliferation because the cell lacks growth limiting 
mechanisms. Cancer cells are able to shutdown apoptosis inducing signaling pathways that enable again the 
evasion of cell death by the tumor. This is another hallmark of cancer which has been associated with the 
inactivation of tumor suppressors.5 
Normal cells can undergo only a limited number of replicative cycles. This limitation is associated with two 
barriers of replication: senescence and crisis. Sencesence is characterized by the cell being vital but not dividing 
anymore. If a cell enters the crisis state, this will lead to cell death.5 Cancer cells on the other hand are immortal 
which allows the infinite division of the cells. The telomeres, protection caps on the ends of chromosomes, have 
been identified as crucial for immortalization. If absent, chromosomal DNA might be end-to-end fused followed 
by bridge-breakage fusion cycles leading to abberant chromosomal structures that threaten cell viability. As a 
consequence, a cell with critically short telomerase will stop cell division, known as replicative senescence.11 
Hence, the telomeres determine how many cell divisions a cell can run through. While in normal cells 
telomerase, an enzyme necessary for telomere elongation, is nearly absent, in cancer cells telomerase is 
expressed at physiologically significant levels12 and active in 90% of all human cancers11. Telomerase expression 
and activity is one factor that mediates tumor cell immortality and thus is another hallmark of cancer.11 
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In addition, tumor cells have increased throughput of nutrients and oxygen and hence increased need for 
evacuation of metabolic waste and carbon dioxide. This is accomplished by the ability of tumor cells to stimulate 
angiogenesis, yet another hallmark of cancer. Through this process new vessels are formed that ensure supply 
of the tumor with nutrients and oxygen and facilitate waste management.  
The ability of cancer cells to invade surrounding tissues and to colonize distant sites of the body has also been 
described as a hallmark of cancer. This multistep process of invasion and metastasis was termed the invasion-
metastasis cascade. First, the cancer cells invade local surrounding tissues and reach the lymphatic and blood 
vessel system through which they can travel. When a cancer cell manages to escape the vessel, it might invade 
the tissue at distant sites of the primary lesion.The great majority of cancer-associated deaths – around 90% - 
can be attributed to the metastasis of the primary tumor rather than the primary tumor itself.13 
A growing body of evidence suggests, that the defects of the immune system and a switch in metabolism of 
cancer cells are drivers for tumor development. The cells in our bodies are constantly monitored by the immune 
system. The vast majority of abberant cells that might eventually become cancerous is eliminated through the 
aid of the immune cells. However, cancer cells manage to circumvent detection by the immune system which 
eventually leads to the development of tumors. Tumor cells often express the protein programmed cell death 
ligand 1 (PD-L1) which binds programmed cell death 1 (PD-1) expressed on the surface of cytotoxic T-cells. 
Through binding of PD-L1 to the immune inhibitory PD-1 the T-cells are not activated leading to the evastion of 
cancer cells from cytotoxic activities by immune cells.14  
Furthermore, it was found that cancer cells especially in regions deeply buried in the tumor mass suffer from 
oxygen shortage which leads to switching their metabolism. In normal cells under aerobic conditions glycolysis 
is followed by the transport of pyruvate to the oxygen-consuming mitochondria. Cancer cells often lack sufficient 
supply with oxygen due to the distance of the cancer cells from blood vessels.15 Thus, glucose is metabolised 
using glycolysis and subsequently pyruvate is converted to lactate. Cancer cells often upregulate glucose 
transporters to increase glucose intake. Although less energy is produced using this pathway, the intermediates 
can be fed into pathways required for the production of nucleotides and amino acids which are necessary for 
growth.5 
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Figure 2: Hallmarks of cancer. Genomic instability and tumor-promoting inflammation enable the development of cancer. Cancer itself is 
characterized by several hallmarks. While most hallmarks are well-established, the concept of deregulated cellular energy metabolism 
and the avoidance of destruction by the immune system are emerging concepts supported by a growing body of evidence. Figure adapted 
according to Hanahan and Weinberg.5 
 
The high incidence of cancer and the high mortality rate motivated scientists and companies to develop 
therapies with the hope to cure cancer patients. Due to extensive research, an increasing knowledge of cancer 
biology led to more and more sophisticated therapy options and simultaneously to decreasing mortality rates. 
A historical overview of cancer therapy development will be given in the following chapter. 
 
3.3. Short History of Cancer Therapy 
 
Before 1950 cancer therapy mainly relied on the surgical removal of tumors, until the invention of the linear 
accelerator added radiotherapy to the portfolio of the oncologist in the 1960s.16 Although, surgery is still a 
common strategy to remove the primary tumor and thereby reduce the number of cancer cells and thus diversity 
it is only infrequently used for the removal of metastases.13 The reason is that surgery and radiotherapy cannot 
eradicate metastases,16 because of the multiple sites of secondary tumors. An effective anti-cancer treatment 
has alsoways to reach every organ in the body. Thus, small molecule drugs, biological molecules and 
immunotherapies have become the focus of todays cancer research. During world war I autopsy findings from 
soldiers dying of exposure to sulphur mustard gas revealed profound lymphoid hypoplasia and 
myelosuppression. This led Gilman and Goodman to the assumption that another mustard gas, nitrogen 
mustard, might be suitable to treat lymphatic tumors. After initial mice experiments, the first patient with non-
Hodgkin lymphoma (NHL) was treated with the nitrogen mustard in 1942, resulting in a tumor remission. 
Although the remission only lasted a few weeks before disease progression set in again, these findings 
demonstrated that tumors might be treated with drugs systemically. Another milestone toward modern 
chemotherapy was the introduction of combination therapy in 1965. The POMP regimen, a drug cocktail 
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consisting of methotrexate, vincristine, 6-MP and prednisone could sucessfully induce long-term remission in 
children with acute lymphoblastic leukaemia (ALL). The growing knowledge of tumor biology led to the 
establishment of targeted chemotherapy. New targets arose including growth factors, signalling molecules, cell 
cycle proteins, modulators of apoptosis and molecules promoting apoptosis.16 Imatinib was one of the 
landmarks of the targeted revolution. The molecule was a moderately potent inhibitor targeting the protein 
BCR-ABL. This protein is a fusion protein of a chromosomal translocation of the two genes which was associated 
with the pathogenesis of chronic myleoid leukaemia (CML). It was shown by Druker, that the imatinib treatment 
of patients with chronic-phase CML led to complete hematological remission in 90% of all cases.16  
Beside small molecules, therapeutic antibodies have also been developed for cancer treatment. After initial trials 
in the 1980 with murine antibodies against carcinoembryonic antigen (CEA) and CD3, two tumor-associated 
antigens, therapeutic antibodies gained more and more interest. These drugs can selectively bind to antigens 
presented on the surface of tumor cells and either inhibit intracellular signaling or recruit immune cells to 
mediate cancer cell killing.17 Another concept arose that combined the cytotoxicity of chemotherapy drugs with 
the selectivity of the therapeutic antibodies. These so called antibody-drug conjugates became a relevant cancer 
treatment option with the first FDA-approval of the ADC Adcetris in the year 2011.18 A graphical overview of the 
developments that led to modern chemotherapy is given in figure 3. 
 
 
Figure 3: Historical overview of ground-breaking developments in cancer therapy. 
 
Although in the last decades a marked decrease in cancer-associated death rate was observed due to improved 
therapy and earlier detection, the numbers of total deaths caused by cancer remain high2 leaving room for 
improvement. Drug combination therapy has the potential to increase the efficacy of the therapy and slowed 
down development of resistance.19 Furthermore, drug combinations might decrease side-effects19 as do 
targeted approaches like tumor-specific drug delivery using ADCs.20 Due to the potential advantages of drug 
combinations and ADCs for cancer therapy the following chapters will deal with these therapy options.  
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3.4. Cancer Therapy - Drug Combinations 
 
Conventional chemotherapeutics distribute unspecifically in the body upon administration often leading to 
severe side-effects like toxicities in healthy tissues, e.g. the bone marrow and gastrointestinal tract. As a result, 
many anticancer drugs suffer from a narrow therapeutic window. Drug resistance also often occurs when 
patients are treated with single agents.21 Combination chemotherapy adresses these issues and is associated 
with several advantages over conventional single agent chemotherapy: (1) Administration of drugs with non-
overlapping toxicites allows the treatment at their individual maxiumum-tolerated dose (MTD), leading to an 
increased efficacy.21 (2) The doses of the individual drugs might be reduced in combination while the therapeutic 
effect can be maintained.19 (3) combination therapy is associated with a slowed down development of 
resistance, because cancerous tissue has to become resistant against two drugs simultaneously.19 (4) Drug 
combinations tend to have an improved selectivity towards the diseased tissue.22 Given these advantages, 
combination therapy promises a surivival benefit of patients treated with a drug combination rather than with 
single-agents.23  
Drug combinations can have either additive, antagonistic or synergistic effects. In case of additivity, the effect 
of a drug combination is exactly the summed up effects of the single agents when given alone. Antagonistic 
effects are observed when one drug weakens the effects of the other drug. Synergism on the other hand is 
observed when the effects of the combination exceed the totalled effects of the single agents.24 Drug 
combinations are especially powerful for drugs that act synergistically, because therapeutic effects are 
maximized while adverse events are minimized.25  
For the identification of synergistic drug combinations several reference models have been developed from 
which three models are currently widely used: Loewe additivity,22,26,27 highest single agent (HSA)28 and Bliss 
independence29 model. These models make different assumptions to quantify combination effects.  
The Loewe additivity model is based on the sham control experiment, where a drug is combined with itself which 
by definition can only lead to additive effects.26 A further development of Loewe additivity is the generalized 
combination index (CI) theorem, which was derived from Loewe additivity by Chou and Talalay.19 
Mathemathically the CI can be expressed as in eq. 1.19,25 
 
 𝐶𝐼 =
𝐷𝐴
(𝐷𝑥)𝐴
+
𝐷𝐵
(𝐷𝑥)𝐵
 Eq. 1 
 
The CI can be calculated according to eq. 1 by inserting the dose of drug A (DA) and drug B (DB) to achieve a 
certain effect level when applied in combination as well as the doses of drug A ((Dx)A) and drug B ((Dx)B) when 
given alone to achieve the very same effect. The doses of the drugs in combination (DA and DB) are known from 
the experimental design and the doses of the single agents to obtain the same effect can be calculated from the 
dose-response curve. A CI of 1 stands for additivity, while CI<1 implicates synergy and CI>1 antagonism.19 This 
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further development of the Loewe additivity model is one of the most widely applied methods to quantify drug 
synergy with more than 7000 citations.25 
The HSA model assumes that in case of an additive combination, the effects of the combination equals to the 
effect of the more active compound, whereas for a synergistic combination the effect is higher than the effect 
of the more active single agent. One major drawback of this model is that even the combination of a drug with 
itself can produce an additional effect,24 because it assumes linear dose-response curves of the individual drugs 
which are commonly shaped logistically or curvilinearly.30 Furthermore, synergy is often only observed when 
one of the compounds is inactive at any concentration,30 which is only true for a limited subset of drugs. 
The Bliss independence model assumes that two drugs exert an effect on their target independently of one 
another.31 The drugs both contribute to the overall effect, however, they must not interfere with each other.30 
The mechanistic assumption that the drugs act independently was critisized, because drug combinations often 
contain compounds with multiple and not fully known modes of action,30 so acting independently might not be 
true for a large number of drug combinations.25 And again, the Bliss independence model fails the sham control 
experiment,25 meaning that a combination of a drug with itself might be considered synergistic.  
To leverage the great potential of possible drug combinations, sophisticated screening methods have been 
developed to uncover potential synergistic effects of certain drug combinations (Figure 4). A simple assay set-
up is the curve-shift assay. In a first step, a serial dilution of two drugs is studied on cells individually. Then the 
two drugs can be combined by two different strategies. One drug might be added to a serial dilution of the 
respective second drug. This might lead to a potentiation, measured as a lowered IC50-value compared to the 
potency of the single agent. Another strategy is to treat cells with a serial dilution of both drugs simultaneously 
at a fixed-ratio. Again, combination effects are determined by comparing the potency of the combination 
treatment with the potency of the individual drugs.  
 
 
Figure 4: Methods to assess synergistic effects of drug combinations. Curve-shift assays: The dose-response of the individial drugs is 
assessed separatedly. The combination can be studied by adding a constant concentration of one drug to a serial dilution of the other 
drug (A) or by adding a serial dilution of both drugs simultaneously to cells at a fixed-ratio (B). Dose-matrix assays: the two drugs are 
added to cells as serial dilution either alone or in combination resulting in a full matrix of doses where every dose of drug 1 is combined 
with each dose of drug 2. This figure was adapted according to Ka et al.26 
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Some short-comings are associated with this methodology because drugs have different effects on each cell line. 
An optimal experimental design requires studying the drug combinations at several effect levels and various 
ratios, since combination effects might depend on the molar ratio between two drugs. Therefore, dose-matrix 
assays deliver a more complete picture of the combination effects. In a dose-matrix experiment, the two drugs 
are tested individually by treating cells with a serial dilution of them and at the same time the cells are treated 
with a mixture of the serial dilutions. As a consequence, every serial dilution of one drug is mixed with varying 
constant concentrations of the respective second drug and the drugs are tested at several fixed-ratios at once.26 
While the evaluation of curve-shift assays can be accomplished by fitting the individual dose-response curves 
using e.g. GraphPad Prism, the evalution of dose-matrix assays might become more challenging. The software 
GeneData Screener might be used for studying dose-matrix assay results.26 This software uses a scoring function 
to discriminate between additive, antagonistic and synergistic drug combinations based on e.g. the LOEWE 
model. 
As already mentioned, besides drug combinations, also targeted approaches for anti-cancer treatment might 
improve efficacy and reduce undesired side-effects. Therefore, the following chapter introduces the concept of 
antibody-drug conjugates and gives a rough overview of production techniques, molecular build-up and 
optimization parameters of this drug class. 
 
3.5. Cancer Therapy - Antibody-Drug Conjugates 
 
The term antibody-drug conjugate describes monoclonal antibodies (mAbs) that act as carriers of cytotoxic 
drugs. The concept behind ADCs is a “biotherapeutic bullet” that specifically targets and kills tumor cells without 
damaging healthy tissues.32 
The underlying idea of ADCs dates back to the 1960’s. However, beginning with the approval by the US Food 
and Drug Administration (FDA) of brentuximab vedotin (Adcetris, Seattle Genetics) in 2011 and trastuzumab 
emtansine (T-DM1, Kadcyla, Roche) in 2013, ADCs have gained more and more interest in academia and 
industry. In the year 2017, nearly 100 ADCs were in preclinical or clinical development and with gemtuzumab 
ozogamicin (Mylotarg, Pfizer) as well inotuzumab ozogamicin (Besponsa, Pfizer) additional ADC approvals 
followed.18,33 
The underlying structure of an ADC is the mAb, which is in most of the cases an immunoglobulin G (IgG) 
molecule. The mAb consists of two identical 50 kDa heavy chains (HCs) and two 25 kDa light chains (LCs) that 
are connected to each other via disulfide bonds. The HCs encompass three constant domains (CH1-3) and a 
variable domain (VH). Similarly, the LCs comprise of a constant domain (CL) and a variable domain (CV). Every 
mAb has a region named “Fragment antigen binding” (Fab) that is formed by the LC and the CH1 and VH regions 
of the heavy chain. This Fab fragment is responsible for the antigen binding. Another important part of a mAb, 
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the “Fragment crystalline” (Fc), consists of the CH2 and CH3 of the HCs. This portion of the antibody mediates 
effector functions through binding to effector cells of the immune system.34  
 
 
Figure 5: Representation of an antibody-drug conjugate. The molecule consists of a monoclonal antibody and a cytotoxic drug that is 
attached to the antibody via a linker. The antibody is build-up of two identical heavy and light chains. CH2 and CH3 of the heavy chains 
form the “Fragment crystalline” (Fc) and the variable domains of the heavy and light chains (VH and VL) together with CL and CH1 form 
the “fragment antigen binding” (Fab) unit. The antigen binding is mediated via the variable domains of heavy and light chain. 
 
An ADC can be generated by connecting a cytotoxic drug to an antibody via a linker (Figure 5). Target selection 
for a therapeutic approach using ADCs is crucial. Antigens are selected that are presented on the surface of 
tumor cells but not or only sparsely on healthy cells.18 This mediates preferential binding to tumor tissues. 
Commonly ADCs are chosen that efficiently internalize into the cells. To induce cell death, the cytotoxic drug of 
the ADC needs to be delivered into the tumor cell. The underlying mode of action of an ADC is depicted in figure 
6. Upon binding of the ADC to an antigen, which is often a cell-surface receptor presented on the tumor cell (1), 
the ADC is internalized into the endosome (2). The endosome can mature to a lysosome (3). Proteolytic 
restriction and an acidic pH degrade the antibody or cleave the linker. This sets free the cytotoxic drug, which is 
typically a microtubule inhibitor or DNA-damager. After release of the drug into the cytoplasm, it can enter the 
nucleus and induce DNA damage (4) or bind and disrupt microtubules (5), which finally leads to cell death.35 
Antibody recycling is a mechanism by which the ADC is trafficked from the endosome back to the cell surface 
and released again (6), mediating increased half-life.36 
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Figure 6: Scheme of internalization route of an ADC. The figure is adapted according to Kitson et al.35 (1) binding of the mAb to a tumor-
specific cell-surface antigen. (2) internalization of the ADC into the endosome. (3) maturation of the endosome to the lysosome, where 
the ADC is degraded and/or the linker is cleaved. The cytotoxic drug is released into the cytoplasm. The drug can diffuse into the nucleus 
where it induces DNA damage (4) or disrupts microtubules (5). The ADC can be trafficked from the endosome back to the cell surface, 
where the ADC is released into the circulation again. 
 
Several criteria need to be met by the drugs. The drugs commonly need to be highly potent with potencies in 
the subnano- to picomolar range, because only a limited amount of ADC finally reaches the tumor site.37 
Furthermore, the drug should have a “chemical handle” that allows modification with the linker. The cytotoxic 
drugs are often hydrophobic, which limits their application, due to decreased solubility of the conjugate and a 
tendency to aggregate. In addition to that, a common resistance mechanism to ADCs is the upregulation of efflux 
pumps. Therefore, the ideal cytotoxic drug is hydrophilic but still efficiently transits into the cytosol, is no efflux 
pump substrate, chemically modifyable and highly potent.18,38 
ADCs currently in preclinical or clinical development use cytotoxic drugs mainly based on microtubule inhibitors. 
71% of all drugs are auristatins, maytansinoids or advanced tubulin inhibitors and the remaining ADCs mainly 
carry drugs that induce DNA damage (Figure 7). Auristatins like monomethyl auristatin E (MMAE, 1) can be found 
in the clinically approved ADC Adcetris and Maytansinoids are represented in the form of DM1 (2) by the 
marketed ADC Kadcyla. Another microtubule inhibitor used in clinical development is tubulysin (3).18 Although 
microtubule inhibitors are very widely used in clinical ADC development, robust activity of microtubule inhibitors 
has only been observed in ALL, Hodgkin’s disease and NHL. In other solid cancer indications such as breast or 
lung cancer, microtubule inhibition has only yielded modest response rates and they are considered inactive in 
most other solid tumors.39 
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Figure 7: Distribution of drugs used for ADCs in preclinical or clinical development. Microtubule inhibitors like auristatins, maytansinoids 
or advanced tubulin inhibitors account for the majority of linker-drugs (LDs). The remaining ADCs comprise mostly DNA-damagers. 
 
Given the limited amount of cancer indications in which microtubule inhibiting agents have shown robust 
activity, other mode of actions need to be exploited. Thus, DNA damagers gain increasing interest. The re-
approved ADC gemtuzumab ozogamicin uses the double-strand break inducer calicheamicin (4) as cytotoxic 
drug.18 Another double-strand inducing agent developed in the ADC context is doxorubicin (5), which is already 
widely applied in anti-tumor therapy as single agent.18,40 Anthracycline-based molecules like doxorubcin induce 
double-strand breaks through intercalating properties, but also through inhibition of topoisomerase I and II 
(TOP1 and TOP2).40 Topoisomerases are important enzymes involved in decreasing topological stress on DNA 
during replication. TOP1 creates a single-strand and TOP2 a double-strand break, which is religated once the 
DNA is relaxed. Upon inhibition of these enzymes, single-strand or double-strand breaks are induced, 
respectively.40 Inhibition of topoisomerase I and II finally leads to apoptosis.41 Exatecan (6) and SN-38 (7) are 
two TOP1 inhibitors that are currently used as drugs for ADC development. Finally, alkylating agents are applied 
as drugs in the ADC field.18 Bifunctional alkylators like pyrrolobenzodiazepine dimers (PBD dimer, 8) can alkylate 
both DNA strands, yielding either intra- or interstrand crosslinks. Monofunctional drugs such as 
indolinobenzodiazepines (IBD, 9) or minor-groove binders from the duocarmycin family like seco-DUBA (10) 
alkylate one DNA strand.  
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Figure 8: Chemical structures of ADC drugs currently in clinical development. Mono-methylauristatin E (1), the maytansinoid DM1 (2) and 
tubulysin (3) belong to the microtubule inhibiting agents. The remaining agents cause DNA damage. Double-strand breaks are induced 
by calicheamcin (4) and doxorubicin (5) and single-strand breaks by exatecan (6) and SN-38 (7). Monofunctional alkylators such as 
indolinobenzodiazepines (9) or minor-groove binders like DUBA (10) form a covalent DNA-adduct on one strand. Bifunctional alkylators 
like the pyrrolobenzodiazepines (8) on the other hand can form intra- or interstrand crosslinks. 
 
Another crucial optimization parameter of an ADC is the linker, because it influences the physicochemical 
properties of the ADC. The linker determines the stability of the ADC in circulation and on-target. Generally, the 
linker should be stable in the circulation to ensure that the ADC can accumulate at the tumor site. Premature 
drug-release can lead to off-target cytotoxicity, which influences the selectivity. However, once the tumor is 
reached and the ADC is internalized, efficient drug release is important to induce cell death in the target cells. 
Several linker-chemistries are used in the ADC field that can be classified as non-cleavable linkers and cleavable 
linkers.42  
Non-cleavable linkers have a greater stability compared to their cleavable counterparts, which is also reflected 
as a higher plasma stability. Associated with this are reduced off-target toxicities which might translate into a 
greater therapeutic window. However, ADCs with non-cleavable linkers rely strongly on efficient internalization 
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to set free the active drug, because full degradation of the ADC is crucial.42 One example of an ADC using a non-
cleavable linker is the approved ADC Kadcyla. The succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-
carboxylate (SMCC) portion has two functions; first, to attach DM1 via its free thiol group to the linker and 
second, to conjugate the linker to the mAb (Figure 9).43 While some cytotoxic drugs tolerate substitution, like 
DM1, other drugs are only active in an unsubstituted state like for instance MMAE.42,44 These drugs require 
cleavable linkers that tracelessly release the drug upon internalization.42 
 
 
Figure 9: Structure of a non-cleavable linker attached to DM1. The thiol of DM1 is used to form a thioether bond with the SMCC moiety 
(red). This part cannot be cleaved and remains attached to the drug. The markush indicates the attachment point at the mAb. Figure 
adapted according to Lu et al.42 
 
Cleavable linkers often use enzymatic degradation for drug release. Cathepsin B is an ubiquitous cysteine 
protease, which is usually found intracellularly in the lysosome. Cathepsin B can be found extracellularly only in 
diseased tissues such as metastatic tumors or rheumatoid arthritis. The intracellular localization of the enzyme 
should mediate a certain stability against premature cleavage.45 In addition to that, Cathepsin B was found to 
be overexpressed in various cancer indications such as adenocarcinomas of the oesophagus and gastic cardia.46 
The approved ADC Adcetris is a conjugate of the mAb brentuximab and the cytotoxic drug MMAE. The linker-
drug consists of the dipeptide valine-citrulline, which is recognized and cleaved by Cathepsin B but also other 
proteases from the cathepsin-family can process the valine-citrulline motif.47 para-aminobenzyl alcohol (PAB) is 
introduced between the drug and the dipeptide, as a self-immolative module. The PAB module decays upon 
protease restriction.48 This ensures that MMAE is set free, without any residual modifications (Figure 10). 
Besides the dipeptide valine-citrulline, several other dipeptide sequences like phenylalanine-citrulline or 
alanine-lysine for Cathepsin B-mediated cleavage45 or alanine-alanine-asparagine for cleavage by the protease 
legumain49 have been evaluated for the use as a linker for ADCs. These sequences have different cleavage rate 
properties45,50 and open-up opportunities for ADC optimization.  
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Figure 10: Chemical structure of cleavable dipeptide linker. N-terminally of the linker-drug, an attachment site for the linker to the mAb 
is indicated as markush. It is followed by the dipeptide valine-citrulline, which can be cleaved by the protease Cathepsin B. The self-
immolative module decays after cleavage, whereby MMAE is set free. 
 
Besides Cathepsin B-cleavable linkers, there are other enzymatically cleavable linkers as depicted in figure 11. 
The glucuronide is selectively cleaved by β-glucuronidase. Comparable to the Cathepsin B-cleavable linkers, a 
self-immolative module is introduced, so that the cleavage occurs tracelessly51,52 Finally, a minor-groove binder 
is released. The linker mediated high solubility, which reduced the levels of aggregates. Glucuronide linkers can 
be considered as an alternative to e.g. dipeptide linkers, because they enable the usage of more hydrophobic 
drugs.53 
 
 
Figure 11: Chemical structures of glucoronide-cleavable linker. The markush indicates the attachment point of the linker to the mAb. The 
sugar glucuronide is cleaved by β-glucoronidase, which leads to the decay of the self-immolative module. The minor-groove binder is 
released as free drug and is able to alkylate DNA. 
 
The FDA approved ADCs gemtuzumab-ozagamicin and inotuzumab-ozagamicin are generated using acid-labile 
hydrazone linkers to connect mAb and the drug calicheamicin (Figure 12).54 These linkers are designed to be 
stable in circulation. Internalization of the ADC leads to localization in the lysosome, where the ADC experiences 
an acidic pH. Consequently, the hydrazone linker hydrolyzes and the drug is released.55 However, hydrazone 
linkers have been associated with unspecific drug release.18 
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Figure 12: Chemical structure of hydrazone-linked calicheamicin and the product of hydrolysis. The acid-sensitive hydrazone in the linker-
calicheamicin is cleaved in the acidic microenvironment of the tumor or the acidic pH of the lysosome. Thereby the carbonyl-function of 
calicheamicin is regenerated and the free drug is obtained. Figure was adapted according to Beck et al.18 
 
Another class of ADC linkers uses cleavable disulfide linkage.18 Due to differences in the reduction potential of 
plasma and the intracellular compartment, disulfide linkers are only susceptible to cleavage inside the cell. 
Furthermore, reduced glutathione levels are up to 1000-fold higher in cancerous cells compared to healthy 
cells.42  
The cleavage mechanism of disulfide linked drugs is rather complicated, as illustrated by the example of ADC 
SG3231 in figure 13. Upon internalization of the ADC into the lysosome, the ADC gets proteolytically restricted. 
This yields an intermediate with a residual cysteine. Then, the drug can enter the cytosol, where reductive 
conditions lead to the cleavage of the disulfide. A free thiol is generated that mediates a cyclization step, which 
finally regenerates the free PBD dimer.56 
 
 
Figure 13: Schematic representation of the decay of disulfide linkers to yield an active PBD dimer. The markush indicates the connection 
to the mAb. Upon internalization into the lysosome, the mAb is degraded. This leaves the drug with a residual cysteine moiety. The 
cysteine-modified drug can diffuse into the cytosol, where glutathion mediates the cleavage of the disulfide. A free thiol is generated, 
which cyclizes and regenerates the active PBD dimer. Figure is adapted according to Pillow et al.56 
 
All in all, the overall success of an ADC is highly dependent on all three modules of an ADC: the antibody, the 
linker and the cytotoxic drug. In addition to that, the conjugation technique majorly impacts efficacy, 
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pharmacokinetics and tolerability.57 One conjugation method comprises the coupling of the linker-drug to 
surface lysines of the mAb. A common IgG molecule has about 80 lysines from which around 20 are solvent 
accessible. As a result, lysine conjugation can lead to an ADC not only varying in the site of drug attachment, the 
drug-distribution, but also in the drug-to-antibody ratio (DAR), namely the number of drugs attached to the 
mAb. The generation of Kadcyla for example is realized by coupling the cytotoxic moiety DM1 to lysines on the 
surface of the mAb, yielding an ADC with an average DAR of 3.5.44  
Another strategy for ADC generation is the controlled reduction of disulfide bonds and subequent coupling of a 
maleiimde-containing linker-drug to the reduced interchain cysteines. Such an approach was followed in the 
production process of Adcetris.57 In this case 4 interchain cysteines are adressible which again leads to a 
heterogenous ADC mixture in terms of DAR and drug distribution.44 
This heterogeneous mixture contains several DAR species that are difficult to purify and characterize.44 
Furthermore, ADC species with high DARs are cleared faster and are prone to aggregate.58 The ADC species with 
a low DAR on the other side have a reduced efficacy due to the smaller amount of drug delivered to the tumor 
cell.59 Much effort was put into the development of site-specific conjugation techniques to overcome the 
difficulties asscociated with heterogenous ADCs. By genetic incorporation of cysteines at defined positions, 
more homogeneous ADCs can be generated as decribed for the THIOMAB approach by Genentech.60 These 
molecules have improved PK, similar efficacy and an increased therapeutic index compared to conventionally 
produced ADCs.57 Another approach to increase homogeneity of the ADCs is the incorporation of unnatural 
amino acids which can be adressed orthogonally to the naturally occuring amino acids. Such an ADC displays 
high efficacy paired with improved PK compared to conventionally generated ADCs.61 However, the production 
of such an ADC is complicated.57 Besides the incorporation of cysteines or unnatural amino acids, enzymatic 
conjugation strategies can be followed. The enzyme transglutaminase facilitates the formation of an amide bond 
between a glutamine side chain and small molecules containing a primary amine. Transglutaminase can be used 
for the conjugation of linker-drugs to Q295, a glutamine in direct proximity of the N-glycan site N297.62 However, 
this requires the removal of the glycan structure prior to conjugation by deglycosylation to increase steric 
accessibility. Another strategy is the incorporation of a LLQG motif into the antibody sequence or the C-terminal 
fusion of the sequence to heavy and light chains.63 Again, site-specific conjugation yielded ADCs with higher 
tolerability compared to ADCs with drugs coupled to the interchain cysteines.64 In addition to transglutaminase, 
the enzyme sortase A can be used for the conjugation of ADCs.65–67 Sortase A recognizes the C-terminal sequence 
LPXTG and cleaves the bond between threonine and glycine. Thereby a thioacyl-intermediate is formed, that 
acceptes N-terminal oligo-glycine residues as nucleophile. A new peptide bond is formed between the theonine 
and the oligo-glycine substrate.64 An overview of the conjugation strategies commonly applied for the 
generation of ADCs is provided in figure 14. 
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Figure 14: Overview of conjugation techniques for the generation of ADCs. Using chemical methods, lysines or upon reduction inter- and 
intrachain cysteines can be adressed. By genetically introducing a cysteine or unnatural amino acids, these residues can be used for 
conjugation. Besides, enzymatic approaches can be applied that use specific recognition sequences for the enzyme. Figure was adapted 
from Perez et al.57 
 
Tolcher states in a review that microtubule inhibitors often lack clinical efficacy and that the exploitation of 
mode of actions other than microtubule inhibition is mandatory to expand the armamentarium of the 
oncologist.39 This might not only lead to higher success rates in clinical development of ADCs but also to 
improved outcomes for anti-cancer treatment of patients. Hence, in this work DNA-damaging ADCs will be 
studied with a special focus on duocarmycin-bearing ADCs which will be discussed in the following chapters.  
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3.5.1. Therapeutic Development of Duocarmycin 
 
Duocarmycins are a class of natural compounds originally isolated from Streptomyces. These highly potent 
molecules have a common molecular build-up, consisting of a DNA-alkylating unit and a DNA-binding unit as 
illustrated by the duocarmycin derivative DUBA (11) (Figure 15 A).68 After binding the minor groove of AT-rich 
regions of the DNA double strand, an addition of N3 of adenine to the activated cyclopropane ring of DUBA 
occurs (Figure 15 B), leading to the alkylation of the DNA (12).69 Although duocarmycins comprise the reactive 
cyclopropane ring, they are considerably stable in aqueous media. However, duocarmycins exhibit remarkable 
alkylation efficiencies and rates In the presence of DNA. Complexes of Duocarmycin SA (DSA, 13) and DNA were 
studied using nuclear magnetic resonance (NMR) spectroscopy to elucidate this phenomenon.70 The two 
subunits of duocarmycins are coplanar in the absence of a ligand. Upon binding in the minor groove of DNA, 
hydrophobic contacts are maximized, leading to a conformational change of DSA. The two subunits are twisted 
with respect to each other, activating the molecule for alkylation (Figure 15 C, 14).69 
 
 
 
Figure 15: Structural representation of duocarmycin and its alkylation reaction. A) Duocarmycin derivative DUBA depicted with marked alkylation unit 
(red) and binding unit (gray). B) Scheme of alkylation reaction. N3 of adenine attacks the least substituted carbon atom of the cyclopropyl ring, which leads 
to the covalent addition of DUBA to adenine. C) Duocarmycin SA activation for alkylation. DSA is coplanar in solution and therefore considerably stable in 
solution. Upon binding of the DNA double helix, DSA maximizes hydrophobic interactions with the DNA. As a result, the subunits experience a twist with 
regard to each other along the X bond which activates the cyclopropyl-ring for alkylation. 3D structure: 1dsa (PDB). 
 
The high cytotoxicity of duocarmycins awoke interest for the application as potential anticancer agents.71 As a 
result, extensive research was done to elucidate the structure-activity relationship of the duocarmycin family.72  
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CC-1065 (15) was the first compound of the duocarmycin family studied for clinical application (Figure 16 A). 
Although the drug prolonged the life span of tumor-bearing mice, it was not curative. Furthermore, delayed 
hepatotoxicity was observed in mice and rabbits at therapeutic doses. As a consequence, efforts were put into 
the modulation of the alkylating properties to maintain efficacy while avoiding toxicities.73 One possibility to 
modulate the alkylation rate is to use a prodrug approach. The duocarmycin derivative carzelesin (16) requires 
a two-step activation to set the active drug free (Figure 16 B). First the phenylurethane promoiety is cleaved 
either chemically or enzymatically, leading to the formation of the seco-prodrug 17 with the chloromethyl-
residue. Next, the molecule undergoes an intramolecular Winstein spirocyclization, which leads to the formation 
of the active drug 18. Carzelesin was less active in vitro than CC-1065 but proved to be more efficacious against 
several human and murine tumour xenografts.74  
 
 
Figure 16: Chemical structures of clinically developed duocarmycin-derivatives. A) Anti-cancer drug CC-1065 B) Activation route of carzelesin (16). The 
promoeity (grey box) of carzelesin is removed chemically or enzymatically. Then an intramolecular spirocyclization step of the seco-derivative 17 leads to 
the formation of the active drug 18. 
 
Despite promising preclinical data, carzelesin demonstrated no activity in various solid tumors and non-hodghkin 
lymphoma in a phase II clinical study conducted by the EORTC, while myelotoxicity was found to be the major 
adverse event.75 Again, no therapeutic window could be established and no clinical development is ongoing.  
Another technology to increase the therapeutic window is the antibody-drug conjugate format. Much effort was 
put into the development of duocarmycin-based ADCs (Table 1).53,76–83 A variety of duocarmycin-derivatives was 
successfully conjugated to antibodies directed against CD19, CD22, CD30, CD56, CD70, CanAg, GD3, human 
epidermal growth factor receptor 2 (HER2), LeY, LY6E.  
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Table 1: Overview of duocarmycin-based ADCs reported in literature. ADC identifyer, corresponding target are listed, as well as conjugation technique 
used for conjugation. The cleavage mechanism is noted and the duocarmycin-derivative studied. The linker is usually attached either to the phenol group 
of the duocarmycin alkylation unit or to a terminal group on the binding unit. Cytotoxicity is scored as an approximation, beginning with IC50<1x10-9 M (+) 
to IC50<1x10-12 M (+++). If in vivo experiments were conducted, it is marked by “+”, otherwise “N.A.”. Abbreviations: minor-groove binder (MGB), binding 
unit (BU), alkylating unit (AU), not available (N.A.) for data. 
ADC Target Conju-
gation 
Cleavage 
mechanism 
Drug Linker 
attachment 
Cytotoxicity/ 
selectivity 
In 
vivo  
Remarks Source 
 CanAg, 
CD19 
Lysine thioether or 
disulfide 
DC1 (19), DC4 
(20), DC44 (21) 
BU +++/+ + highly hydrophobic LD, modified by 
phosphate on phenol 
76 
 CanAg Lysine thioether or 
disulfide 
DC1 (19) BU +/+ N.A. highly hydrophobic LD 77 
 GD3 Lysine Ala-Val DU-257 (22) BU +/+ N.A. Linker attached to binding unit 78 
 CD30, CD70 Thiols β-
Glucuronide 
MGB (23) AU ++/+ N.A. Sugar-cleavable linker studied due to 
supposedly higher hydrophilicity 
53 
 CD22, LY6E Thiols Val-Cit CBI-TMI (24), DSA 
(13) 
AU +/+ N.A. Ether bond to connect linker and 
drug 
79 
 CD19 Thiols Dilsulfide DC1 (19) BU +++/+ N.A.  80 
 CD56 Thiols Val-Cit seco-DUBA (25)  +++/+ +  81 
 CD30, 
CD70, LeY 
Thiols Val-Cit or 
Val-Lys 
MGB (23), CBI-TMI 
derivative (26) 
AU ++/+ N.A. Extensive research on decreasing the 
hydrophobicity 
84 
SYD985 HER2 Thiols Val-Cit seco-DUBA (10) AU +++/+ + Clinically developed ADC by Synthon 82 
 
BMS-
936561 
CD70 Thiols Val-Cit Duocarmycin-
derivative (27) 
BU N.A.  Evaluated in phase I clinical trials, 
development haulted 
18 
MGC-
018 
B7-H3 Thiols Val-Cit seco-DUBA (10) AU N.A. + Mice xenograft, well-tolerated in 
cynomolgus monkeys 
85 
 
The listed studies used conjugation techniques addressing the cysteines and lysines of the mAb. The linkers 
encompass non-cleavable, or reductively cleavable disulfides, β-glucoronide cleavable linkers and cathepsin B-
cleavable dipeptide linkers with the motifs alanine-valine, valine-citrulline or valine-lysine.  
The duocarmycins were connected to the linkers, following two strategies. First, the linker was attached to the 
alkylating unit via a phenolic alcohol or anilinic amine (Figure 17, duocarmycins 10, 13, 23, 24 and 26). The 
advantage of this approach was that the drugs were kept in their inactive seco-form. Only upon linker cleavage 
the drug underwent spirocyclization leading to the activation of the duocarmycin. However, the use of stable 
non-cleavable linkers was only possible with the second approach, where the linker was attached to the binding 
unit of the duocarmycins (Figure 17, duocarmycins 19, 20, 21, 22 and 27). Here, already cyclized duocarmycins 
were often used as exemplified by duocarmycin 22 (Figure 17). This had the disadvantage that the drug was 
prone to nucleophilic attack at the cyclopropane ring, potentially leading to the inactivation of the drug. 
Promoieties were attached to the phenolic hydroxyl group of the alkylating unit to avoid premature inactivation 
of the drug (Figure 17, duocarmycins 20, 21, and 27). 
In summary, the ADCs were efficacious in vitro against and selective towards antigen-positive cells regardless of 
antibody, conjugation technique, linker, cleavage mechanism and duocarmycin-variant. 
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Figure 17: Chemical structures of duocarmycin derivatives applied in the ADC format. The structures of DC1 (19), DC4 (20), DC44 (21), 
DU-257 (22), a minor groove binder (23), seco-DUBA (10), DSA (13), CBI-TMI (24) and a derivative of this molecule (26) are depicted. Red 
boxes indicate the attachment point of the linker. 
 
A duocarmycin-based ADC currently in clinical development by the dutch pharmaceutical company Synthon is 
SYD985 (28) (Figure 18). This ADC consists of the duocarmycin prodrug seco-DUBA (10) which is connected via a 
cathepsin B-cleavable dipeptide linker to the anti-HER2 antibody trastuzumab. Upon cleavage of the dipeptide 
linker the self immolative module decays and the prodrug seco-DUBA (10) is liberated which spiro-cyclizes to 
form the active drug DUBA (11). The ADC is generated by coupling the maleimide moiety of the linker to the 
interchain cysteines of the antibody. This results in a rather heterogeneous mixture of ADC species differing in 
the attachment site as well as in the DAR. In an additional purification step using hydrophobic interaction 
chromatography the final product SYD985 can be obtained with a DAR of 2.8 consisting mainly of the DAR=2 and 
DAR=4 species.82 SYD985 demonstrated superior activity compared to Kadcyla in HER2 over- and low-expressing 
breast cancers as well as ovarian and uterine carcinosarcoma with HER2/Neu expression.86,87 In a phase I dose-
escalation trial no dose-limiting toxicities and no grade 3 or 4 adverse events were observed, indicating good 
tolerability.88 In the expanded study grade 3/4 adverse drug reactions were observed such as neutropenia and 
conjunctivitis.89 Nevertheless, SYD985 had a manageable safety profile89 and as a consequence SYD985 was 
advanced to clinical phase III trials for metastatic breast cancer in 2017.90  
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Figure 18: Schematic representation of SYD985 and the mechanism of drug liberation. The ADC 28 consists of the anti-HER2 antibody 
trastuzumab and a linker-drug. The linker-drug is conjugated to the mAb by addressing the interchain cysteines. Upon C-terminal cleavage 
of the dipeptide valine-citrulline motif (gold), the self-immolative module (gray) decays. This ensures the traceless liberation of the 
prodrug seco-DUBA (10, orange). The active species 11 (red) is formed through an intramolecular cyclization step. 
 
As pointed out in the previous chapters, DNA damage can cause severe damage to a cell causing either cell 
death, senescence or mutations in the genome that might lead to cancer development. Due to the detrimental 
effects of DNA damage on cell fate, a sophisticated response has evolved to cope with DNA insults. Hence, cells 
respond to duocarmycin-alkyation lesions with a complex system of DNA-repair, cell cycle regulation, damage 
tolerance or even apoptosis summarized as DNA-damage response. Due to its complexity, several chapters will 
be dedicated to the DDR to shed light on the sophisticated mechanisms that have evolved to deal with DNA-
damage. 
 
 
 
 
 
 
 
 
  
CO
2
HCl
seco-DUBA
seco-DUBA
self-immolative
module
Cathepsin B-
cleavage site Residue for
conjugation
trastuzumab
Winstein
cyclization
DUBA
CathB
28 
10 11 
   27 
3.6. DNA Damage and Replication Response 
 
Every cell is constantly challenged by thousands of DNA damage events every day. Ultraviolet light, 
environmental factors like cigarette smoke, industrial chemicals but also the DNA-damaging drugs mentioned 
in chapter 3.5 cause DNA lesions.91 Cell division largely relies on the accurate duplication of the genome of a cell 
and the segregation of the genomic information to the daughter cells.92 The DNA lesions however can lead to 
abberations of the DNA like mutations and genome rearrangements, which might have devastating effects on 
cell fate.91 In order to deal with the DNA damage the cells have evolved a sophisticated DNA-damage response 
machinery (Figure 19) that comprises the ability to detect DNA lesions which is followed by a cellular signaling 
cascade that promotes DNA repair.93 Cell cycle arrest might be induced which also regulates DNA replication.94 
This is escpecially important, because many DNA lesions become detrimental when the cell replicates its 
genome.93 In addition to repair, DNA damage might be also tolerated in order to complete DNA synthesis. If DNA 
damage is not repaired orderly, the cell will undergo apoptosis or become senescent.95 The DNA damage 
response is particularly important since persistant DNA damage might lead to genomic instability which has been 
described as one of the fundamental reasons for the development of cancer.96 
 
 
Figure 19: Cellular response to DNA damage. In order to manage DNA damage independently of the form of the lesion, cells have different 
options. Cells regulate cell cycle to gain time for DNA-damage repair. Cell cycle arrest is also interconnected with the regulation of the 
replication. If DNA lesions cannot be repaired, the damage might be tolerated to make sure the whole genome is duplicated. If the 
damage cannot be tolerated, apoptosis or senescence are the consequence. 
 
The cell undergoes a full cell cycle with every cell division. Gap or Growth Phase I (G1) is followed by S phase in 
which the genome is duplicated. Another growth phase (G2) preceedes cell division in mitosis phase (M). Several 
checkpoints are present to prevent DNA damage to be taken into the next phase. The G1/S checkpoint makes 
sure DNA damage is repaired or removed before the genome is replicated in S phase. During S phase the intra-
S checkpoint might be triggered to delay replication. This provides additional time for the cell to repair DNA 
lesions and to ensure the genome is fully replicated. G2/M is the last opportunity to prevent that damage is 
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taken into cell division. In this critical step underreplicated DNA or DNA-double strand breaks lead to mitotic 
catastrophe and finally cell death. The cell cycle and cell cycle checkpoints are depicted in figure 20.95 
 
 
 
Figure 20: Cell cycle and checkpoints. The cell grows in gap or growth phase (G1) to proceed with the duplication of the genome in S 
phase (S). Subsequently, another gap or growth phase (G2) prepares the cell for cell division (M). Several checkpoints can be activated 
to ensure no damage is taken into the next cell cycle phase. Figure adapted from O’Connor.95 
 
The repair of DNA lesions however is mediated by several DNA repair pathways (Figure 21), which are activated 
depending on the type of DNA damage. Although the pathways have distinct roles in repair of DNA damage they 
are also linked to each other.95 Oxidative lesions, alkylation lesions and single-strand breaks (SSB) are mainly 
accomplished by base-excision repair (BER).91 Double-strand break (DSB) repair however relies on two repair 
pathways: homologous recombination repair (HRR) and non-homologous end joining (NHEJ).95 Althouth HRR 
has a higher fidelity in repair,95 it requires the presence of a sister chromatid and thus is restricted to S or G2 
phase.97 NHEJ on the other hand does not require the presence of a sister chromatid.95 The nucleotide-excision 
repair (NER) pathway is specialized on the removal of bulky DNA lesions that distort the structure of the DNA 
double helix. During replication wrong base-pairing, nucleotide insertions but also deletions can occur. These 
lesions are repaired by mismatch repair (MMR). Alklyation damage of nucleobases might be removed by direct 
reversal pathway. Besides DNA damage caused by exogenous factors the duplication of the genome is prone to 
DNA damage events during DNA replication as well. To prevent exhaustive DNA damage as a result of replication 
stress, fork protective measures are induced. 
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Figure 21: DNA-damage and repair pathways. Depending on the type of DNA-lesions, different DNA repair pathways are recruited that 
involve several DNA damage repair enzymes. Single-strand breaks are resolved by base-excision repair. Double-strand breaks are repaired 
by either homologous recombination or non-homologous end joining. Nucleotide excision repair is specialized in the removal of bulky, 
DNA structure-distorting lesions while mismatch repair corrects base mismatches, insertions or deletions. Alkylation damage on 
nucleobases is removed by the direct reversal mechanism. Replication stress can induce the stalling of replication forks which activates 
ATR. The members of the PIKK family ATR, ATM and DNA-PK are marked in red. Figure adapated according to Lord and Ashworth91 as 
well as Blackford and Jackson93. 
 
The three kinases of the phosphoinositide 3-kinase (PI3K)-related kinases (PIKK), namely ataxia telangiectasia-
mutated (ATM), ATM and Rad3-related (ATR) and DNA-dependent kinase (DNA-PK) play an essential role in the 
activation of the DDR (Figure 21, marked in red) and will be discussed in detail in the following.93  
 
3.6.1. ATR – Key Kinase in Replication Stress Response 
 
ATR is involved in replication stress response. Thus, the replication process is portrayed as an introduction into 
the topic.  
The survival of a biological organism relies on the replication of the genetic information. This process can be 
divided into two primary parts that include the melting of the DNA double strand to yield two separate single 
strands and subsequent semi-conservative replication of each strand. Because the human genome is 3 giga 
basepairs large, successful replication is a biological masterpiece in which many proteins are involved. Sites of 
replication initation, so called origins of replication, are distributed over the whole genome to start replication 
at different site.98 The origins are often G-rich sequences and CpG islands that form nucleosome-free regions 
(NFRs) and quadruplex structures. The process of replication is depicted in figure 22. Thus, the origin-recognition 
complex (ORC) can access DNA and is loaded together with the helicase-loader protein CDC6 to these origins in 
G1 phase.99 The pre-replication complex is formed by loading two inactive MCM2-7 helicases together with the 
chaperone CDT1.100 At the same time, CDT1 and CDC6 are ejected from the double hexamer, which forms the 
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pre-replication complex (pre-RC).101 After the cell enters S phase, the pre-RC is subsequently activated by the 
formation of the CMG complex consisting of CDC45, the two helicases MCM2-7 and GINS.102 Finally, a 
bidirectional replication fork is formed through melting of the DNA-double helix and the recruitment and 
tethering of the replisome proteins including the polymerase to the MCM2-798,102 While MCM2-7 helicase is 
necessary to open the DNA double helix and to facilitate bidirectional movement, the two polymerases DNA-
polymerase ε and δ synthesize the leading and lagging strand, respectively.103 The process of origin licensing 
over loading of MCM2-7 helicase onto DNA and formation of the bidirectional replication fork that finally 
duplicates the DNA is depicted in figure 22. 
 
 
Figure 22: Scheme of replication initiation. The origin recognition complex (ORC) together with CDC6 bind and are loaded onto the origin. 
The ORC-CDC6 complex facilitates the assembly of the pre-replication complex (pre-RC) consisting of the MCM2-7 double hexamer. 
Subsequent dissociation of ORC and the loading of GINS and CDC45 to the double hexamer in S phase leads to the formation of the pre-
initiation complex, also called CMG. Replisome components are recruited and tethered to the MCM2-7 helicase. A bidirectional 
replication fork is formed and DNA is replicated.98 
 
The replication process frequently encounters challenges such as shortage of dNTPs104 or histones105. In case of 
depletion of dNTP pools, the DNA-polymerases stall leading to a stalled replication fork. Helicases and DNA-
polymerases become uncoupled whereby long stretches of ssDNA are formed.94 The ssDNA is then coated with 
replication protein A (RPA) which protects the DNA from nucleolytic restriction.106 In order to limit damage, the 
Claspin-TIPIN-Timeless complex restrains helicase movement to keep ssDNA under a certain level.107 But if this 
process fails and RPA levels are diminished this might lead to the replication catastrophe which is accompanied 
by fork collapse and subsequent DNA breaks.94 Several other sources may lead to replication stress which in this 
case also manifests in the stalling of replication forks. Stalled replication forks are formed when DNA secondary 
structures and replicative sequences slow down DNA-polymerization.108 Furthermore, DNA-RNA hybrids so 
called R loops formed during transcription pose a barrier for the polymerases.109 In addition, the DNA suffers 
from torsional stress during replication which is commonly resolved by topoisomerases.110 However, these 
enzymes can pose a replication barrier, too.111 The physical barries that are encountered by the helicases and 
DNA-polymerases are depicted in figure 23 A. One common mechanism to resolve replication barriers is the 
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firing of a neighboring dormant origin to rescue the stalled fork and to complete replication in time. Additionally, 
a multitude of processes are involved to respond to replication stress.  
A central role in replication stress response plays ATR and its downstream target CHK1. Long stretches of ssDNA 
coated with RPA lead to the recruitment of ATR mediated by ATRIP.103 The Rad9-Rad1-Hus1 (9-1-1) complex 
binds to the dsDNA-ssDNA junction through Rad17 with subsequent recruitment of TOPBP1.108 The interaction 
of ATR with the 9-1-1 complex and TOPBP1 as well as ETAA1 results in the full activation of ATR. The kinase ATR 
however has several functions which will be discussed in detail. The processes to overcome these barriers are 
depicted in figure 23 B. 
 
 
 
 
Figure 23: Scheme of replication stress response. A) Representation of types of replication stress. Helicase opens DNA double strand and 
DNA-polymerases replicate DNA. ssDNA is formed during replication which is coated with RPA to protect the single strand from 
degradation. The DNA replication encounters torsional stress, DNA secondary structures and R loops that can lead to the stalling of the 
replisome. Furthermore polymerases might encounter DNA lesions or low dNTP pools that slow down polymerization. These challenges 
ultimately lead to fork stalling. B) Replication stress response. DNA polymerases stall when they encounter a replication fork barrier. 
Upon binding of the 9-1-1 complex, TOPBP1 is recruited. ATRIP and ETAA1 bind to the protein complex and ATR is activated leading to 
several downstream processes. Another possibility of rescuing a stalled fork is the firing of a nearby dormant origin. The Claspin-TIPIN-
Timeless complex slows down helicases. Otherwise helicase and DNA-polymerase become uncoupled, leading to the excessive formation 
of ssDNA. Figure was adapted according to O’Connor and Forment103. 
 
ATR can activate p53 which induces the transcription of the CDK inhibitor p21 through which G1/S checkpoint is 
established.103 Furthermore, ATR phosphorylates CHK1 which again has a multitude of targets that regulate cell 
cycle and fork stabilization. One target are phosphatases CDC25A, CDC25B and CDC25C. By phosphorylation of 
the phosphatase CDC25A, it is marked for ubiquitinylation and subsequent degradation. CDC25A removes 
phosphorylation of CDK1 and CDK2 promoting cell cycle arrest at G1/S transition, in S phase and G2/M transition. 
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CHK1-mediated phosphorylation of CDC25C leads to the nuclear exclusion of CDC25C. This leads to the inhibition 
of CDK1 and subsequent G2 arrest. Phosphorylation of CDC25B by CHK1 also results in sequestration of the 
phosphatase in this case from centromers thereby inhibiting centrosomal CDK1 promoting G2 phase arrest. G2 
arrest can also be accomplished by CHK1-mediated phosphorylation of WEE1 which in turn phosphorylates 
CDK1. Besides the role of CHK1, it is responsible in the recruitment of translesion synthesis which ignores DNA 
damage to ensure full DNA replication.108 
It has to be ensured that stalled forks maintain their structure to be able to restart after the replication block is 
removed by DNA repair enzymes. Abberant remodeling damages the forks which manifests in fork collapse and 
DNA double strand breaks. Besides their role in cell cycle regulation, ATR and CHK1 have fork-protective 
functions that include inhibition of fork remodeling.103 SMARCAL1, an enzyme with remodeling actvity, is 
inhibited by ATR phosphorylation. This in turn protects DNA from processing by SLX4. CHK1 also phosphorylates 
Rad51, a key enzyme in homologous recombination repair. Rad51 is recruited to foci of DNA damage promoting 
repair. Another important function of activated CHK1 is the blockade of replication initiation factor CDC45, which 
slows down replication. This gains time for the cell to repair damaged DNA and to complete DNA synthesis.108 If 
DNA-damage cannot be repaired orderly, persistant cell cycle arrest leads to apoptosis or senescence.103 The 
effects of ATR activation are summarized in figure 24. 
While the PIKK kinase ATR has proven to be essential for the cellular response to DNA replication stress, two 
additional kinases of the PIKK family – ATM and DNA-PK – have an important role in the repair of DNA double-
strand breaks. Their contribution to DNA maintenance will be described in the following chapter. 
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Figure 24: ATR downstream signaling. ATR phosphorylates CHK1 which in turn phosphorylates phosphatases CDC25A, CDC25B and 
CDC25C. Thereby CDC25A is marked for ubiquitinylation and subsequent degradation. CDC25B and CDC25C are excluded from their 
target CDK1 by centrosomal or nuclear exclusion as result of phosphorylation, respectively. By degrading or relocating the CDC25A/B/C 
phosphatases CDK1 is kept in its inactive, phosphorylated state. CHK1 also activates WEE1 which phosphorylates CDK1 thereby inhibiting 
CDK1 activity. ATR activation leads to the activation of p53. As a consequence p21 is transcribed and CDK2 inhibited. Inactivation of 
CDK1/2 leads to cell cycle arrest. Through these processes cell cycle is regulated as indicated by the check symbol in the table. 
Phosphorylation of CDC25A by CHK1 leads to cell cycle arrest in G1, S or G2 phase, whereas the phosphorylation of CDC25B or CDC25C 
by CHK1 effects arrest in G2 as does CHK1-mediated WEE1 activation. p53 phosphorylation results in G1 arrest.  
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3.6.2. ATM and DNA-PK – Central Kinases in Double-Strand Break Repair 
 
Double-strand breaks can result from endo- and exogenous insults such as radiation, free radicals or 
radiomimetic drugs. In contrast to single-strand breaks, no template strand is available for the repair of the DSBs 
rendering DSBs the most hazardous DNA lesion. When DSBs are left unrepaired, termed residual DSBs, they are 
particularly lethal to the cells.112 ATM and DNA-PK both are involved in the repair of DNA double-strand breaks 
however through different molecular mechanisms. DNA-PK promotes the repair mechanism NHEJ which repairs 
most of the DNA double-strand breaks. Homologous recombination repair, which is promoted by ATM, is mainly 
used when double-strand breaks occur at replication forks.  
NHEJ is initiated when KU70 and KU80 bind to the ends of the double-strand. As a result, DNA-PK is recruited to 
the double strand and activated. This in turn leads to the recruitment of additional repair factors such as XRCC1, 
DNA ligase IV, XRCC1-like factor (XLF) and Artemis that help bringing the DNA ends closely together and 
religating the lesion.93 
HRR on the other hand is initiated by the MRE11-Rad50-NBS1 (MRN) complex that recruites and activates ATM. 
As a result, DNA ends are processed so that ssDNA is produced. Then Rad51 binds to the damaged strand and 
helps invading a sister chromatid strand to use it as a repair template.93 Activated ATM induces downstream 
signaling via phosphorylation of CHK2. CHK2 subsequently phosphorylates p53 resulting in transcription of CDK 
inhibitior p21 and G1 arrest. Additionally cell cycle arrest is accomplished through CHK2-mediated 
phosphorylation of CDC25 phosphatases.113 The cell cycle regulation mediated by ATM has a crucial role in 
preventing residual DSBs being taken into the next cell cycle phase.112 
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3.7. Objective of this Work 
 
A common modality to treat cancer besides surgery or radiotherapy is chemotherapy. However, 
chemotherapeutic agents target not only cancer cells but also normal cells. This lack of specificity towards the 
diseased tissue leads to off-target toxicities. Furthermore, chemotherapeutic agents often have to be applied at 
MTD to achieve a therapeutically relevant effect. As a result, chemotherapy is mostly applied as a drug cocktail 
to increase efficacy. But still, chemotherapy suffers from a narrow therapeutic window.114  
To overcome toxicity issues of conventional chemotherapy, the concept of ADCs gained momentum. These 
molecules promised to decrease off-target effects by selectively delivering the cytotoxic drug to the tumor 
tissues.115 ADCs open up the possibility to use highly potent drugs, that otherwise could not be used as 
therapeutic agents.116 However, second generation ADCs still had a narrow therapeutic window caused by 
technological problems. The ADCs used for example chemical conjugation techniques such as lysine conjugation 
or coupling to interchain cysteines. This led to heterogenous ADCs, varying in DAR and drug distribution. The 
conjugation of highly hydrophobic molecules resulted in ADC aggregation and fast clearance.18 Technological 
improvements such as reduction of hydrophobicity58 or site-specific conjugation techniques117 contributed to an 
improved therapeutic window of 3rd generation ADCs.118 Although much progress has been made, dose-limiting 
toxicities like neutropenia, thrombocytopenia or ocular toxicity still accompany ADC treatment.119 A graphical 
representation of the therapeutic window of ADCs compared to chemotherapy is depicted in figure 25 A. 
 
 
Figure 25: Schematic representation of the therapeutic window of single agent chemotherapy compared to A) 2nd and 3rd generation 
ADCs or B) combination chemotherapy. A) was adapted from Beck et al.18 
 
Another way of improving the therapeutic window is the treatment with more than one drug. Synergistic drug 
combinations have been shown to increase the efficacy of the treatment. This allows to decrease the dose while 
maintaining the efficacy. Lower doses however might decrease adverse events, especially if the toxicity profiles 
of the individual drugs differ. Furthermore, combination treatment might be designed to exert a certain 
selectivity for the diseased tissues.22 As a result, combination therapy potentially increases the therapeutic 
window of the therapy when compared to single agent chemotherapy (Figure 25 B). 
The goal of this work is the introduction of another treatment modality that combines the advantages of 
targeted therapy and combination therapy. Therefore ADCs shall be combined with small molecule drugs to 
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increase the efficacy of both drugs. A schematic representation of the expected therapeutic windows as 
surrogate for the safety of a treatment is depicted in figure 26.  
 
 
Figure 26: Scheme of expected therapeutic windows. Classical chemotherapy has a rather narrow therapeutic window. The therapeutic 
window of a drug can be improved by applying combination therapy or by targeting the drug specifically to the tumor tissues. The 
therapeutic window might be even further increased by using a combination of targeted therapy and combination therapy, namely 
targeted combination therapy. 
 
Since microtubule-targeting ADCs showed limited efficacy during clinical evaluation,39 the focus of this work is 
laid on DNA-damaging payloads. For the DNA-alkylating drug duocarmycin no combination therapy has been 
reported so far. Therefore, a drug combination screening will be performed with the small molecule DUBA to 
discover a synergistic combination partner for duocarmycin. The small molecules will be selected based on 
literature data suggesting a role in duocarmycin lesion repair. Subsequently, ADCs will be generated to study if 
synergistic drug combinations of small molecules might be translated to the ADC format. Finally, an in vivo 
xenograft model might be established to assess the safety profile of the combination treatment. 
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4. Methods and Materials 
 
4.1. Reagents 
 
Merck Millipore, Merck KGaA: 
Ammonium sulfate, Calcium chloride, Citric acid, Disodium hydrogen phosphate dihydrate, Dithiothreitol, 
glycerol, Kanamycindisulfate, Sodium chloride, Sodium dihydrogen phosphate hydrate, methanol, sodium azide, 
MilliQ-water, Triton X-100, Tween-20, hydrochloric acid 
 
Activate Scientific: 
Captisol 
 
Colorcon: 
K4Premium Methocel 
 
Calbiochem: 
Tris(hydroxymethyl)-aminomethan-hydrochloride (Tris-HCl) 
 
Sigma-Aldrich Laborchemikalien GmbH: 
Ampicillin sodium salt, Hydroxyurea, propidium iodide, 
 
Thermo Fisher, Gibco: 
DMEM high Glucose (no phenol red), DMEM GlutaMax, RPMI-1640 GlutaMax, 100 mM sodium pyruvate, goat 
serum, phosphate buffered saline (PBS) 1x and 10x, Lipofectamine RNAiMAX, 0,05% Trypsin-EDTA 
 
Invitrogen: 
Alexa Fluor® 488 F(ab')2 fragment of goat anti-rabbit IgG (H+L) 
 
Cell Signaling: 
Phospho-CHK1 (Ser345, 133D3) rabbit mAb 
 
Roth: 
Bovine serum albumin 
 
GE Healthcare: 
Accutase,  
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Dharmacon: 
5X siRNA buffer 
 
Pools of siRNA against CHK1 (CHEK1), ATR, PLK1 and a non-targeting siRNA was purchased from Dharmacon with 
the following sequences: 
 
siGENOME Human CHEK1 (1111) SMARTpool siRNA: 
GCAACAGUAUUUCGGUAUA 
GGACUUCUCUCCAGUAAAC 
AAAGAUAGAUGGUACAACA 
AGAUAUGAAGCGUGCCGUA 
ON-TARGETplus Human ATR (545) SMARTpool siRNA: 
GAGAAAGGAUUGUAGACUA 
GCAACUCGCCUAACAGAUA 
CCACGAAUGUUAACUCUAU 
CCGCUAAUCUUCUAACAUU 
ON-TARGETplus Human PLK1 (5347) SMARTpool siRNA: 
GCACAUACCGCCUGAGUCU 
CCACCAAGGUUUUCGAUUG 
GCUCUUCAAUGACUCAACA 
UCUCAAGGCCUCCUAAUAG 
siGenome Non-Targeting siRNA Pool #1: 
UAGCGACUAAACACAUCAA 
UAAGGCUAUGAAGAGAUAC 
AUGUAUUGGCCUGUAUUAG 
AUGAACGUGAAUUGCUCAA 
 
Antibody sequences 
 
Amino acid sequence of αHER2 antibody as published by drug bank accession entry DB00072 in the year 
2009.120 Genetic modifications are marked in bold font. 
 
Heavy chain: 
EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQM
NSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGA
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LTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPPKSCDKTHTCPPCPAPELLGGPSVFLFPPKP
KDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALP
APIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKS
RWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 
 
Light Chain with SrtA recognition motif: 
MKLPVRLLVLMFWIPASLSDIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGS
RSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKV
DNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECGGGGSGGGGSGGGGSLPET
GS 
 
Amino acid sequence of αEGFR antibody Cetuximab. Genetic modifications are marked in bold font. 
 
Native heavy chain: 
QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKM
NSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALT
SGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDT
LMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIE
KTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW
QQGNVFSCSVMHEALHNHYTQKSLSLSPGK 
 
Heavy chain with SrtA recognition motif  
QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKM
NSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALT
SGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDT
LMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIE
KTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW
QQGNVFSCSVMHEALHNHYTQKSLSLSPGKLPETGS 
 
Light chain with spacer and SrtA recognition motif: 
DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQ
QNNNWPTTFGAGTKLELKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDS
TYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECGGGGSGGGGSGGGGSLPETGS 
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Light chain with SrtA recognition motif: 
DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQ
QNNNWPTTFGAGTKLELKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDS
TYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECLPETGS 
 
Amino acid sequence of αHEL antibody. Genetic modifications are marked in bold font. 
 
Light chain with spacer and SrtA recognition motif: 
DIQMTQSPSSLSASVGDRVTITCRASGNIHNYLAWYQQKPGKAPKLLIYYTTTLADGVPSRFSGSGSGTDYTFTISSLQPEDIATY
YCQHFWSTPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSK
DSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECGGGGSGGGGSGGGGSLPETGS 
 
Native heavy chain: 
QVQLQESGPGLVRPSQTLSLTCTVSGFSLTGYGVNWVRQPPGRGLEWIGMIWGDGNTDYNSALKSRVTMLKDTSKNQFSLR
LSSVTAADTAVYYCARERDYRLDYWGQGSLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSG
VHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLM
ISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTI
SKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQ
GNVFSCSVMHEALHNHYTQKSLSLSPGK 
 
Amino acid sequence of αMETxEGFR antibody. Genetic modifications are marked in bold font. 
 
SEED GA heavy chain with scFv: 
DIQMTQSPSSLSASVGDRVTITCRASQSIGTNIHWYQQKPGKAPKLLIKYASESISGVPSRFSGSGYGTDFTLTISSLQPEDVATYY
CQQNYNWPTTFGQGTKVEIKGGGGSGGGGSGGGGSGGGGSEVQLVQSGAEVKKPGASVKVSCKASGFSLTNYGVHWMR
QAPGQGLEWIGVIWSGGNTDYNTPFTSRVTITSDKSTSTAYMELSSLRSEDTAVYYCARALTYYDYEFAYWGQGTLVTVSS 
 
SEED AG heavy chain: 
METDTLLLWVLLLWVPGSTGEVQLVQSGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYY 
ADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDRRITHTYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGC
LVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPC
PAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD
WLNGKEYKCKVSNKALPAPIEKTISKAKGQPFRPEVHLLPPSREEMTKNQVSLTCLARGFYPKDIAVEWESNGQPENNYKTTPS
RQEPSQGTTTFAVTSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKTISLSPGK 
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Light chain with SrtA recognition motif: 
METDTLLLWVLLLWVPGSTGEPVLTQPPSVSVAPGETATIPCGGDSLGSKIVHWYQQRPGQAPLLVVYDDAARPSGIPERFSG
SKSGTTATLTISSVEAGDEADYFCQVYDYHSDVEVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVA
WKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHKSYSCQVTHEGSTVEKTVAPTECSLPETGS 
 
Amino acid sequence of αMET antibody. Genetic modifications are marked in bold font. 
 
Light chain with SrtA recognition motif: 
METDTLLLWVLLLWVPGSTGEPVLTQPPSVSVAPGETATIPCGGDSLGSKIVHWYQQRPGQAPLLVVYDDAARPSGIPERFSG
SKSGTTATLTISSVEAGDEADYFCQVYDYHSDVEVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVA
WKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHKSYSCQVTHEGSTVEKTVAPTECSLPETGS 
 
Heavy chain: 
EVQLVQSGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLY 
LQMNSLRAEDTAVYYCAKDRRITHTYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNS 
GALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSV 
FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK 
CKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDS 
DGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 
 
Drugs 
 
Name No. Structure Provided by 
ATRi 1 1 
 
Lab. Dr. 
Dorsch 
AZ20 2 
 
Lab. Dr. 
Burgdorf 
AZD6738 3 
 
Lab. Dr. 
Jonczyk, 
Pharmacon 
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BAY1895344 4 
 
Lab. Dr. 
Burgdorf 
BAY286 5 
 
WuXi AppTec 
BAY73 6 
 
WuXi AppTec 
VE-822 (VX-970, 
M6620 
Berzosertib) 
7 
 
Lab. Dr. 
Burgdorf, 
VWR, Vertex 
Pharmaceutic
als Inc. 
 13 
 
Xdcexplorer 
Co., LTD. 
 24 
 
Xdcexplorer 
Co., LTD. 
 29 
 
Lab. Dr. Carl 
Deutsch 
 30 
 
Lab. Dr. Carl 
Deutsch 
 31 
 
Lab. Dr. Carl 
Deutsch 
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 32 
 
Moradec LLC. 
 33 
 
Xdcexplorer 
Co., LTD. 
 34 
 
Lab. Dr. Carl 
Deutsch 
 10 
 
Lab. Dr. Carl 
Deutsch 
KU-55933  
 
Selleck 
Chemicals 
LLC. 
M3814  
 
Lab. Dr. 
Fuchss 
NU7441  
 
Selleck 
Chemicals 
LLC. 
AZD7762  
 
Selleck 
Chemicals 
LLC. 
LY2603618  
 
ChemScene 
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Amuvatinib  
 
Selleck 
Chemicals 
LLC. 
AZD1775  
 
PharmaBlock 
Inc. 
Bleomycin A5  
 
Cayman 
Chemical 
Company 
Ciliobrevin D  
 
Merck KGaA 
Cmpd31  
 
Lab. Dr. 
Finsinger 
CP724714  
 
Biomol GmbH 
Etoposide  
 
Selleck 
Chemicals 
LLC. 
Hycanthone  
 
Prestwick 
Chemical Pc 
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Lapatinib  
 
AOKBIO Inc. 
Olaparib  
 
Lab. Dr. 
Fuchss 
Tranespimycin  
 
BioTrend 
Chemikalien 
GmbH 
TH588  
 
Lab. Dr. Ross 
Gemcitabine  
 
Cayman 
Chemical 
Company 
SN-38  
 
TCI Chemical 
Industry Co., 
LTD. 
MMAE  
 
Lab. Dr. Klein 
LD-1  
 
Moradec LLC. 
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LD-2  
 
Lab. Dr. 
Deutsch 
LD-3  
 
Lab. Dr. 
Deutsch 
LD-4  
 
Lab. Dr. 
Deutsch 
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LD-5  
 
Lab. Dr. 
Deutsch 
LD-6  
 
Lab. Dr. 
Deutsch 
LD-7  
 
Levena 
Biopharma 
LD-8  
 
Levena 
Biopharma 
12
4
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LD-9  
 
Lab. Dr. 
Deutsch 
 
Engelhart Pharmacy: 
Kadcyla, Herceptin 
 
4.2. Commercially available systems 
 
ExpiFectamine™ 293 transfection kit  Life Technologies Corp., Germany  
JetStarTM 2.0 Plasmid Purification Kit  Genomed GmbH, Germany  
QIAPrep Spin Miniprep Kit  Qiagen, Germany  
QuikChange® Site-Directed  
Mutagenesis Kit  
Stratagene, United States of America 
Gels and buffers for SDS-PAGE:  
NuPAGE 4-12% Bis-Tris Gel  
NuPAGE LDS Sample Buffer (4x)  
NuPAGE Sample Reducing Agent (10x) NuPAGE 
MES SDS running buffer (20x)  
Life Technologies Corp., Germany  
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4.3. Consumable material 
 
Cannula, Sterican 27G B. Braun Melsungen AG, Germany 
15 ml, 50 ml falcon tube  Becton Dickinson GmbH, Germany  
CellCulture Flasks adherent  Greiner Bio-One GmbH, Austria 
Centrifugal filter, Amicon® Ultra-4K and 15K  Merck Millipore, Merck KGaA, Germany  
HiLoadTM 16/600 SuperdexTM 200 pg column  GE Healthcare Europe GmbH, Germany  
HiTrapTM 1 mL Protein A HP column  GE Healthcare Europe GmbH, Germany  
HisTrapTM 1 mL HP and HisTrapTM 5 mL HP  GE Healthcare Europe GmbH, Germany  
NuPAGE® 4-12% Bis-Tris Gels  Life Technologies Corp., Deutschland  
Oral gavage Fuchigami, Japan 
PD-10 column  GE Healthcare Europe GmbH, Germany  
Polypropylene cap  Agilent Technologies, United States of America  
Polypropylene vial  Agilent Technologies, United States of America  
Safe Lock Tubes 0.2, 1.5, 2.0, 5.0 mL  Eppendorf AG, Germany  
Steriflip® Sterile filter 50 ml 0.22 and 0.45 μm  Merck Millipore, Merck KGaA, Germany  
Syringe, Imnifix-F B. Braun Melsungen AG, Germany 
 
4.4. Devices 
 
Chromatography system, ÄKTAxpress  GE Healthcare Europe GmbH, Germany  
Balance, NewClassic MF  Mettler-Toledo Intl. Inc., Swiss  
Cell counter, Vi-CELLTM XR  Beckman Coulter, United States of America  
Cell counter, Countess (lab. Blume) Thermo Scientific GmbH, Germany 
Cell disrupter, EmulsiFlex C3  Avestin Inc., Canada  
Centrifuge, Megafuge 1.0R  Heraeus Holding, Germany  
Centrifuge, Multifuge 3 S-R  Heraeus Holding, Germany  
Centrifuge, Sorvall® Evolution RC  Heraeus Holding, Germany  
Centrifuge 5415R and 5415D  Eppendorf AG, Germany  
Dispenser D300e Tecan Group Ltd., Switzerland 
High performance liquid chromatography, 1260 
Infinity (1290 autosampler)  
Agilent Technologies, United States of America  
Incubator, Heracell 150  Thermo Scientific GmbH, Germany  
Cell incubator, Heracell 240 (lab. Blume) Thermo Scientific GmbH, Germany 
Incubator, Kelvitron®  Heraeus Holding, Germany  
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Incubator, Reach-In CO2 Incubator Model3951  Thermo Scientific GmbH, Germany  
Plate reader, Synergy 4 BioTek, Inc., United States of America 
Plate reader, Envision 2104 multiplate reader Perkin Elmer Inc., United States of America 
LaminarAir Flow  Heraeus Holding, Germany  
Shaking incubator, Multitron HAT  Infors AG, Germany  
Magnetic stirrer, RCT basic  IKA®-Werke GmbH & CO. KG, Germany  
Microwave, Inverter  Sharp K.K., Japan  
Migration chamber  Life Technologies Corp., Germany  
NanoDrop ND-1000 spectrophotometer  Thermo Scientific GmbH, Germany 
Single channel pipets Eppendorf AG, Germany  
Shaker, Variomag Monoshake (lab. Blume) Thermo Scientific GmbH, Germany 
16-channel Viaflow II pipets INTEGRA Biosciences AG 
ThermoMixer F1.5  Eppendorf AG, Germany  
ThermoMixer comfort  Eppendorf AG, Germany  
Ultracentrifuge, Sorvall® RC-5C Plus  Heraeus Holding, Germany  
Ultra Confocal High Content Screening System, 
ImageXpress (lab. Blume) 
Molecular Devices, LLC, United States of America 
Washer, Powerwasher (lab. Blume) Tecan Group Ltd., Switzerland 
 
4.5. Buffer and Solutions 
 
Buffer for Hydrophobic Interaction Chromatography 
Buffer A: 1.5 M Ammoniumsulfat, 25 mM Tris, pH 7.5 
Buffer B: 20 % Isopropanol, 25 mM Tris, pH 7.5 
 
Buffer for Protein A chromatography 
Binding buffer: 150 mM NaCl, 20 mM Tris-HCl pH 7.5 
Elution buffer: 0.1 M citric acid pH 3.0 
Neutralization buffer: Tris-HCl pH 9.0 
 
Buffer for purification via SEC 
Mobile phase: PBS, pH 7.0 
 
Buffer for analytical SEC 
Mobile phase: 50 mM NaP, 0.4 M Na Perchlorate, pH 6.3 
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Reaction buffer 
150 mM NaCl, 50 mM Tris-HCl pH 7.5 
 
4.6. Antibody Expression 
 
The expression of antibodies is based on the protocol supplied for ExpiFectamineTM 293 Transfection Kit (Life 
Technologies Corp.). 1250 μL Opti-MEM are mixed with 80 μL Expifectamine and incubate for max. 5 min. 
Afterwards 12.5 μg of heavy and light chain plasmid are diluted in 1250 μL Opti-MEM. SEED-antibodies carry 
two different heavy chains. Heavy chain plasmid for GA- and AG-strand and light chain, are mixed in the mass-
ratio 1:1:1. Both solutions are united, forming reaction mixture, and incubated for 30 min. Meanwhile cell 
density of Expi293TM cells is determined using ViCell cell counter (Beckman Coulter). The cells were used if the 
viability is greater than 95%. Cells are diluted to 3.0x106 cells mL-1 in Expi293TM Expression Medium to a total 
volume of 21 mL, which was tempered at 37 °C. The reaction mixture is added to the cell suspension while 
shaking. The cells are shaken at 37 °C and 5% CO2. After 16-18 h 150 μL Enhancer 1 and 1.5 mL Enhancer 2 are 
added. The expression took place while shaking at 37 °C and 5% CO2 for four days. The antibodies are isolated 
by collecting the supernatant after centrifugation (6000 g/10 min/4 °C). The supernatant is filtered sterilely 
using Steritop 0.22 μm or Steriflip 0.22 μm filters (Merck Millipore, Merck KGaA). Antibodies are purified by 
proceeding with Protein A chromatography. This procedure can be scaled-up by keeping the ratios of reagents 
equal. 
 
4.7. Transformation 
 
Transformations were performed using 50 μL chemically competent cells, which were thawed on ice and 
subsequently mixed with 50 ng plasmid solution. After 30 minutes incubation on ice, the cells were tempered 
for 30 seconds at 42 °C. Afterwards 250 μL SOC-medium were added, followed by 45 minutes of incubation at 
37 °C while shaking. The cell suspension was centrifuged for 1 min at 16 krcf. The supernatant was discarded, 
whereas the cells were resuspended in the remaining solution. The suspension was plated on agar-plates, 
containing antibiotic. The plates were incubated overnight at 37 °C. 
 
4.8. Plasmid Amplification 
 
Plasmids were amplified by transformation of One Shot TOP10 Chemically Competent E. coli. The purification 
was performed using JetStarTM 2.0 Plasmid Purification Kit if high plasmid yield is needed for protein expression. 
The purification procedure began with harvesting of the overnight culture. The cells were lysed, followed by 
precipitation and centrifugation. The supernatant is applied on a pre-packed anion exchange column. Since the 
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deoxyribonucleic acid (DNA) backbone is negatively charged, the DNA is bound by the positively charged column 
matrix. A low salt washing step removes ribonucleic acid (RNA), carbohydrates and proteins. DNA was then 
eluted under high salt conditions. By precipitation of DNA using alcohol, the DNA was desalted.  
For the amplification of plasmid for sequencing purposes QIAPrep Spin Miniprep Kit was used. The purification 
procedure is comparable to JetStarTM 2.0 Plasmid Purification Kit procedure, but DNA is adsorbed to the silica 
membrane of QiaPrep columns at high salt concentrations and eluted at low salt concentrations. 
 
4.9. ADC Generation 
 
The conjugation of linker-drugs can be achieved using several techniques. Some of these techniques require 
prior modification of the antibody. The antibody formats used in this thesis are depicted in figure 27. Formats 
A, B and C are designed for enzymatic modification using sortase A. In the case of format A and B, a conventional 
IgG molecule is elongated C-terminally by a (G4S)3-spacer and the sortase A recognition sequence LPETGS or by 
the sortase A recognition sequence LPETGS only. Format C is a bispecific antibody-format generated using the 
strand-exchange engineered domain (SEED) technology. This allows to combine a scFv and a Fab portion that 
bind to different antigens. Additionally, the Fab is elongated C-terminally by the sortase A recognition motif 
LPETGS. Format D enables the production of ADCs with up to four drugs per mAb. Therefore LCs contain (G4S)3-
spacer and the sortase A recognition sequence LPETGS and the HCs are extended C-terminally by the SrtA 
recognition motif LPETGS. For the conjugation of maleimide containing linker-drugs native mAbs (format E) can 
be utilized.  
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Figure 27: Antibody formats used in this thesis. A) LCs of antibody are elongated C-terminally by the motif (G4S)3LPETGS. B) LCs of antibody 
are elongated C-terminally by the motif LPETGS. C) SEED antibody carrying scFv on one chain, and a Fab on the other chain. The Fab is 
elongated C-terminally by a LPETGS sequence. D) Antibody carrying a total of four SrtA sites. A (G4S)3LPETGS SrtA recognition motif is 
fused C-terminally to the LCs, and a LPETGS sequence C-terminally to the HCs. E) Native mAb.  
 
During this work, several purification methods were used, which are summarized in figure 28. After conjugation 
of the mAb using either thiol coupling or enzymatic conjugation via SrtA, the crude ADC mixture needs to be 
purified to deplete excess linker-drug, conjugation reagents or enzymes. A convenient strategy is the purification 
via preparative SEC (route A), which diretly yields a purified ADC. The use of Protein A chromatography always 
implies additional purification step that exchange the buffer to ensure ADC storage in an appropriate buffer. 
Therefore, Protein A chromatography is followed by desalting (route B). However, this method further dilute 
the sample, which might require a concentration step (route C). Another route uses Protein A chromatography, 
followed by desalting. If aggregates are present, prepartive SEC can be used to deplete high molecular species. 
Due to dilution of the sample, concentration yields the purified ADC (route D). 
 
SGTEPL
LPETGS(G4S)3
LPETGS(G4S)3SGTEPL
SGTEPL
A B C
(G4S)3 LPETGS(G4S)3SGTEPL
D
SGTEPL LPETGS
E
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Figure 28: Purification routes for the generation of ADCs. The linker-drug is conjugated to yield a crude ADC mixture. Purification can be 
achieved via several routes. A) Preparative SEC. B) Protein A chromatography and desalting to change the buffer. C) Protein A 
chromatography, followed by desalting to exchange the buffer. Subsequently, the ADC mixture can be concentrated again. D) Protein A 
chromatography, followed by desalting to exchange buffer. Aggregates can be removed by preparative SEC, and the sample can be 
concentrated. These routes yield a purified ADC. 
 
4.10. Sortase A-Mediated Conjugation Reaction  
 
The reaction is carried out using 10 equivalents of oligo-glycine cytotoxic substrate per SrtA recognition motif of 
the antibody. 0.37 equivalents Sortase A are applied compared to antibody. Sortase A has a binding site for 
calcium ions. The binding of calcium ions slows the motion of Sortase A, thereby allowing the binding of the 
substrate to Sortase A. This leads to an eightfold increase in activity.121 
 
13.5 μM (1 eq) antibody construct  
5 mM (375 eq) CaCl2  
133 μM (10 eq) oligo-glycine substrate per SrtA recognition motif.  
5 μM (0.37 eq) eSrtA  
 
The reagents and buffer are mixed in the described manner. The reaction mixture is diluted with reaction buffer 
to adjust the given concentrations. The reaction is performed by incubation of the mixture at 22 °C for 30 
minutes. The addition of SrtA marks the start of reaction. The reaction is stopped by addition of 750 eq EDTA, 
Conjugation
Protein A
chromatography
Desalting
Final product
Concentration
n n
Protein A
chromatography
Desalting
Preparative SEC
Protein A
chromatography
Desalting Preparative SEC Concentration
A
B
C
D
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which removes free calcium ions from the solution by forming a complex. The final concentration of antibody in 
solution is adjusted to 13.5 μM by addition of a sufficient amount of buffer. 
 
4.11. Protein A Chromatography 
 
The basis for the purification of IgG antibodies is the high binding affinity of Staphylococcus aureus protein A to 
the Fc region of IgG-type antibodies. The binding between protein A and IgG antibodies takes place at 
physiological pH and ionic strength, whereas the binding is disrupted at low pH resulting in elution of the 
antibody. It was shown, that IgG molecules usually elute at pH 3.0.122 
Antibody purification: Preparative protein A-affinity chromatography was performed on ÄKTAXpress (GE 
Healthcare) chromatography system using HiTrapTM 1 mL of 5 mL Protein A HP column (GE Healthcare). Upon 
binding of the antibody to the column, it was washed with binding buffer. Afterwards elution was performed in 
one step by washing the column with 100 % elution buffer. The antibody was eluted in 1.5 mL fractions onto 
100 μL neutralizing buffer into a 96-deepwell plate. The fractions were analyzed using SDS-PAGE regarding purity 
and pooled accordingly. 
ADC purification: ADCs were purified as described before, but on an ÄKTA Purifier (GE Healthcare) 
chromatography system using HiTrapTM 1 mL 5 mL Protein A HP column (GE Healthcare). The sample was applied 
on the column using an autosampler by SunChrom. Fractions of 1 mL were eluted into 1.5 mL tubes containing 
100 µL neutralization buffer. ADC containing fractions were pooled. 
 
4.12. Preparative SEC 
 
The separation principle of SEC is based on differences in elution time of analytes caused by differences in their 
size. The stationary phase of the SEC column is composed of spherical particles, which have pores. Small 
molecules can diffuse into the pores, while larger molecules cannot enter the pores and pass through the matrix 
directly. This leads to an elution of the largest molecules first, followed by smaller molecules in the order of their 
size.122  
In the course of this work SEC was used to remove aggregates from antibody preparations, as well as to separate 
ADCs from conjugation reagents such as enzyme Sortase A and toxin excess. SEC purification was carried out on 
a Agilent 1260 HPLC system (Agilent Technologies). The flow rate was 0.5 mL min-1 and the samples were 
separated using a Superdex 200 10/30 increase column (GE Healthcare). Samples were eluted in 0.5 mL fractions 
and pooled to yield the final product. Preparative SEC for the preparation of αHER2-1 purified via route D was 
performed on ÄKTAXpress (GE Healthcare) chromatography system using HiLoadTM 16/600 SuperdexTM 200 pg 
column. Therefore the column was washed with water with subsequent equilibration with the mobile phase. 
After injection, the sample was eluted isocratically at a flow rate of 1 mL min-1 and peaks are collected 
fractionating. 
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4.13. Analytical HIC 
 
The drug-to-antibody ratio (DAR) of an ADC can be determined using hydrophobic interaction chromatography 
(HIC). Therefore, proteins are applied in an aqueous mobile phase containing high concentration of chaotropic 
salt. The individual proteins bind to the stationary phase based on their hydrophobicty and are eluted by gradual 
reduction of salt content in the order of least to most hydrophobic.123 The different ADC species and unreacted 
mAb are separated based on the drug-load. The weighted area-under-curve of the chromatogram can be used 
to calculate the DAR of the ADC. A representative chromatogram is depicted in figure 29. 
 
Figure 29: Hydrophobic interaction chromatogram of an ADC. The ADC was prepared using interchain cystein conjugation. This led in the 
formation of a heterogenous mixture of mAb and ADCs with a DAR of 2,4,6 and 8. Figure copied from HIC column catalogue123. 
 
All samples were prepared by dilution to a final concentration of 1.5 M ammonium sulfate using sample 
preparation buffer. Analytical HIC of Sortase A-generated ADCs was performed using HPLC-system (Agilent 
Technologies) which was equipped with MAB PAK Butyl, 4.6x50 mm column (Thermo Scientific). The UV-VIS 
detector used wavelengths 220 nm and 280 nm. Measurements were performed at a flow rate of 1 mL min-1 
applying a gradient of 0 to 100 % buffer B in 20 min. The HPLC-runs were performed at 30 °C. The column was 
washed subsequently with 100 % buffer B. Data were processed using ChemStation of LC 3D systems (Agilent 
Technologies). 
 
4.14. Analytical SEC 
 
The monomeric content of mAb and ADC samples was determined by analytical SEC. It was performed on Infinity 
1260 HPLC system by Agilent Technologies with a TSK-GEL Super SW 3000 SEC 4.6 x 300 mm column. Elution 
was performed isocratically at a flow rate of 0.35 mL min-1. 
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4.15. Buffer Change 
 
The change of buffer is performed using PD-10 Desalting Columns (GE Healthcare), which contain Sephadex G-
25 Medium. The underlying chromatography method is size exclusion chromatography, where the sample is 
separated based on the size of the molecules.122 The elution of proteins often uses harsh buffer conditions that 
may lead to a decrease in quality of the protein sample. As a consequence buffer has to be changed for storage. 
For desalting the column was equilibrated by application of three column volumes storage buffer. Then 2.5 mL 
protein solution were applied on the column, followed by elution using 3.5 mL storage buffer into a fresh falcon. 
 
4.16. Thawing of Mammalian Cancer Cells  
 
The cells provided as cryovial at -80 °C were thawed in a water bath at 37 °C until the ice was dissolved. The cells 
were resuspended and transferred to a 50 mL falcon tube. The cell suspension was centrifuged 
(5 min/500 rpm/RT). The supernatant was removed in vacuo and the pellet was resuspended in 5 mL cell culture 
medium. At this point, cells were either used in a cytotoxicity assay directly, or were given into a T75 flask 
containing 10 mL cell culture medium. 
 
4.17. Culturing of Mammalian Cancer Cells 
 
The cells were usually cultured in T75 cell culturing flasks in an incubator at 37 °C in a 5% CO2 humid atmosphere 
and passaged every 3 to 4 days. For passaging, medium was removed in vacuo, cells were washed with PBS (3x) 
and 1 mL 0.05% Trypsin-EDTA were added. The completion of the detachment reaction was examined visually. 
When all cells were detached, 9 mL medium were added to the cells to stop the detachment reaction. Depending 
on the growth rate of the cells, they were splitted 1:2 to 1:4 and reseeded into a fresh T75 flask containing 10 mL 
of medium. The cells were incubated in an incubator at 37 °C in a 5% CO2 humid atmosphere afterwards. Cell 
culturing media and quality control are summarized in appendix 1 and appendix 2, respectively. 
 
4.18. Curve-Shift Assays 
 
In the past chapters, the synergy of duocarmycins and duocarmycin-bearing ADCs with ATR inhibitors was 
displayed. In this chapter, potentiation effects of duocarmycin-bearing ADCs with ATRi were studied to further 
elucidate the synergistic effects. Therefore a curve-shift assay system was established which is depicted 
schematically in figure 30. In a first step, a dose-response curve (DRC) is obtained by treating a certain cell line 
with an inhibitor. The maximum non-efficacious dose (MNED) can be derived from this DRC. MNED is the highest 
dose, that can be added to a certain cell line without affecting the viability. The activity of the ADC is confirmed 
in a separate experiment. Finally, a combination experiment can be conducted. Therefore, the ADC and ADC 
plus inhibitor at MNED are added to the cells. The inhibitor is tested in parallel at MNED as a control. Due to the 
   58 
application of inhibitor at MNED, no reduction in cell viability caused by the inhibitor is expected. Three 
outcomes are possible: 1) The combination of ADC plus inhibitor is equipotent as the ADC only. This would 
suggest additive effects only. 2) The combination of ADC plus inhibitor is less potent than the ADC alone. Such a 
result would be interpreted as depotentiation. 3) The combination of ADC plus inhibitor is more potent than the 
ADC alone. In this case, the potency of the ADC is potentiated. 
 
 
Figure 30: Set-up for curve shift assay. Dose-response curves are depicted to explain the general experimental set-up for curve-shift 
assays. 
 
Potentiation effects are expressed as dose-reduction indices (DRI), which can be calculated by dividing the IC50-
value of ADC by the IC50-value of ADC plus inhibitor according to eq. 2. 
 
 𝐷𝑅𝐼 =  
𝐼𝐶50 𝑜𝑓 𝐴𝐷𝐶 
𝐼𝐶50 𝑜𝑓 𝐴𝐷𝐶 𝑝𝑙𝑢𝑠 𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑜𝑟
 Eq. 2 
 
Curve-shift assays were conducted as follows: The cell number and viability was determined using ViCellTM-XR 
(Beckman Coulter) and seeded in opague 96-well plate (10k viable cells/well). After seeding, the plate was 
incubated (37 °C, 5% CO2) in a humid chamber overnight. Compounds were diluted in the appropriate medium, 
added to the cells and the plate was incubated (37 °C, 5% CO2, 6 d) in a humid chamber. After 30 min 
equilibration at room temperature, CellTiter-Glo reagent (Promega) was added. After the plate was shaken 
(3 min, 550 rpm, rt) it was incubated (10 min, rt) and luminescence was read on a synergy 4 plate reader 
(BioTek). Evaluation was performed using GraphPad Prism version 6.05. Therefor luminescence values were 
normalized to luminescence values of non-treated cells and dose-response was fitted with 4-point logistic fit. 
 
4.19. Dose-Matrix Assays 
 
Dose-matrix combination assays were performed as described above, but performed in opague 384-well plates 
(2k viable cells/well). Compounds were added using Tecan D300e liquid. Protein solutions were supplemented 
with 0.3% Tween-20 (final) and diluted to 1 µM. All wells were normalized to the maximum amount of DMSO 
(maximum 0.4%) or Tween-20 added. Read out of luminescence was performed on Envision 2104 Multilabel 
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Reader (Perkin Elmer) and data were evaluated using Genedata Screener® version 14.0.6-Standard (Genedata 
AG). Luminescence values were normalized to luminescence of non-treated cells and dose-response was fitted 
using Smart Fit. Synergy scores were calculated using LOEWE synergy model. 
 
4.20. Knock-Down Experiments 
 
0.7*106 viable cells were seeded in a T25 flask, 5 mL of medium were added and the cells were incubated at 37 
°C and 5% CO2 overnight. The transfection was carried out as follows: 2.5 µL Lipofectamine RNAiMAX were 
diluted with 247.5 µL OptiMEM and a 0.3 µM siRNA (ATR, CHK1 or non-targeting siRNA) solution was prepared 
in OptiMEM to yield 250 µL final volume. The solutions were mixed and incubated for 20 min at room 
temperature, followed by the addition of 500 µL cell culture medium. The cell culture medium was removed 
from the cells, washed with PBS (3x) and the transfection mix was added to the cells. After 4 h incubation at 37 
°C and 5% CO2, the transfection mix was removed in vacuo. The cells were washed with medium (3x), 5 mL 
medium were added and the cells were incubated for 60 h at 37 °C and 5% CO2. Then cells were detached, and 
seeded into 384-well plates. Then a cytotoxicity assay was performed as described before in chapter 0, but with 
one compound only. 
 
4.21. Statistical Analysis 
 
Statistical analysis was performed using the two-sided T.TEST formula in Microsoft Excel assuming unequal 
variance. The Null hypothesis for curve-shift assays was that the combination of two compounds is equally 
cytotoxic as the single agents alone. The Null hypothesis for synergy experiments was that the two combinations 
are equally synergistic. Graph annotations: *: P<.05, **: P<.01, ***: P<.001, ****: P<.0001. 
 
4.22. Xenograft Experiment 
 
Female H2d Rag2 mice, 6-8 weeks old, were obtained from Taconic Biosciences, LLC. A xenograft was established 
by harvesting NCI-N87 cells from cell culture, mixing the cells 1:1 with Matrigel and injecting 2.5x106 cells 
subcutaneously into the flank of the mice. The tumor volume was assessed twice weekly by length 
measurements in two dimensions using calipers. The volume was calculated following eq. 3 where the length L 
is the longest tumor length and W is the shortest tumor length. 
 
 𝑉𝑡𝑢𝑚𝑜𝑟 =  
𝐿 ∗ 𝑊2 
2
 Eq. 3 
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After an initial tumor growth phase, mice were randomized and assigned to treatment groups comprising 10 
animals. The initial tumor volume amounted to approximately 100 mm³ when treatment started. Vehicle 
treated mice obtained a solution of 0.5% Methocel, 0.25% Tween-20 in water. A single dose of 1.0 mg/kg ADC 
αHER2-6 dissolved in 10 mM histidine, 8% trehalose, 0.05% Tween-20, pH 6.0 buffer was given intravenously 
into the tail vein. The 50 mg/kg AZD6738 and ATRi 1 were given per oral dissolved in 0.5% Methocel, 0.25% 
Tween-20 in water once daily for two weeks. Mice were weighted twice weekly to assess the body-weight during 
the treatment period. The criteria to terminate the study for single animals were skin ulzerations, tumor length 
exceeding 15 mm or tumor exceeding 10% of the body weight. In addition, body weight loss was a criterium for 
termination if body weight loss exceeded 20% accompanied with a haggard appearance, body weight loss 
exceeded 20% on three successive days or if body weight loss exceeded 25% of the adjusted body weight. 
Treatment groups were completely terminated if less than eight animals/group were left and therefore no 
statistical analysis could have been performed. The tumor response criteria were as follows: 1) treatment result 
was termed tumor progression if the change in tumor volume was > 73% at the end of the observation phase 
compared to the start of treatment. 2) Tumor stasis was reached if the tumor volume change was between -
66% and 73% of initial tumor size at the end of treatment. 3) A tumor reduction of more than 66% at the end of 
treatment was termed regression. 4) Treatment result was termed complete regression if the tumor was non-
palpable or < 20 mm³ at the end of treatment. The study was executed by Louisa Huettel and directed by Ana 
Hecht. 
 
4.23. Cellular CHK1 Phosphorylation Inhibition 
 
This assay was performed in the laboratory of Beatrix Blume, department of Cellular Pharmacology, Merck KGaA. 
3500 HT29 cells (medium see appendix 1) per well were seeded in 30 µL into a black 384-well plate. Cells were 
incubated for 1 h at 22 °C followed by overnight incubation at 37 °C, 10% CO2, and 90% relative humidity. Serial 
dilutions of ATRi were added to the cells simultaneously with hydroxyurea at a final concentration of 3 mM. 5 µL 
7X PBS/HEPES were added and DMSO yielding 0.5% final. The plate was incubated for 4 h at 37 °C, 10% CO2, and 
90% relative humidity. Supernatant was removed using Tecan-Powerwasher. Cells were fixed by the addition of 
30 µL/well 4% poly-formaldehyde in PBS and subsequent incubation for 15 min at 22 °C. Cells were washed once 
with 80 µL PBS and supernatant was removed using Tecan Powerwasher. 40 µL per well -20 °C cold methanol 
were added and it was incubated 10 min at 22 °C. Cells were washed once with 80 µL PBS and supernatant was 
removed using Tecan Powerwasher. 30 µL per well of 0.2% Triton solution in PBS were added to the cells and it 
was incubated for 10 min at 22 °C. Cells were washed once with 80 µL PBS and supernatant was removed using 
Tecan Powerwasher. 25 µL of 10% goat serum, 1%BSA, 0.1% Tween-20, 0.1% sodium azide in PBS were added 
and it was incubated for 60 min at 37 °C. The supernatant was removed and it was stained with 25 µL 1° antibody 
(phospho-CHK1 (Ser345, 133D3) rabbit mAb) in 1% BSA, 0.1% sodium azide in PBS overnight at 4-8 °C. It was 
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washed trice with 80 µL PBS and the supernatant was removed. 25 µL 2° antibody (Alexa Fluor® 488 goat anti-
rabbit F(ab')2 fragment) and 0.2 µg/mL propidium iodide in 1% BSA, 0.1% sodium azide in PBS were added. The 
plate was incubated for 60-90 min at 37 °C. It was washed trice with 80 µL PBS and 80 µL PBS supplemented 
with 0.1% sodium azide were added. The plate was sealed with transparent adhesive seals. Images were aquired 
at IMX Ultra and images were analyzed using Metaexpress 5.3. 
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5. Results 
 
5.1. Screening for Synergistic Drug Combination Partner for Duocarmycins 
 
The screening of synergistic drug combinations can be accomplished by performing a dose-matrix assay. 
Therefore, two drugs are serial diluted and mixed at every dose level, yielding a dose-matrix. The drug 
combination can be additive if the effects of the combination are identical to the added effects of the single 
agents. However, the effects of the combination might also be stronger than the activity of the single agents. 
This scenario is termed synergy, whereas weaker combination effects compared to the single agents are termed 
antagonism. A dose-matrix assay is depicted schematically in figure 31 which illustrates the outcomes of a dose-
matrix assay: additivity, antagonism and synergy. 
 
 
Figure 31: Scheme of experimental set-up of dose-matrix assays for the determination of synergy scores. Serial dilutions of DUBA with 
increasing concentrations from left to right and serial dilutions of the DDRi from top to bottom are added to cells alone or in combination. 
The cells respond to the treatment strongly (dark) or weakly (light). Three cases have to be considered: 1) Additivity: The compounds do 
not interact and the resulting response of the cells does not exceed the response of the single agents. 2) Antagonism: The effect of the 
combination is weaker than the effect of the single agents. 3) The response to the combination treatment is stronger than the effect of 
the single agents. 
 
The screening was conducted by serial diluting the duocarmycin derivative DUBA (10) and the DDRis. The serial 
dilutions were added to HCC-1954 or MDA-MB-468 cells either alone or in combination subsequently. Figure 32 
illustrates the process of the determination of synergy scores examplarily. DUBA was combined in a dose-matrix 
assay with hycanthone (Figure 32 A). The cell viability was measured after 6 d of treatment using the CellTiter-
Glo assay kit. The signals of the cell viability assay were normalized to untreated cells and fitted. Subsequently, 
a prediction of additive effects according to Loewe additivity model was calculated for every dose-pair of DUBA 
and DDRi based on single agent activity. By substracting the modeled data from the fitted data, an excess matrix 
was generated. The excess matrix can be considered as a visualization of the differences between model and 
actual data which also highlights spots of either high synergy or antagonism. The quantification of the 
combination effects, however, was performed by calculating synergy scores. Thererfore, a weighted volume 
between the model and the fitted actual data was calculated using the GeneData Screener software which is 
expressed as a synergy score (S) according to the definition of the synergy score by Krueger et al.22 In case of the 
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combination of DUBA and Hycanthone, the synergy score amounts to 0.1 indicating addtivity. The same 
procedure was repeated for the combination of DUBA and AZD6738 (Figure 32 B). The excess matrix identified 
a hotspot of additional cytotoxicity at concentrations of 160 to 630 nM AZD6738 and 0.16 to 0.039 nM DUBA. 
In this range the activity of the combination killed up to 69% more of the cancer cells than the combination 
would have killed if the combination was additive. The additional cell cytotoxicity of the combination translated 
into a synergy score of 7.6. Besides synergy score, the potency of the drugs in monotherapy was obtained from 
these experiments. When plotting the activity data of the drugs DUBA and AZD6738 against the corresponding 
concentrations (Figure 32 B, green and violet box), a dose-response is yielded which was fitted using a logistic 
function. The potency was obtained from this dose-response curve. The resulting dose-response curves are 
depicted in figure 32 C.  
The scattering of S was determined in a sham control experiment to define a cutoff for classifying a combination 
as truly synergistic or antagonistic. Thus seven different compounds were combined with itself on four different 
cell lines and the three-σ confidence interval was calculated around the mean of the measurement. According 
to these experiments, a combination with S in the range 0.6 to -0.7 had a probability of 99.7% to be additive. 
For the sake of convenience the cutoff was set to a value of ±1. 
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Figure 32: Route to synergy scores based on GeneData Screener data evaluation. Cells were treated with a dose-matrix of Hycanthone 
and DUBA or AZD6738 and DUBA. The assay was developed using the CellTiter-Glo kit. Finally, data were loaded into GeneData Screener 
and data were normalized to untreated cells. A) Data of the combination of DUBA plus Hycanthone. The signals were fitted and model 
data were generated based on LOEWE synergy model. Therefore, single agent data were used to predict signals that would arise if the 
combination was additive. By subtracting the model from the fitted data, an excess matrix is generated that visualizes differential effects 
between the data obtained from the experiment and the model of additivity. The excess matrix has excesses ranging from plus to minus 
single digit activities. The combination of Hycanthone and DUBA led to a synergy score of 0.1 indicating additivity. B) Combination data 
of DUBA combined with AZD6738. Data were handled as in A. The excess matrix shows maximum excess activities of around -69 indicating 
a strong deviation of the data from the model. The combination of DUBA with AZD6738 is synergistic with a synergy score of 7.6. C) Dose-
response curve of DUBA (green) and AZD6738 (violet). The data are obtained from fitted data in B by plotting the activity of either drug 
against the logarithm of the dose when given alone to the cells. 
 
Synergy scores (S) were obtained from the combination experiments that indicated additivity (-1>S<+1) if model 
and actual response were equal. If the actual response exceeded the model, a combination was synergistic (S>1) 
while it was antagonistic (S<1) if cells treated with the combination responded weaker compared to the single 
agents than to the combination treatment. The magnitude of the score determined the extent of the 
combination effects. 
A low-throughput screening was performed to identify a synergistic combination partner for duocarmycin. 
Therefore, 17 small molecule DNA damage response inhibitors (DDRis) were selected that were either 
interfering with DNA damage repair, cell cycle regulation, DNA remodeling or that induced DNA damage based 
Alkylator DDRi Valid qAC50 [M] nHill R²
DUBA ☑ 3.190E-10 1.39 0.999
AZD6738 ☑ 2.272E-6 1.814 0.9888
A 
B 
C 
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on literature data indicating a potential role in the repair of duocarmycin-induced lesions. The inhibitors with 
corresponding target and mode auf action are summarized in table 2.  
 
Table 2: Inhibitors used in the screening. Target enzyme and mode of action of each inhibitor are listed and a class is assigned according 
to the function of the enzyme. 
Inhibitor Target Mode of action Class 
Amuvatinib multiple tyrosine kinases124 Decreased Rad51 expression124, thus impairing HR125 
DNA repair 
 
Lomeguatrib 
O6-alkylguanine-DNA-
alkyltransferase126 
Removes alkylation adducts at O6 of guanine126 
NU7441 DNA-PK127 Double-strand repair127 
Olaparib PARP97 SSB sensing97 
Tanespimycin  
Downregulation of ERCC1 mRNA128, required in 
NER129 
TH588 MTH1130 Oxidation damage repair131 
AZD1775 WEE1132 
Blocking of G2/M transition for elongated period of 
time for DNA repair133 
Cell cycle 
 
AZD6738 ATR133 Cell cycle and DNA damage response regulation133 
AZD7762 CHK1133 Cell cycle arrest, DNA repair regulation133 
cmpd31 NEK1134 Essential for ATR activity135 
KU-55933 ATM133 Impaired HR and NHEJ133 
LY2603618 CHK1133 Cell cycle arrest, DNA repair regulation133 
Bleomycin A5  induces double strand breaks136 DNA damage 
Etoposide TOP2137 Double-strand breaks137 DNA remodeling 
CP-724714 HER2138 HER2 inhibition impairs ATR activation138 Other 
Hycanthone  RNA synthesis inhibitor Other 
Lapatinib HER2/EGFR139 HER2 inhibition impairs ATR activation138 Other 
Ciliobrevin D Cytoplasmic dynein140 
Intracellular trafficking hinders delivery of repair 
enzymes141 
Protein transport 
 
First, inhibitors were selected that were directly involved in DNA repair. Fork collapse as a result of duocarmycin-
induced replication fork stalling might lead to double-strand breaks.142 Thus, it was hypothesized that inhibitors 
of repair pathways involved in the repair of double-strand breaks might synergize with duocarmycin. Therefore 
amuvatinib, a down-regulator of homologous recombination repair, the ATM inhibitor KU-55933 or the DNA-PK 
inhibitor NU7441 were combined with duocarmycin. The synergy score of KU-55933 plus DUBA exceeded the 
cutoff for synergy on HCC-1954 cells (S=2.1±1.2) barely, indicating either off-target inhibition or the formation 
of double strand breaks as a result of duocarmycin-treatment. The combination of duocarmycin-variant DUBA 
with DNA-PKi NU7441 or amuvatinib did not yield a synergy score exeeding the cutoff. 
Besides the inhibition of double-strand repair, Bleomycin A5 and the topoisomerase II inhibitor Etoposide were 
combined with DUBA to overload repair capacities. On HCC-1954 cells Bleomycin A5 combined with DUBA 
exceeded the cutoff barely (S=1.6±1.0) while the combination was in the range of additivity on MDA-MB-468 
cells (S=0.4±1.0). The combination of Etoposide with DUBA led to additive effects on both HCC-1954 (S=-0.7±0.5) 
and MDA-MB-468 cells (S=-0.3±0.2). 
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The second group of selected DNA repair inhibitors was involved in the repair of damaged bases. Base excision 
repair is required for the direct removal of bulky DNA lesions. It was shown, that the base excision repair enzyme 
DNA glycosylase AlkD of Bacillus cereus mediates the removal of lesions caused by the duocarmycin-analogue 
yatakemycin.143 Therefore, the effects of inhibiting a human glycosylase using the O6-alkylguanine-DNA-
alkyltransferase inhibitor Lomeguatrib were studied. Only weak synergistic effects with high variance were 
observed when Lomeguatrib was combined with duocarmycin on the cell line MDA-MB-468 (S=2.8±2.3) while 
additivity was observed on HCC-1954 cells (S=0.1±1.3). In addition to Lomeguatrib another BER inhibitor, TH588, 
was combined with DUBA. TH588 inhibits MTH1, which is involved in the resection of oxidatively damaged 
bases.130,131 However, on HCC-1954 (S=-0.2±0.3) and MDA-MB-468 cells (S=-0.4±0.3) additive effects were 
observed. 
The repair pathway for the removal of damaged nucleobases is nucleotide excision repair (NER). It plays a role 
in the repair of duocarmycin alkylation lesions. In the presence of helicase II and DNA polymerase I, CC-1065 
(15) lesions were excised by ABC excinuclease.144 However, NER was not recruited of cell extracts of NER-
proficient HeLa cells.145 Only few NER inhibitors were commercially available, so the HSP90 inhibitor 
Tanespimycin was studied in combination experiments. The inhibitor down-regulated expression of ERCC1, a 
key enzyme in NER.128 On HCC-1954 the combination of DUBA with Tanespimycin (S=1.4±0.4) exceeded the 
cutoff.  
A more general approach that impairs DNA damage repair was decreasing the capacity of the cells to import 
DNA damage response proteins to the nucleus. Microtubule-targeting agents like vincristine inhibited the 
translocation of the DNA repair enzymes to the nucleus leading to an accumulation of the proteins in the 
cytoplasm.141 It was hypothesized that, upon duocarmycin-treatment, the dynein inhibitor ciliobrevin D might 
hinder the transport of the DNA damage response enzymes to the nucleus and thereby increase the 
accumulation of DNA damage. However, the combination of ciliobrevin D with duocarmycin-derivative DUBA 
exceeded the cutoff only barely on the cell line HCC-1954 (S=1.2±0.6) while on MDA-MB-468 cells additive 
effects were observed (S=0.2±0.5). These results were in line with the combination experiments of the 
microtubule inhibiting ADC Kadcyla plus AZD6738. The synergy scores of Kadcyla combined with AZD6738 were 
S=1.1±0.3 on MDA-MB-453 and S=0.3±0.2 on NCI-N87 cells indicating only additivity. 
The third group of studied inhibitors included drugs that abrogate checkpoint regulation. The WEE1 kinase is 
involved in checkpoint regulation. Activity of WEE1 lengthens the G2 phase to gain time for the repair of DNA 
damage accumulated in S phase. When WEE1 is inhibited by AZD1775, the G2/M checkpoint is abolished which 
leads to the cells entering mitosis. WEE1 inhibition synergizes with CHK1/2 inhibition in patient-derived 
xenograft models in mice and generally sensitizes cells for treatment with DNA damaging agents.133 The 
combination of DUBA and AZD1775 was additive in our study on HCC-1954 (S=0.8±0.1) and MDA-MB-468 
(S=0.1±0.4) cells. The enzyme PARP1 plays an important role in several repair pathways like homologous 
recombination repair, non-homologous end joining and also base-excision repair. Furthermore, it binds to 
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stalled-replication forks (SRFs) and is activated by the presence of SRF. Cells lacking PARP1 are sensitive to 
treatment with hydroxyurea and excess thymidine which causes replication fork collapse or stalling, 
respectively.146 Since the treatment with duocarmycin leads to the formation of stalled replication forks,147,148 
this suggests a potential role in the sensing of duocarmycin-induced DNA lesions. In this study, olaparib 
combined with DUBA displayed additive effects on HCC-1954 (S=0.6±0.4) and minor synergistic effects on MDA-
MB-468 cells (S=1.1±0.1).  
ATR and CHK1 kinases are crucial enzymes in the cell cycle but also DNA-damage response regulation. In this 
report, the ATRi AZD6738 and the CHK1i LY2603618 as well as AZD7762 were identified as synergistic 
combination partners of DUBA. The ATRi AZD6738 strongly synergized with DUBA on HCC-1954 cells (S=6.9±0.7) 
and MDA-MB-468 cells (S=5.7±1.0). The synergy was stronger for ATRi AZD6738 plus DUBA than for LY2603618 
plus DUBA on HCC-1954 (S=4.1±0.3, P=.00002) and MDA-MB-468 cells (S=4.4±1.7, P=.3). Again, the combination 
of AZD6738 with DUBA also exceeded the synergy observed for AZD7762 combined with DUBA on HCC-1954 
(S=3.6±0.4, P=.0002) and on MDA-MB-468 cells (S=2.6±0.2, P=.01).  
Functional HER2 was described to be essential for the activation of the G2/M checkpoint following irradiation 
of MCF7 cells. HER2 inhibition led to abolished ATR and CHK1 signaling following treatment of MCF7 with 
irradiation.138 Since in the course of this work, it was shown that ATR and CHK1 synergized with DUBA, it was 
studied whether the dual-epidermal growth factor receptor and HER2 inhibitor Lapatinib or the HER2 inhibitor 
CP724714 synergized with DUBA. The combination of both inhibitors with DUBA resulted in additive effects on 
HCC-1954 and MDA-MB-468 cells. 
NEK1 is a kinase associated with ATR and ATRIP that regulates the interplay between these two kinases.135 
Although originally designed for the inhibition of NEK2, cmpd31 inhibits NEK1 with a potency of 0.17 µM.134 
Thus, cmpd31 was combined with DUBA. On HCC-1954 (S=0.3±0.1) and MDA-MB-468 cells (S=0.4±0.2) only 
additivity was observed. The results of the dose-matrix assays are depicted in figure 33.  
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Figure 33: Results of the synergy screening. Duocarmycin variant DUBA was combined with DDRi on HCC-1954 and MDA-MB-468 cells 
and the combination effect was reported as synergy score. A cutoff synergy score of ±1 was defined. In this range, S of combinations is 
assumed to be additive, S>1 indicates synergism, S<1 indicates antagonism. Individual data points from independent experiments are 
depicted as well as the mean of the biological replicates as bar. 
 
Since kinase inhibitors often display off-target effects, ATR and CHK1 levels were decreased using siRNA knock-
down to prove the essential role of these enzymes for the survival of the cells treated with duocarmycin. 
Therefore, HCC-1954 cells were seeded into T25 flasks and left to adhere overnight. Then the cells were washed 
with PBS, and subsequently ATR, CHK1 and non-targeting siRNA were added. The cells were incubated for 4 h, 
washed with medium and incubated for 3 d. Cells were detached and seeded into 384-well plates. They were 
treated with duocarmycins for 6 d. Cell viability was determined via CellTiter-Glo assay kit, and data were 
evaluated using GraphPad Prism. The knock-down efficiency was evaluated using quantitative PCR (performed 
by Nicole Hoelzer) (Table 3). 
 
Table 3: Knock-down efficiency of ATR and CHK1 as determined by quantitative PCR. The efficiency of individual experiments is noted. 
Cells Knock-down efficiency [%] 
ATR KD 90, 74 
CHK1 KD 63, 15 
 
The results are displayed in figure 34. DUBA was more potent on ATR knock-down (IC50=0.25 nM) and CHK1-
knock-down cells (IC50=1.1 nM) compared to cells treated with non-targeting siRNA (IC50=1.5 nM). Similar results 
were obtained for DDM which was again more potent on ATR (IC50=0.014 nM) and CHK1 (IC50=0.133 nM) knock-
down cells than on control cells (IC50=0.23 nM). The differences between CHK1 and non-targeting siRNA treated 
cells were small, but DUBA was 5.8-fold and DDM 17.3-fold more potent on ATR knock-down cells than on 
control cells.  
   69 
D
U
B
A
D
D
M
0 .0 1
0 .1
1
1 0
IC
5
0
 [
n
M
]
A T R  K D
C H K 1  K D
C o n tro l
 
Figure 34: Potency of DDM and DUBA on cells treated with ATR or non-targeting siRNA. Individual data points and mean of IC50-values as 
black bar are displayed. 
 
All in all, the combination of DUBA with the ATRi AZD6738 yielded superior synergistic effects compared to DUBA 
plus CHK1i LY2603618 or AZD7762. In addition, the potentiation of the duocarmycins was stronger on ATR 
knock-down versus CHK1 knock-down cells. Taken together, it was proceeded with studying the drug 
combination of duocarmycin with ATR inhibitors due to their consistently stronger synergistic effects. So far, 
only the duocarmycin variant DUBA was studied in combination with ATRi. To ensure that synergistic effects are 
also observed with other duocarmycin variants, a library of duocarmycins variants with varying properties 
caused by different alkylating and binding units were evaluated in combination with ATRi in the following 
experiments. 
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5.2. Synergistic Drug Combinations of a Duocarmycin library with ATR inhibitor AZD6738 
 
A series of duocarmycin variants was studied after the identification of the synergistic drug combination DUBA 
plus AZD6738. This should verify that the observed synergy is not an effect caused by DUBA, but duocarmycins 
in general. Therefore, the duocarmycin variants were clustered into two groups according to their structural 
features. In the trimethoxy indole (TMI)-series, the binding unit of the duocarmycin is kept constant, while the 
alkylating unit varies. The alkylating unit of Duocarmycin SA (13) and CBI-TMI (24) consist of a tricyclus, however, 
with different stereoelectronic properties. The alkylating unit of the latter have a chiral center. Contrasting this, 
three achiral duocarmycin variants were investigated. From these, two variants, duocarmycin 35 and 36, had a 
bicyclic alykalting unit, while 37 had a monocyclic alkylating unit. The structures of the TMI-series are 
summarized in table 4.  
Table 4: Chemical structures of duocarmycins from the TMI-series. In the trimethoxy indole (TMI)-series, the binding unit is kept constant, 
while the alkylating unit varies. Cytotoxicity of the duocarmycin variants was determined by treating HCC-1954 cells with the compounds. 
The potency of the duocarmycin variants is expressed as mean of IC50±SD of N=3 biological replicates except in case of variant 35, where 
mean and individual IC50 values are noted. Synergy scores were obtained by combination treatment of HCC-1954 cells with the 
duocarmycin variant and AZD6738. Synergy scores are depicted as S±SD of N=3 biological replicates. Compounds 35 to 37 were kindly 
provided by the laboratory of Dr. Carl Deutsch, department of ADCs and Targeted NBE Therapeutics, Merck KGaA. 
Alkylating unit Binding unit No. IC50 [nM] S 
 
 
13 0.3±0.1 4.1±0.4 
 
24 24±32 6.1±1.2 
 
35 43.5 (44, 43) 5.2±0.2 
 
36 3.0±0.4 6.7±0.8 
 
37 1200±536 2.8±0.5 
 
The TMI-series might elucidate the influence of the alkylating unit on the synergy between duocarmycins and 
ATR inhibitors. The cyclopropabenzindole (CBI)-series (Table 5) was used to study the influence of the binding 
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unit on the synergistic effects between duocarmycin variants and ATRi. In the CBI-series, the alkylating unit is 
kept constant with only minor modifications like methyl or hydrogen in R1 and the binding unit is varied.  
 
Table 5: Chemical structures of duocarmycins from the CBI-series. In this series, the alkylating unit is a CBI-unit with either methyl- or 
hydrogen in position R1 of the alkylating unit. The binding unit in position R2 is varied. Cytotoxicity was determined by treating HCC-1954 
with the duocarmycins. Synergy scores were obtained by combination treatment of HCC-1954 cells with the duocarmycin variant and 
AZD6738. Data of 10 and 38 are IC50±SD and S±SD of N=7 or N=9 biological replicates, respectively. For experiments with N=2 biological 
replicates, mean and individual IC50 values are noted in brackets. Compounds 40 and 10 were kindly provided by the laboratory of Dr. 
Carl Deutsch, department of ADCs and Targeted NBE Therapeutics, Merck KGaA. 
Alkylating unit Binding unit No. IC50 [nM] S 
 R1 R2 R3    
 
H 
 
 
38 0.11±0.05 5.6±1.7 
H 
 
39 0.16 (0.21, 0.11) 5.1 (4.8, 5.3) 
Me 
 
 
40 1.6 (1.7, 1.5) 6.7 (6.3, 7.2) 
Me 
 
10 0.3±0.1 6.9±0.7 
 
To study synergistic effects of the duocarmycin variants in combination with the ATRi AZD6738, HCC-1954 cells 
were treated either with the single agents or with a combination of the two respective drugs. After 6 d of 
treatment, CellTiter-Glo luminescent assay was performed and the luminescence was read on Envision Reader. 
The results were analyzed using GeneData Screener as described before. The outcome of the assay was the 
potency of the duocarmycin variants and synergy scores for each variant combined with AZD6738.  
The potencies in the TMI-series on HCC-1954 cells were scattered strongly (Table 4). While DSA (13) had a 
subnanomolar IC50-value of 0.3±0.1 nM, the duocarmycin variant with the monocyclic alkylating unit 37 had a 
micromolar IC50-value of 1.2±0.5 µM. The potencies of the remaining duocarmycin variants in the TMI-series lay 
in between. Duocarmycin 36 had a potency in the single-digit nanomolar range with 3.0±0.5 nM, and 24 and 35 
have IC50-values of 24±32 nM and 43.5 nM, respectively. The potencies of the duocarmycins in the CBI-series 
were distributed more evenly (Table 5). Duocarmycin DM (38) had an IC50-value of 0.12±0.03 nM and DUBA (10) 
an IC50-value of 0.2±0.1 nM. Compound 39 had a potency of 0.16 nM and duocarmycin 40 a potency of 1.6 nM. 
The previously determined cutoff for synergy scores of 1 was exceeded by all compounds tested. However, the 
synergy scores varied strongly in the TMI-series. While the duocarmycin with the bicyclic, achiral alkylating unit 
36 reached a synergy score of 6.7±0.8 in combination with AZD6738, it was followed by the duocarmycins with 
tricyclic, chiral alkylating units CBI-TMI (24) (S=6.1±1.2) and DSA (13) (S=4.1±0.4). Drug 35 with the bicyclic, 
achiral alkylating unit had a score of 5.2±0.2 when given together with AZD6738. The weakest synergistic effects 
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were reached with the duocarmycin 37 comprising the monocyclic, achiral alkylating unit (S=2.8±0.5). The 
differences were less pronounced in the CBI-series. The duocarmycins DDM (38) and 39 had synergy scores close 
to each other (S=5.6±1.7 and S=5.1, respectively). The duocarmycins with the methyl-CBI unit as alkylating unit 
also had comparable synergy scores. While DUBA (10) had a synergy score of S=6.9±0.7 when combined with 
AZD6738, the combination of the DUBA-progenitor 40 with AZD6738 reached S=6.7.  
The drugs DDM (38) and DUBA (10) were chosen for further experiments. After it was proven that duocarmycins 
synergized with the ATRi AZD6738 regardless of their structural features, it should be investigated whether the 
duocarmycin variant DUBA also synergizes with other inhibitors of ATR.  
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5.3. Biological Activity of ATR Inhibitors  
 
In the combination experiments with AZD6738 it was confirmed that the duocarmycin variant plays a role in the 
extent of the synergistic effects. In this work, several different ATR inhibitors were investigated to elucidate the 
influence of the ATRi on the combination effects. An overview of the chemical structures of the ATRi studied in 
this report is given in figure 35. The ATRi were clustered into four groups. The ATRi from Astra Zeneca AZ20 and 
AZD6378 are closely related with an identical core unit. Bayer ATR inhibitors also had identical core units. The 
three Bayer ATRi differed only in R1. The phase I ATRi BAY1895344 carried a pyrazole residue and the ATRi 
BAY73, published as example 73 in a Bayer AG patent149, was carrying a methanesulfone pyridine residue in R1. 
The Bayer ATRi BAY286, published as example 286, carried a methanesulfone moitety in R1. While the ATRi 1, 
filed in a patent by Fundación Centro Nacional de Investigaciones oncológicals Carlos III (CNIO)150, was 
comparable to the Astra Zeneca ATRi series, the compound VE-822 from Vertex was structurally unrelated to 
the remaining clusters. 
 
 
Figure 35: Chemical structures of the ATRi studied in this work. The ATRi can be clustered into four structural groups. In case of the Astra 
Zeneca series, two closely related drugs were tested. The Bayer cluster comprises three ATRi with a similar core structure. The ATRi from 
Merck ATRi 1 and VE-822, formerly from Vertex, form distinct clusters. 
 
The structure determines the biological activity of the drugs. Table 6 summarizes characteristic properties and 
the chemical structures of the ATRi. Two compounds developed by Astra Zeneca were studied, namely AZ20 
(ATRi 2) and phase I ATRi AZD6738 (ATRi 3). Furthermore, compounds from Bayer were included. The phase I 
ATRi BAY1895344 (ATRi 1) was studied, as well as two ATRi, published as example 73 or example 286 in a patent 
by Bayer AG149, termed BAY73 (6) and BAY286 (ATRi 5), respectively. In addition, ATRi 1 and Merck’s phase I ATRi 
VE-822 (ATRi 7) were investigated. Cellular cytotoxicity was represented by the anti-proliferative potency on 
HCC-1954 cells.  
AZD6738 was the least potent ATRi in the panel (2.2±0.7 µM) followed by AZ20 with an IC50-value 1.6±0.5 µM. 
VE-822 was potent in submicromolar range with a potency of 0.9±0.4 µM. The potency increased with ATRi 1 
(0.4±0.2 µM) and the drugs from Bayer BAY1895344 (0.05±0.02 µM), BAY73 (0.12±0.03 µM), BAY286 (0.08±0.02 
µM). In addition, cellular cytotoxicity was determined on NCI-N87 and MDA-MB-453 cells. While ATRi 1 was 
AZ20 X=O, Y=CH
AZD6738 X=NH, Y=N
BAY1895344
BAY73
BAY286
Astra Zeneca Merck Bayer Vertex
ATRi 1
VE-822
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potent in the same range on NCI-N87 (0.36±0.07 nM) and on MDA-MB-453 (0.32±0.5 nM) cells as on HCC-1954, 
the potency of BAY1895344 varied stronger between the cell lines. It was remarkably less potent on NCI-N87 
(0.3±0.3 nM) and MDA-MB-453 (0.2±0.2 nM) when compared to HCC-1954 cells. AZD6738 on the other hand 
was more around twice as potent on NCI-N87 (0.98±0.09 nM) and MDA-MB-453 (1.1±0.3 nM) cells compared 
to the potency on HCC-1954 cells. 
Another assay was used to study the cellular effects of the ATRi on the cells according to Kawasumi et al.151 
Replication stress is induced in HT29 cells by treatment with hydroxyurea. As a result CHK1 is phosphorylated in 
an ATR-dependent manner. ATR inhibitors block the ATR-mediated phosphorylation of CHK1. The extent of CHK1 
phosphorylation inhibition was assessed subsequently by staining of phospho-CHK1. The assay set-up is depicted 
in figure 36. The results were kindly provided by the laboratory of Dr. Beatrix Blume.  
 
 
Figure 36: Assay set-up for the determination of CHK1 phosphorylation inhibition by ATRi. HT29 cells were incubated with hydroxyurea 
with or without ATR inhibitors. Cells were fixed, permeabilized and subsequently stained with an anti-phospho-CHK1 antibody. The latter 
antibody was stained with a flurescently labeled mAb. While cells stressed with hydroxyurea were positive for anti-phospho-CHK1 
staining, the signal was dose-dependently suppressed in cells treated with HU and ATRi. The quantification of cells positive or negative 
for staining allowed the determination of the potency of the ATRi. Figure adapted according to Kawasumi et al.151 and the picture of the 
384-well plate was obtained online from nexelcom152. 
 
The inhibition of CHK1 phosphorylation upon treatment with hydroxyurea on HT29 cells was used to rank the 
ATRi. While AZ20, AZD6738 and VE-822 inhibited phosphorylation of CHK1 in the triple-digit nanomolar range 
(135 nM, 287±153 and 197±78 nM, respectively), ATRi 1 (9±5 nM) and the Bayer ATRi BAY1895344 (7±4 nM), 
BAY286 (2.4 nM), BAY73 (4±3 nM) showed comparable potencies in the single-digit nanomolar range. The 
cellular CHK1 inhibition potency data were kindly provided by the laboratory of Beatrix Blume, department of 
Cellular Pharmacology, Merck KGaA. 
  
HU
HU + ATRi
HT29 cells
+HU
+ATRi
Data 
analysis
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Table 6: Summary of ATR inhibitors. Trivial name and structure are depicted. The cellular toxicity on HCC-1954, NCI-N87 and MDA-MB-
453 cells and the inhibition of hydroxy urea induced phosphorylation of CHK1 on HT29 cells are noted as mean±SD of IC50-values. The 
data are displayed as mean±SD and the number of individual experiments is noted in brackets. The cellular CHK1 inhibition potency data 
were kindly provided by the laboratory of Dr. Beatrix Blume, department of Cellular Pharmacology, Merck KGaA. 
 Cytotoxicity IC50 
Inhibition of CHK1 
phosphorylation IC50 
ATRi No. Structure HCC-1954 NCI-N87 MDA-MB-453 HT29 
   µM nM 
ATRi 1 1 
 
0.4±0.2 (9) 0.36±0.07 (3) 0.32±0.5 (3) 9±5 (9) 
AZ20 2 
 
1.6±0.5 (7) - - 135 (130, 140) 
AZD6738 3 
 
2.2±0.7 (21) 0.98±0.09 (3) 1.1±0.3 (6) 287±153 (9) 
BAY1895344 4 
 
0.05±0.02 (9) 0.3±0.3 (3) 0.2±0.2 (4) 7±4 (4) 
BAY286 5 
 
0.08±0.02 (5) - - 2.4 (3.8, 0.95) 
BAY73 6 
 
0.12±0.03 (7) - - 4±3 (4) 
VE-822 (VX-
970, M6620 
Berzosertib) 
7 
 
0.9±0.4 (7) - - 197±78 (95) 
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5.4. ADC generation 
 
5.4.1. Generation of Duocarmycin-Bearing ADCs 
 
In this work, several duocarmycin-bearing ADCs were generated based on antibodies targeting cancer-related 
receptor-tyrosine kinases HER2, EGFR and mesenchymal–epithelial transition (MET). The linker-drugs that were 
coupled to these antibodies were specified by the tag LD-X, where X refers to the index number of a specific 
structure. The name of the resulting ADC was composed of the target or the name of the antibody and the linker-
drug index number. For instance, an ADC composed of linker-drug 1 (LD-1) and the anti-EGFR (αEGFR) antibody 
or anti-HER2 (αHER2) carried the name αEGFR-1 or αHER2-1, respectively.  
The linker-drugs for the generation of duocarmycin-bearing ADCs are summarized in table 7. The basic structure 
of the linker-drugs utilizes a dipeptide valine-citrulline linker, which can be cleaved by cathepsin B. The dipeptide 
is followed by a self-immolative module, which ensures efficient drug release upon cleavage. The self-
immolative module carries either a methyl group or a diethylgycol moiety in R2 position. The basic structure is 
elongated N-terminally at R1. The linker-drugs LD-1 to LD-5 contain a N-terminal triple-glycine sequence to 
enable Sortase A (SrtA)-mediated conjugation. Several modifications were introduced to increase the solubility 
of the linker-drugs. LD-2 and LD-5 are modified with ethyleneglycol. Since charge can also mediate solubility, LD-
3 contains a lysine which is positively charged at physiologial pH. LD-6 was conjugated via chemical conjugation 
techniques. LD-7 is modified N-terminally by a maleiimde motif for the conjugation to thiols. In both linkers, an 
ethyleneglycol unit is incorporated to increase solubility. The duocarmycin-variants DDM (LD-1), DUBA (LD-2 to 
LD-6) and DSA (LD-7) were used as drugs in R3. 
 
 
 
Figure 37: Chemical structures of the duocarmycin-variants DUBA (10), DDM (38) and DSA (13) studied in the ADC format. The drugs are 
displayed in the seco-form. 
 
10 38 13 
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Table 7: Duocarmycin-based linker-drugs used for ADC preparation in this thesis. R1: Linker-drugs LD-1 to LD-5 are modified N-terminally 
with a triple-glycine motif that is recognized by SrtA. LD-2 to LD-5 contain modifications that increase the hydrophilicity. Thus, 
ethyleneglycol units are introduced in LD-2 and LD-5. LD-3 comprises a lysine residue and hence is positively charged at a physiological 
pH. LD-6 was prepared by chemical conjugation to the αHER2 antibody. LD-7 carries a N-terminal maleimde residue for conjugation using 
thiol coupling and ethyleneglycol units for increased solubility. R2: Methyl group or diethyleneglycol is used. Diethyleneglycol increases 
solubility. R3: Linker-drugs contain Duocarmycin DM (LD-1), DUBA (LD-2 to LD-6) or DSA (LD-7). The linker-drugs 2 to 6 were kindly 
provided by the laboratory of Dr. Carl Deutsch, department of ADCs and Targeted NBE Therapeutics, Merck KGaA. 
 
Linker-drugs R1 R2 R3 
1 
 
Me 
 
2 
  
 
3 
 
Me 
 
4 Not disclosed Me 
 
5 
 
Me 
 
6 Not disclosed 
 
 
7 
 
Me 
 
 
The conjugation of LD-1 to the αHER2 mAb was performed using SrtA-conjugation. Therefore, antibody 
modified C-terminally with (G4S)3-LPETGS was mixed with LD-1, CaCl2 solution and buffer. Then SrtA was added 
to start the reaction. After 30 min of shaking at 22 °C, the reaction was stopped by adding an excess of EDTA. 
The sample was then subjected to Protein A chromatography. The flow through was discarded, and after a 
2
12
4
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washing section, the ADC was eluted using an acidic pH shift. After buffer exchange and concentration, the 
resulting purified ADC was analyzed by analytical HIC and SEC. The chromatograms of such a purification are 
exemplarily shown in figure 38. 
 
 
Figure 38: Chromatograms of ADC preparation and analysis. A) Chromatogram of preparative Protein A chromatography. The sample 
was subjected to a protein A column. Up to 20 mL eluent flew through before the ADC was washed and eluted by an acidic pH shift. 
Fractions were collected and pooled. The UV-signal is shown in blue, the conductivity in brown. In green, ratio buffer B/buffer A is 
displayed. B) Chromatogram of analytical scale SEC. The blue signal is the UV-absorption. 98.8 % of the ADC was monomeric. C) HIC 
chromatogram of purified ADC. The blue signal is the UV-absorption. 0.27% unconjugated mAb at retention time 11.238 min, 2.87% of 
monofunctionalized ADC at retention time 13.076 min and ADC with a DAR of 2 at retention time 14.265 min were detected. This ADC 
composition had an overall DAR of 1.97. 
 
The αHER2 mAb was used as a tool antibody in the course of this work to study the impact of duocarmycin 
linker-drugs on the producibility of ADCs. Therefore, LD-1 to LD-5 were conjugated to the αHER2 mAb via SrtA-
mediated conjugation in analytical scale reactions at first. The LD-4 could not be conjugated to the αHER2 mAb, 
since the resulting product was precipitated. LD-5 was successfully conjugated to the αHER2 mAb in an analytical 
scale reaction. However, the conjugation reaction was incomplete, leading to an ADC with a DAR of 
A B
C
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approximately 1. The linker-drugs LD-1, LD-2, and LD-3 were successfully coupled to the αHER2 mAb using 
antibody-format A in preparative scale. In this setting, homogeneous ADCs with a DAR>1.85 were prepared and 
the monomer content of the ADC was at least 95%. While the DUBA-based linker-drugs LD-2 and LD-3 were 
conjugated to the αHER2 mAb in excellent or very good yield, respectively, the preparation of αHER2-1 was 
performed in poor to good yield. 
In addition to that, LD-1 was conjugated to the αEGFR mAb cetuximab, and the mAbs αMET, αMETxEGFR and 
αHEL. The resulting ADCs were prepared in acceptable yields. While a DAR von 1.90 was achieved in the 
preparation of αHEL-1, the preparation of αEGFR-1 and αMET-1 yielded ADCs with a DAR of 1.70 and 1.68, 
respectively. In the case of the αMETxEGFR-1 ADC a DAR of 0.89 and 0.95, respectively, was achieved. The 
monomer content of these ADCs was acceptable, except for αMET-1, where the monomer content was the 
lowest with 93.6%. 
 
Table 8: Overview of generated duocarmycin-based ADCs using SrtA conjugation. The column “App.” contains the appendix number 
under which data such as HIC and SEC profile can be found. 
mAb 
mAb 
format 
Linker-
drug 
Purification 
route 
Yield [µg] (%) Yield [%] DAR Monomer [%] App. 
αHER2 A 1 D/C/C 2760/1443/2850 34.4/28.8/71.0 1.97/1.89/1.96 98.8/95.6/96.7 4/5/6 
αEGFR B 1 C 1350 66.5 1.70 98.2 7 
αMET B 1 B 1064 52.4 1.68 93.6 8 
αMETxEGFR C 1 A/A 503/620 57%/74.3 0.95/0.89 98.4/98.4 9/10 
αHEL A 1 C 2400 47.8 1.90 97.2 11 
αHER2 A 2 B 1984 97.8 1.85 97.4 12 
αHER2 A 3 A 2150 81.1 1.93 99.3 13 
αHER2 A 4 - - - Precipitated -  
αHER2 A 5 - - - 0.99 - 14 
α-GP B 1 D 1215 60.0 1.57 89.4 15 
 
The duocarmycin-bearing ADCs αHER2-6 and αEGFR-7 were kindly provided by the laboratory of Dr. Nicolas 
Rasche. The results of the characterization are summarized in table 9. The ADC αHER2-6 was generated using 
chemical conjugation techniqes resulting in an ADC with a DAR of 1.90. αEGFR-7 was produced by conjugation 
of LD-7 to the interchain cysteines. A DAR of 1.54 was achieved. Both ADCs did only contain negligible amounts 
of aggregates. 
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Table 9: Overview of duocarmycin-based ADCs which were kindly provided by the laboratory of Dr. Nicolas Rasche, department of ADCs 
and Targeted NBE Therapeutics, Merck KGaA. αEGFR-7 was generated using thiol coupling. 
mAb mAb format Linker-drug DAR Monomer [%] 
αHER2 Not disclosed 6 1.90 98.8 
αEGFR Native (E) 7 1.54 99.7 
 
5.4.2. Generation of Control ADCs 
 
As a negative control for combination experiments, a MMAE linker-drug 8 was conjugated to cetuximab using 
cysteine conjugation. The LD was purchased from Levena Biopharma. This ADC was kindly provided by the 
laboratory of Dr. Nicolas Rasche, department of ADCs and Targeted NBE Therapeutics, Merck KGaA. 
 
 
Figure 39: chemical structure of control linker-drug 8. The linker-drug consists of a maleimide for cystein conjugation, a valine-citrulline 
dipeptide sequence for Cathepsin B-mediated cleavage and the cytotoxic drug MMAE (1). 
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5.5. Cytotoxicity of Duocarmycin-Based ADCs 
 
In this chapter, the anti-proliferative effects of duocarmycin-based ADCs are described. The cytotoxicity of ADC 
αHER2-1 was studied on HER2-positive cells. The cell panel encompassed the breast-cancer cell lines BT-474, 
HCC-1954, JIMT-1, MDA-MB-361, MDA-MB-453 and SK-BR-3 as well as the lung adenocarcinoma cell line Calu-
3. Furthermore, the ADC was tested on a HER2-negative breast cancer cell line MDA-MB-468. αHER2-1 was 
active in the double-digit picomolar to single-digit nanomolar range on the HER2-positive cell lines and showed 
only weak cytotoxicity on HER2-negative cell line MDA-MB-468 in the lower triple-digit nanomolar range. The 
ADCs αHER2-2 and αHER2-3 were as cytotoxic as αHER2-1 on Calu-3, HCC-1954 and SK-BR-3 cells. However, 
Kadcyla was 5- to 45-fold less potent on Calu-3 compared to the duocarmycin-based ADCs. Kadcyla, as well as 
αHER2-2 and αHER2-3 were potent in the double-digit nanomolar range on antigen-negative cells. The non-
targeting ADC αHEL-1 exhibited weak anti-proliferative effects on HER2-positive cells in the double- to triple 
digit nanomolar range. The ADC αHER2-6 had subnanomolar IC50-values on NCI-N87 and MDA-MB-453, which 
was comparable to the effects of Kadcyla. αHER2-6 was comparably as potent as αHER2-2 on NCI-N87 cells. 
 
Table 10: Cell killing potencies of αHER2-duocarmycin ADCs αHER2-1, αHER2-2 and αHER2-3 on HER2-positive cell lines and the HER2-
negative cell line MDA-MB-468. The control ADCs Kadcyla and αHEL-1 were tested in parallel. HER2-positive cell lines are indicated by 
plus sign independently of the total amount of receptor on the surface. Data: IC50±SD of N≥3 biological replicates or if less than three 
indpendent experiments were performed, mean and individual IC50-values in brackets. Cytotoxicity data are obtained from assays in the 
96-well format. a: Assay performed in 384-well format. 
  IC50 in nM 
 HER2 αHER2-1 αHER2-2 αHER2-3 αHER2-6 Kadcyla αHEL-1 DDM (38) DUBA (10) 
BT-474 + 1.0 (1.2, 0.70) - - - - - - - 
Calu-3 + 0.9±0.4 4±2 1.5±0.9 - 41±22 - - - 
HCC-1954 + 1±1 2±1 1±1 - 0.50±0.03 230±35 0.11±0.07a 0.30±0.07a 
JIMT-1 + 0.41±0.07 - - - - - 0.14 (0.20, 0.074)a 3±2a 
MDA-MB-361 + 0.1±0.02 - - - - 29±3 - - 
MDA-MB-453 + 0.3±0.1 - - 0.5±0.4a 0.23±0.04a 339±179 0.14 (0.15, 0.13)a 0.3±0.1a 
NCI-N87 + - 0.15±0.03a - 0.3±0.4a 0.10±0.02a - - 1.2±0.5a 
SK-BR-3 + 0.08±0.03 0.16±0.05 0.15±0.05 - 0.2±0.1 42±14 - - 
SK-OV-3 + 0.2±0.1 - - - - - - - 
MDA-MB-468 - 140±47 28±7 17±4 - 43±9 56 0.02±0.01a 0.06±0.02a 
 
Muller and Milton stated that at early drug development stages, where only in vitro data are available, the 
therapeutic index might be assessed on the basis of on- and off-target selectivity. Although the target selectivity 
does not necessarily correlate with an increased therapeutic index in vivo, there are many examples where 
higher target selectivity also led to improved therapeutic window.153 Therefore, the selectivity indices (SI) of an 
ADC towards antigen-expressing cells were calculated according to eq. 4 to rank the ADCs. The selectivity index 
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of an idividual ADC was determined by dividing the IC50 on target negative cells by the IC50 on target-positive 
cells.  
 
 𝑠𝑒𝑙𝑒𝑐𝑡𝑖𝑣𝑖𝑡𝑦 𝑖𝑛𝑑𝑒𝑥 =  
𝐼𝐶50 𝑜𝑓 𝐴𝐷𝐶 𝑜𝑛 𝑡𝑎𝑟𝑔𝑒𝑡 𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒 𝑐𝑒𝑙𝑙𝑠
𝐼𝐶50 𝑜𝑓 𝐴𝐷𝐶 𝑜𝑛 𝑡𝑎𝑟𝑔𝑒𝑡 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒 𝑐𝑒𝑙𝑙𝑠
 Eq. 4 
 
Selectivity indices for the individual ADCs are depicted in figure 40. The ADC αHER2-1 is the most selective ADC 
tested with a mean selectivity index of 639. The ADCs αHER2-2 and αHER2-3 with mean selectivtiy indices of 67 
and 43 are weakly less selective than Kadcyla with a mean selectivity index of 110. The non-targeting ADC αHEL-1 
has a mean selectivity index of approximately one, which indicates that αHEL-1 exerts cell killing properties 
target-independent. The small molecule drugs DDM and DUBA killed MDA-MB-468 cells at lower doses than 
other cell lines studied, leading to selectivity indices of 0.15 and 0.14, respectively. 
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Figure 40: Selectivity indices of αHER2-duocarmycin ADCs αHER2-1, αHER2-2 and αHER2-3 carrying different linker-drugs, Kadcyla and 
aHEL-1 on HER2-presenting cell lines. The selectivity indices were calculated by dividing the IC50-value of the individual molecule on HER2-
negative cell line MDA-MB-468 by the IC50-value of the molecule on the indicated HER2-positive cell lines. The bar represents the mean 
of the selectivity indices for every ADC.  
 
Besides the αHER2 and αEGFR mAb, an αMET and a bispecific αMETxEGFR mAb were used for ADC generation. 
The resulting ADCs were studied for their anti-proliferative properties (Table 11). The surface expression of the 
receptors EGFR and MET was reported in literature67 and classified as positive for 10- to 100 thousand copies, 
as double-positive for 100 to 1000 copies and as triple positive for >1000 copies per cell. The ADCs αEGFR-1 and 
αMET-1 were potent on EGFR- and MET-postive cells in the subnanomolar range, except for αEGFR-1 on MKN-
45, where the ADC had an IC50 value of 45 nM. αMETxEGFR-1 was less potent on the studied cell lines with IC50 
values in the single-digit nanomolar range. The ADC αEGFR-7 killed A431 and MDA-MB-468 cells in the 
subnanomolar range. On EGFR-negative MCF7 cells, the Duocarmycin DM-bearing ADC αEGFR-1 and the DSA-
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carrying αEGFR-7 were considerably less potent in the single- to doubledigit nanomolar range. The free drugs 
DDM and DSA were potent on all cell lines regardless of surface receptor status in the subnanomolar range. 
 
Table 11: Cell killing potencies of αMET-1, αEGFR-1 and αMETxEGFR-1 ADC on cell lines with differential expression of EGFR and MET. 
For N<3 biological replicates the potency is reported as mean of IC50 with individual measurements in brackets. Asteriks indicate that an 
assay was performed, but the fit was ambigous and no IC50-value was obtained. Receptor densities were classified according to 
literature67. Receptor densities of 10x103-100x103 copies were classified as “+”, 100x103-1000x103 classified as “++” and densities 
>1000x103 were classified as “+++”. a: receptor densitiy obtained from internal data. The IC50-values of DDM were already presented in 
table 10. 
   IC50 in nM 
 EGFR MET αMET-1 αMETxEGFR-1 C-1 C-7 DDM DSA (13) 
A431 ++ + - - 0.17±0.04 0.21±0.02 0.055±0.005 0.21±0.02 
A549 + + - - * * 0.1±0.1 0.33±0.07 
HepG2 - (+) - - * * - - 
MCF7 -a -a - - 27±8 9±5 0.164±0.004 0.06±0.02 
MKN-45 + ++ 0.80 (1.2, 0.41) 2.7 (3.8, 1.6) 45 (0.72, 88) - - - 
MDA-MB-468 +++ + 0.91 (0.12, 0.59) 1.9±0.2  0.12±0.08 0.06±0.02 0.02±0.01 0.14±0.07 
NCI-H1975 + + 0.14 (0.20, 0.077) 7.7 (9.3, 6.2) 0.11 (0.15,0.058) - - - 
 
To further elucidate differences between the individual cetuximab-duocarmycin ADCs, selectivity indices were 
calculated according to eq. 4 using the IC50-values of the ADCs αEGFR-1 and αEGFR-7 and the respective small 
molecule counterparts on EGFR-positive cell lines and the EGFR-negative cell line MCF7. The results are 
depicted in figure 41. The ADC αEGFR-1 was more selective towards the cell lines A431 (SI=162) and MDA-MB-
468 (SI=222) compared to ADC αEGFR-7 (SI=40 on A431 and 148 on MDA-MB-468). αEGFR-1 was selective 
towards NCI-H1975 cells (SI=257) but showed no selectivity for MKN-45 cells (SI=0.6). The mean selectivity 
indices for αEGFR-1 accounted to 161 and for αEGFR-7 to 94. The small molecule duocarmycins DDM and DSA 
did not show selectivity for EGFR-overexpressing cell lines (SImean=0.5 and 0.3, respectively). 
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Figure 41: Selectivity indices of anti-EGFR αEGFR-1 and αEGFR-7 ADCs for EGFR-overexpressing cell lines. The selectivity was calculated 
by dividing the IC50-value of the individual molecules on EGFR-negative cell line MCF7 by the IC50-value on the indicated EGFR-positive 
cell lines. Selectivity for different EGFR-positive cell lines is indicated by shades of grey. The bar represents the mean of selectivity indices 
over the cell lines treated with a certain ADC. 
 
5.6. Synergy of Duocarmycin-ADCs with ATRi 
 
The small molecule duocarmycins synergized with ATR inhibitors on HCC-1954. ADCs were generated to study 
the translatabiliy of the combination effects observed with the small molecule combinations with ATRi to 
duocarmycin-carrying ADCs. 
 
5.6.1. Synergy of Combinations of αHER2-Duocarmycin ADCs and ATRi 
 
HCC-1954 were treated with DDM, DUBA and the corresponding DDM-bearing αHER2-1 and DUBA-carrying ADC 
αHER2-2 (Figure 42) in combination with AZD6738 for 6 d. Then, cell cytotoxicity was determined using CellTiter-
Glo kit. Luminescence was read on Envision reader and data were evaluated using GeneData Screener. The 
combination of DDM with AZD6738 (S=5.6±1.7) was comparably synergistic as the corresponding ADC αHER2-1 
(S=5.1±2.0). The same conclusion can be drawn for the combination of DUBA with AZD6738 (6.9±0.7) and 
αHER2-2 plus AZD6738 (7.2±1.0).  
As positive controls, SN-38 and Gemcitabine were combined with AZD6738 on HCC-1954 cells. SN-38 as well as 
Gemcitabine synergized with AZD6738 (S=7.2±0.8 and S=6.9±0.3). The microtubule inhibitor MMAE, however, 
synergized weakly with the ATRi AZD6738 (S=2.2±0.1) as well as microtubule inhibiting ADC Kadcyla combined 
with AZD6738 (S=1.3±0.7) on HCC-1954 cells. In this case, one measurement was excluded that yielded a synergy 
score of 6.4. Thus, αHER2 mAb trastuzumab and DM1 were combined with AZD6738 to elucidate the influence 
of the two molecular portions on the synergistic effects. Trastuzumab did not synergize with AZD6738 on HCC-
1954 cells (S=-0.2±0.2) while DM1 and AZD6738 led to synergistic cell killing (S=2.8±0.5). 
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Furthermore, the influence of different ATRi on the synergistic effects of the combination with ADC αHER2-2 or 
the corresponding small molecule DUBA was studied on HCC-1954 cells. The combination of αHER2-2 with ATRi 
1 was significantly stronger (P=.03) with a score of 12.5±1.7 than the combination of αHER2-2 with AZD6738 on 
HCC-1954 cells. When combining the ADC αHER2-2 with BAY1895344 it was also significantly stronger (P=.003) 
with a synergy score of 13.1±1.0 than αHER2-2 combined with AZD6738. The ATRi VE-822 and AZ20 synergized 
with αHER2-2 comparable to AZD6738 with synergy scores of 5.7±0.3 and 5.8±0.4, respectively. BAY73 
combined with αHER2-2 had the highest synergy score with 14.4±1.1. BAY286 plus αHER2-2 had a synergy score 
in the mid range of 10.4±0.2. The synergy scores of DUBA combined with the ATRi AZ20 (S=5.1±0.5), ATRi 1 
(S=12.0±0.6), BAY1895344 (S=12.8±0.5), BAY73 (S=12.4±0.8), BAY286 (S=9.5±0.8) and VE-822 (S=5.3±0.6) on 
HCC-1954 cells were in good comparison to the ADC αHER2-2 combined with the respective same ATRi. 
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Figure 42: Synergy scores of duocarmycin-based ADCs and small molecules in combination with AZD6738 on HCC-1954. Individual data 
points are displayed as well as the mean of the individual points represented by a bar. 
 
In a next experiment, the ADCs αHER2-2 and αHER2-6 were combined with the three ATR inhibitors AZD6738, 
ATRi 1 and BAY1895344 on NCI-N87 and MDA-MB-453 cells. As a control, the small molecules DUBA and 
Gemcitabine and as ADC control Kadcyla were combined with the ATRi AZD6738 (Figure 43). On NCI-N87 cells 
αHER2-2 synergized in increasing order with the ATRi AZD6738 (S=3.7±0.7), ATRi 1 (S=7.1±0.8) and BAY1895344 
(S=7.6±0.4). The combination of αHER2-2 plus ATRi 1 (P=.008) and BAY1895344 (P=.0007) were significantly 
more synergistic than the combination of the ADC plus ATRi AZD6738. The same trend was observed for the 
combination of another DUBA-ADC αHER2-6. Again, the combination with AZD6738 (S=3.0±0.05) showed the 
lowest score, ATRi 1 (S=6.1±0.4) a mid-range and BAY1895344 (S=7.0±0.2) the highest score. In direct 
comparison, S of the combination of αHER2-6 with AZD6378 was significantly lower than the combination of 
αHER2-6 with ATRi 1 (P=.009) and BAY1895344 (P=.0002). As a positive control, DUBA was combined with the 
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ATRi AZD6738. A synergy score of S=3.1±0.6 proves the synergy between the duocarmycin-derivative and the 
ATRi. The combination of αHER2-6 with AZD6738 was comparably synergistic as the combination of its small 
molecule counterpart DUBA with AZD6738 (P=.3). The negative control Kadcyla showed only additive effects 
when combined with AZD6738 (S=0.3±0.2), while the benchmark Gemcitabine barely exceeded the cutoff score 
when combined with the ATRi AZD6378 (S=1.1±0.5). The duocarmycin-ADC αHER2-6 synergized significantly 
stronger with the ATRi AZD6738 compared to the negative control Kadcyla (P=.003) and the positive control 
Gemcitabine (P=.001). 
Similar results were obtained on MDA-MB-453 cells. Here, αHER2-2 synergized with the ATRi AZD6738 
(S=9.1±2.1), ATRi 1 (S=13.3±0.3) and BAY1895344 (S=14.7±2.3) in increasing order. The same trend was observed 
for αHER2-6 plus AZD6738 (S=9.5±0.9), ATRi 1 (S=11.4±1.4) and BAY1895344 (S=15.8±0.5). Gemcitabine 
synergized slightly stronger with AZD6738 on MDA-MB-453 (S=1.6±1.2) than on NCI-N87. The negative control 
combination of Kadcyla with AZD6738 reached a synergy score of 1.1±0.3 which is just above the cutoff score 
indicating very weak synergy. The positive control DUBA synergized with AZD6738 also on MDA-MB-453 cells 
(S=5.0±0.5) but significantly weaker than the combination of αHER2-6 with the corresponding ATRi (P=.01). 
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Figure 43: Synergy scores of combinations of duocarmycin-bearing ADCs αHER2-2 and αHER2-6 with different ATRi on NCI-N87 or MDA-
MB-453 cells. As controls, the small molecules DUBA and Gemcitabine and, as negative control, Kadcyla were included. Bars represent 
the mean of independent biological replicates. 
 
A total of seven ATRi were investigated in this study to elucidate the effect of the ATRi on the combination 
effects with duocarmycin and duocarmycin-based ADCs on HCC-1954, MDA-MB-453 and NCI-N87 cells. The 
synergy scores of the individual ATRi (as presented in figure 42 and figure 43) combined with the duocarmycin 
DUBA or DUBA-based ADCs were plotted against their potency to inhibit the phosphorylation and thus activation 
of CHK1 after HT29 were stressed by treatment with hydroxyurea. The plots are depicted in figure 44. A 
correlation between the ATRi potency and the synergy scores was observed for the small molecule DUBA with 
the ATRi on HCC-1954. This finding was confirmed with the ADC αHER2-2 combined with the ATRi library on 
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HCC-1954. The same correlation was observed for αHER2-2 and αHER2-6 combined with a subset of ATRi on 
MDA-MB-453 and NCI-N87 cells. 
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Figure 44: Correlation between synergy score and cellular CHK1 phosphorylation inhibition on HT29 cells. The more potent the ATRi in 
terms of CHK1 phosphorylation inhibition the higher the synergy score. This correlation was shown for combinations of the small 
molecule drug DUBA with several ATRi on HCC-1954 cells. The correlation was reproduced for the same ATRi combined with the ADC 
αHER2-2 on HCC-1954. A subset of the ATRi was combined with αHER2-2 and another DUBA-based ADC αHER2-6 on MDA-MB-453 and 
NCI-N87 cells.  
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5.6.2. Synergy of Combinations of αEGFR-Duocarmycin ADCs and ATRi 
 
In the previous chapters, the combination of αHER2-duocarmycin ADCs with ATRi was studied. To validate that 
the concept of combining duocarmycin-modified ADCs with ATRi can be translated to additional antibodies, 
cetuximab-based duocarmycin-ADCs were investigated. Therefore, the EGFR-positive cell lines A549, A431 and 
MDA-MB-468 as well as EGFR-negative MCF7 cells were treated with DDM-based αEGFR-1, DSA-based αEGFR-7 
in combination with AZD6738. As controls, the cells were also treated with the MMAE-ADC αEGFR-8 and the 
small molecule duocarmycins DDM and DSA. After 6 d of treatment, cell viability was determined using CellTiter-
Glo reagent. Luminescence was read on an Envision reader and evaluation took place using GeneData Screener. 
Data are depicted in figure 45. The negative control ADC αEGFR-8 had synergy scores in the range of additivity. 
The positive control DDM had synergy scores ranging from 2.0±1.1 on A549 to 6.0±1.0 on MDA-MB-468 cells. 
The synergy scores of the small molecule DSA were comparable on A431, MDA-MB-468 and MCF7. However, 
DSA did not synergize with AZD6738 on A549 cells but showed additive effects. While the synergy of the 
combination of αEGFR-1 plus AZD6738 was very similar on A549 (S=3.9±1.0), A431 (S=3.9±0.3) and MDA-MB-
468 (S=4.2±0.3) cells, the synergy score on MCF7 (S=2.2±0.1) was significantly lower compared to αEGFR-1 
combined with AZD6738 on MDA-MB-468 (P=.006) or A431 (P=.01). However, the effects were less distinct for 
the combination of the DSA-ADC αEGFR-7 combined with the ATRi. The synergy score of C-7 plus AZD6738 
amounted to 4.4±0.6 on A431, 2.9±1.1 on A549 and 3.2±0.4 on MDA-MB-468 cells. This combination reached a 
synergy score of 2.3±0.1 on the EGFR-negative cell line MCF7, which is significantly lower than the combination 
given to A431 cells (P=.03). 
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Figure 45: Synergy scores of combinations of cetuximab-duocarmycin ADCs with the ATRi AZD6738 on EGFR-positive cell lines and the 
EGFR-negative cell line MCF7. As a control, Cetuximab-MMAE was combined with the ATRi AZD6738. Individual data points are displayed 
as well as the mean of the experiments. 
 
 
 
 
   89 
5.6.3. Dose-Reduction of αHER2-Duocarmycin Combinations with ATRi 
 
A strategy for improved safety of a combination therapy is the reduction of the administered doses. It was 
demonstrated in the previous chapters that duocarmycin-bearing ADCs combined with ATRi unfolded synergistic 
toxic effects towards cancer cells. But the expression of synergistic effects in terms of a synergy score did not 
allow an estimation on how much the dose of the drugs in a combination might be lowered while maintaining 
the same cellular effects. Therefore, it was studied how strong the potency of the duocarmycin-bearing ADCs 
was increased when ATRi were added at sub-efficacious doses. 
The determination of dose-reduction indices (DRI) in a maximum non-efficacious dose (MNED) curve-shift assay 
is a 3-step process as depicted exemplarily in figure 46. The cytotoxicity of the ADC is confirmed in a cell viability 
assay in an initial step. Here, HCC-1954 cells were treated with αHER2-1, the αHER2 mAb trastuzumab (T) and a 
control ADC αHEL-1 for 6 d and cell viability was measured using CellTiter-Glo kit. While αHER2-1 had an IC50-
value of 1.1 nM, the naked mAb did not show any anti-proliferative effects. The isotype control ADC αHEL-1 
reduced the cell viability at 250 nM to 75% but was considerably less cytotoxic as αHER2-1. In the second step, 
the MNED of the ATRi was determined. Therefore, the cells were treated with ATRi 1 and the dose-response 
curve (DRC) was plotted to identify MNED which was in this case 40 nM. It was proceeded to the last step qith 
these data, the MNED curve-shift assay. Therefore, HCC-1954 cells were treated with a serial dilution of αHER2-1 
or a serial dilution of αHER2-1 supplemented with 40 nM ATRi 1. In order to obtain a full DRC for the 
combination, the starting concentration of the ADC was lowered compared to the experiment in step 1. The 
IC50-value of αHER2-1 was 2.5 nM. The combination of αHER2-1 with 40 nM ATRi 1 had a potency of 0.059 nM. 
This potentiation of the combination compared to the ADC alone can be expressed as a DRI of 42. ATRi 1 did not 
reduce cell viability at 40 nM. 
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Figure 46: MNED-curve shift assay for the determination of dose-reduction indices as a 3-step process. 1) Cytoxocity of the ADC αHER2-
1 was confirmed in a cell viability experiment. 2) The inhibitor potency of ATRi 1 was titrated to identify the MNED. 3) MNED-curve shift 
assay is performed by serial diluting the ADC αHER2-1. The serial dilution of αHER2-1 was added to HCC-1954 cells either alone or with 
ATRi 1 at the previously determined MNED. This led to a leftward shift of the ADC toward lower potencies. The inhibitor was added at 
MNED to the cells as a quality control demonstrating no effect on cell viability. 
 
MNEDs were determined for AZD6738 and VE-822 on a panel of HER2-positive cell lines and on the HER2-
negative cell line MDA-MB-468, because cell lines might respond differently to the combination treatment of 
αHER2-1 and ATRi. In addition, the MNED of BAY73 and ATRi 1 were determined on HCC-1954 cells. The MNEDs 
for the HER2-positive cell lines and the HER2-negative cell line MDA-MB-468 are summarized in table 12.  
 
Table 12: Summary of maximum non-efficacious doses on HER2-positive cell lines and HER2-negative cell line MDA-MB-468. 
 MNED in nM 
Cell line AZD6738 BAY73 ATRi 1 VE-822 
BT-474 1000 - - 1000 
Calu-3 400 - - 80 
HCC-1954 250 14 40 250 
JIMT-1 80 - - 80 
MDA-MB-361 111 - - - 
MDA-MB-453 111 - - 40 
MDA-MB-468 300 - - 300 
SK-OV-3 150 - - 125 
SK-BR-3 150 - - 125 
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Then, the cells were treated with either ADC alone or with a combination of αHER2-1 with AZD6738 or VE-822 
at the corresponding MNED. The IC50-values of the monotreatment and the combination treatment are 
summarized in table 13. Although, in all cases the IC50-values of the combination was lower than the IC50-value 
of the ADC alone, only in few cases the difference was significant. The potency of the ADC alone was 1±1 nM on 
HCC-1954 cells. In combination with 250 nM AZD6738 or 250 nM VE-822, the potency of the combination was 
lowered to 0.3±0.3 nM or 0.3±0.2 nM, respectively. The potentiation effect was significant in both cases (P=.03 
and P=.03, respectively). The IC50-value of αHER2-1 on JIMT-1 was 0.41±0.07 nM. The combination of αHER2-1 
with 80 nM of the ATRi AZD6738 led to a significant higher potency with an IC50-value of 0.19±0.03 nM (P=.03). 
The potency of the combination of αHER2-1 with 111 nM AZD6738 on MDA-MB-361 (IC50=0.03±0.01) was also 
significantly more potent than the monotreatment with αHER2-1 (IC50=0.10±0.02). The potentiation effects 
were also studied on the HER2-negative cell line MDA-MB-468. The potency of the ADC alone was 140±47 nM. 
If 300 nM AZD6738 or 300 nM VE-822 were added, the potency was 19±4 nM or 44±17 nM. The combination of 
αHER2-1 with AZD6738 or VE-822 was significantly more potent than the monotherapy with αHER2-1 alone 
(P=.00009 or P=.0004, respectively). 
 
Table 13: Potencies of ADC αHER2-1 alone or in combination with AZD6738 and VE-822 on a HER2-positive cell panel and a HER2-negative 
cell line MDA-MB-468. The ATRi were added at constant concentration to the ADC αHER2-1 (MNED, see table 12). Potencies of the ADC 
αHER2-1 on the cell panel are already listed in chapter 5.5, table 10, but repeated for comparison. Data are mean±SD for N≥3 biological 
replicates (except for BT-474 where experiments were conducted twice). P-values were added if the combination treatment was 
significantly more potent than the monotreatment. 
  IC50 in nM 
 HER2 αHER2-1 αHER2-1+AZD6738 αHER2-1+VE-822 
BT-474 + 1.0 (1.2, 0.70) 0.086 (0.095, 0.077) 0.079 (0.10, 0.057) 
Calu-3 + 0.9±0.4 0.3±0.1 0.6±0.2 
HCC-1954 + 1±1 0.3±0.3 (P=.03) 0.3±0.2 (P=.03) 
JIMT-1 + 0.41±0.07 0.19±0.03 (P=.03) 0.24±0.02 
MDA-MB-361 + 0.10±0.02 0.03±0.01 (P=.02) N/D 
MDA-MB-453 + 0.3±0.1 0.05±0.01 0.13±0.03 
SK-BR-3 + 0.08±0.03 0.036±0.006 0.05±0.02 
SK-OV-3 + 0.2±0.1 0.07±0.04 0.05±0.02 
MDA-MB-468 - 140±47 19±4 (P=.00009) 44±17 (P=.0004) 
 
The potentiation effects of combination treatment versus monotreatment can be elucidated in a more detailed 
fashion by calculating dose-reduction indices using eq. 2. The potency of a combination is enhanced compared 
to the monotherapy with increasing DRI. The results of this calculation are displayed in figure 47. The DRIs of 
the combination αHER2-1 plus VE-822 on Calu-3, JIMT-1 and SK-BR-3 were below two. In most of the cases, DRIs 
of two to five were reached. The combination of αHER2-1 with AZD6738 exceeded a DRI of five on HCC-1954 
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(DRI=5.4), MDA-MB-453 (DRI=6.4) and MDA-MB-468 (DRI=7.4). DRIs greater then ten were reached for αHER2-
1 combined with AZD6738 (DRI=11.1) and VE-822 (DRI=12.0) on BT-474 cells. 
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Figure 47: Dose-reduction indices of the combination of αHER2-1 with AZD6738 or VE-822 on a panel of HER2-positive cell lines and the 
HER2-negative cell line MDA-MB-468. The ATRi were given at their individual MNED (Table 12) in the combination groups.  
 
Furthermore, HCC-1954 cells were co-treated with ADC αHER2-1 and the ATRi AZD6738, VE-822, ATRi 1 and 
BAY73 to study the effect of the ATRi on the DRI (Figure 48). The ADC alone had an IC50-value of 1.4±1.2 nM, 
while the combination of ADC with 250 nM AZD6738 was 5.4-fold more potent with IC50=0.26±0.33 nM (P=.03). 
The combination of αHER2-1 with VE-822 was comparably potent (IC50=0.33±0.17 nM) and again significantly 
more potent than the monotreatment with αHER2-1 (P=.03). A DRI of 4.3 was obtained for αHER2-1 combined 
with VE-822. The combination of ADC with 40 nM ATRi 1 or 14 nM BAY73 strongly potentiated ADC potency 
(IC50=0.074±0.022 nM and IC50=0.030±0.008 nM, respectively). The combination of αHER2-1 and ATRi 1 achieved 
a DRI of 27.1, while the combination of the ADC with BAY73 led to a 47.1-fold potentiation. It can be stated that 
αHER2-1 plus BAY73 or ATRi 1 are significantly more potent than αHER2-1 alone (P=.01 and P=.01, respectively) 
based on these data. For clarity, the DRIs of the combinations of αHER2-1 with the four different ATRi AZD6738, 
VE-822, ATRi 1 and BAY73 are depicted in figure 48 B. 
  
   93 

H
E
R
2
- 1

H
E
R
2
- 1
+
A
Z
D
6
7
3
8

H
E
R
2
- 1
+
V
E
-8
2
2

H
E
R
2
- 1
+
A
T
R
i 
1

H
E
R
2
- 1
+
B
A
Y
7
3
1 0 -1 1
1 0 -1 0
1 0 -9
1 0 -8
H C C -1 9 5 4
IC
5
0
 [
M
]
 

H
E
R
2
- 1
+
A
Z
D
6
7
3
8

H
E
R
2
- 1
+
V
E
-8
2
2

H
E
R
2
- 1
+
A
T
R
i 
1

H
E
R
2
- 1
+
B
A
Y
7
3
0
5
1 0
1 5
2 0
2 5
3 0
3 5
4 0
4 5
5 0
D
R
I
H C C -1 9 5 4
 
Figure 48: Combination of ADC αHER2-1 with ATRi AZD6738, VE-822, ATRi 1 and BAY73 on HCC-1954 cells. The ATRi are given at their 
individual MNEDs in the combination treatment groups as summarized in table 12. A) The IC50-values of the single agent and combination 
groups are depicted as individual data points. The black bar indicates the mean of the IC50-values for each group. B) DRI of αHER2-1 
combined with the ATRi are plotted. The DRI were calculated from the IC50-values shown in A). 
 
Major differences in the synergy scores were observed when combining small molecule duocarmycins with 
AZD6738. Thus, potentiation effects of DUBA-based ADCs should be compared to potentiation effects of DDM-
carrying ADCs when combined with different ATRi. The potencies of DDM-based ADC αHER2-1 alone or in 
combination with AZD6738 and VE-822 are already summarized in table 13. In addition to these experiments, 
potencies of DUBA-based ADCs αHER2-2 and αHER2-3 alone or in combination with AZD6738 and VE-822 were 
studied on HER2-positive cell lines HCC-1954, Calu-3 and SK-BR-3 and HER2-negative cell line MDA-MB-468. 
While αHER2-2 and αHER2-3 had IC50-values in the single-digit nanomolar range on HCC-1954 and Calu-3 cells, 
the ADCs were potent in the subnanomolar range on SK-BR-3 cells. On MDA-MB-468 cells, the DUBA-based ADCs 
were considerably less potent than on the HER2-positive cell lines, with IC50-values in the double digit nanomolar 
range. The effects of the ADCs were potentiated when adding AZD6738 or VE-822 at their respective MNED for 
every cell line to the ADCs. Although this trend was observed for all the combinations of αHER2-2 and αHER2-3 
with AZD6738 and VE-822, the effects were significant only for the potentiation effects of αHER2-2 plus AZD6738 
(P=.04) and VE-822 (P=.04). 
 
Table 14: Potencies of the DUBA-bearing ADCs αHER2-2 and αHER2-3 as well as control ADC Kadcyla alone or in combination with 
constant doses of AZD6738 and VE-822 at MNED. The MNEDs of ATD6738 and VE-822 for each are summarized in table 12. Data are 
mean±SD of N≥3 biological replicates. 
  IC50 in nM 
  αHER2-2 αHER2-3 Kadcyla 
 HER2 - AZD6738 VE-822 - AZD6738 VE-822 - AZD6738 VE-822 
HCC-1954 + 2±1 0.10±0.02 0.097±0.006 2±1 0.09±0.02 0.15±0.04 0.50±0.03 0.4±0.2 0.3±0.2 
Calu-3 + 4±2 0.7±0.4 0.931±0.164 1.5±0.9 0.4±0.1 0.6±0.2 41±22 37±22 41±23 
SK-BR-3 + 0.16±0.05 0.035±0.007 0.061±0.015 0.15±0.05 0.039±0.001 0.071±0.005 0.2±0.1 0.19±0.02 0.12±0.07 
MDA-MB-468 - 28±6 2.3±0.4 5.14±2.056 17±4 1.4±0.3 5±3 43±9 30±1 31±1 
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The control ADC Kadcyla was comparably potent HCC-1954, SK-BR-3 and MDA-MB-468. On Calu-3, Kadcyla was 
considerably less potent than the duocarmycin-carrying ADCs αHER2-2 and αHER2-3. However, this effect was 
not significant. 
A summary of DRIs of DDM-bearing ADC αHER2-1, DUBA-carrying αHER2-2 and αHER2-3 and control ADC 
Kadcyla combined with AZD6738 and VE-822 at constant dose on HCC-1954, Calu-3, SK-BR-3 and MDA-MB-468 
is displayed in figure 49. On HCC-1954 cells, the highest DRIs were reached with the DUBA-ADCs. The potency 
of αHER2-2 was enhanced strongly by addition of AZD6738 (21.5-fold) or VE-822 (22.9-fold). Weaker 
potentiation effects were achieved by combining αHER2-3 with AZD6738 (18.5-fold) or VE-822 (11.7-fold) at 
MNED. The combination of DDM-bearing ADC αHER2-1 with AZD6738 reached considerably lower DRIs of 5.4 
or 4.3 when AZD6378 or VE-822 were added, respectively. The negative control ADC Kadcyla had DRIs of 1.4 and 
1.5 when combined with AZD6738 or VE-822, respectively. The trend of DUBA-bearing ADCs combined with ATRi 
being superior to DDM-bearing ADC αHER2-1 plus ATRi was reproduced on Calu-3, SK-BR-3 and MDA-MB-468 
although less pronounced. Kadcyla combinations with the ATRi had consistently DRIs<2. 
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Figure 49: Comparison of DRIs of αHER2-1, αHER2-2 and αHER2-3 and Kadcyla when combined with constant concentrations of the ATRi 
AZD6738 and VE-822. The DRIs were calculated using the IC50-values in table 13 and table 14. The ATRi were added to the ADC at MNED 
(Table 12). 
 
In order to compare the potentiation effects of DDM-bearing ADCs with DUBA-carrying ADCs and the negative 
control Kadcyla, DRIs were condensed and depicted in figure 50 A. The potentiation effects of DUBA-based ADCs 
αHER2-2 and αHER2-3 when combined with ATRi were stronger (DRI=9.8 and 7.2, respectively) than the 
potentiation of DDM-based αHER2-1 combinations with ATRi (DRI=3.6). The mean DRI of Kadcyla plus ATRi 
amounts to 1.3. Furthermore, the potentiation effects of the ATRi AZD6738 and VE-822 when added to the 
duocarmycin-bearing ADCs on the different cell lines were compared (Figure 50 B). In all cases, the mean of DRIs 
of the combination AZD6738 with duocarmycin-ADCs was higher compared to the combination of VE-822 with 
duocarmycin-based ADCs.  
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Figure 50: DRIs of duocarmycin-bearing ADCs combined with ATRi. A) DRI of the combination of ATRi with duocarmycin-bearing ADCs 
αHER2-1, αHER2-2 and αHER2-3 as well as Kadcyla were condensed regardless of cell line. Individual data points are displayed and the 
mean is indicated by a black bar. These data are already presented in figure 49. B) DRI of ATRi combined with duocarmycin-bearing ADCs. 
The results were condensed regardless of which ADC-variant was used. Individual data points are displayed and the mean is indicated by 
a black bar. 
 
Every cell line studied in the course of this work had a differential tolerability of the ATR inhibitors, reflected by 
the different MNEDs. In chapter 5.5 selectivity indices were introduced that allowed the comparison of different 
ADCs. However, in the case of combination treatment, varying constant concentrations of ATRi were added to 
the cells together with the duocarmycin-ADC. This impaired the calculation of selectivtiy indices for drug 
combinations. As a result, it was necessary to determine the potency of ADC combined with constant 
concentrations of ATRi on MDA-MB-468. In the following experiments the dependency of the DRI on the 
constant dose of ATRi added to the ADC in combination experiments was investigated. Figure 51 illustrates that 
the IC50-value of the ADC alone was decreased by the addition of either VE-822 or AZD6738 in a dose-dependent 
manner.  
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Figure 51: Dose-dependency of potentiation effects. MDA-MB-468 cells were treated with ADC αHER2-1 and increasing doses of VE-822 
(left) or AZD6738 (right). Individual data points are displayed and the mean is represented by a black bar. 
 
The data presented in figure 51 enabled the calculation of selectivity indices according to eq. 4. Therefore, the 
IC50-value of αHER2-1 combined with a constant concentration of 111 nM AZD6378 on MDA-MB-468 
(53±16 nM) was divided by the IC50-value of αHER2-1 combined with 111 nM AZD6738 on MDA-MB-453 
A B 
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(0.05±0.01 nM). This resulted in a selectivity index of 1010 for the combination treatment at that specific dose 
of ATRi. In comparison to that, the selectivity index of the monotherapy using αHER2-1 amounted to 414. 
Selectivity indices for the monotherapy, combination treatment of αHER2-1 with AZD6738 or VE-822 are 
depicted in figure 52. Since the MNED of the ATRi on BT-474 and the MNED of AZD6738 on Calu-3 exceeded the 
MNED of the HER2-negative cell line MDA-MB-468, no selectivity index was calculated in these cases. 
Furthermore, MDA-MB-468 cells were not treated with 40 nM VE-822, so no SI was calculated for that case. 
The selectivity of αHER2-1 was 153 towards Calu-3 cells, 138 towards HCC-1954 cells and 337 towards JIMT-1 
cells. Higher selectivity indices were reached for αHER2-1 on MDA-MB-453 (SI=460) and SK-OV-3 (SI=690). Triple 
digit indices were obtained when MDA-MB-361 cells or SK-BR-3 cells were treated with αHER2-1 (SI=1380 or 
1725, respectively). When treating HCC-1954, SK-BR-3 and SK-OV-3 cells with αHER2-1 and AZD6738 
simultaneously, the SI were decreased compared to monotherapy. The SI towards HCC-1954 amounts to 100, 
towards SK-BR-3 to 1105 and towards SK-OV-3 cells to 571 when treated with the combination. The selectivity 
was increased when αHER2-1 and AZD6738 were given to JIMT-1 (SI=379), MDA-MB-361 (SI=1749) or MDA-MB-
453 cells (SI=1060) at the same time. The combination treatment of Calu-3 cells with VE-822 and αHER2-1 had 
slighly increased selectivity towards Calu-3 (SI=172) compared to monotherapy. On HCC-1954 cells the 
selectivity of the monotherapy (SI=138) and the combination therapy (SI=140) was equal. On JIMT-1 cells the 
combination of αHER2-1 with VE-822 was more selective towards antigen-positive cells (SI=429) than the 
treatment with αHER2-1 alone, while on SK-BR-3 cells a lower SI of 1640 was obtained for the combination when 
compared to monotherapy. αHER2-1 combined with VE-822 was comparably more selective towards SK-OV-3 
cells (SI=1640) than the ADC alone. 
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Figure 52: Comparison of selectivity indices for monotherapy and combination therapy for αHER2-1 combined with either AZD6378 or 
VE-822 at the respective MNED. Selectivity indices were calculated according to eq. 4 for cells treated with ADC only.  
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5.6.4. Potentiation Effects of Glycoprotein Binding-Duocarmycin DM ADC when Combined with ATRi 
 
Furthermore, it was studied whether the potentiation effects observed with the αHER2-based ADCs on HER2-
positive cells might be translated to other targeted antigens, two glycoprotein (GP)-expressing cell lines were 
treated with GP-binding ADC αGP-1 alone or ADC combined with the ATRi AZD6738 and VE-822 at their 
respective MNED for 6 d. Afterwards, the cell viability was determined using CellTiter-Glo assay. The potencies 
of the cell viability assays are summarized in figure 53. The ADC as single agent had an IC50-value of 5±2 nM on 
GP-expressing cell line 1 and 1.4±0.6 nM on GP-expressing cell line 2. The potency of the ADC αGP-1 was 
enhanced 7.5-fold on GP-expressing cell line 1 cells by the addition of 300 nM AZD6738, which resulted in an 
IC50-value of 0.7±0.3 nM. The addition of 300 nM VE-822 decreased the potency of the combination to 
1.1±0.5 nM which is 4.7-fold more potent than the single agent. On GP-expressing cell line 2 similar results were 
obtained. αGP-1 combined with 300 nM AZD6738 had an IC50-value of 0.3±0.2 nM, which is the equivalent of a 
4.2-fold dose-reduction. The addition of 300 nM VE-822 to the ADC decreased the potency 4.5-fold leading to a 
potency of 0.3±0.2 nM. 
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Figure 53: Potencies of αGP-1 as single agent or combined with constant doses of ATRi AZD6738 and VE-822 on GP-positive cells MDA-
MB-468 and WISH. The inhibitors were given at MNED to the cells. The individual IC50-values of biological replicate experiments are 
displayed. 
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5.7. In Depth Investigation of Drug Combinations of ATRi with Duocarmycin 
 
The combination effects of a drug combination were quantified in previous experiments via synergy scores. 
Therefore, six doses of each compound were mixed with each other to obtain a 6x6-dose-matrix from which a 
synergy score was derived by calculating the weighted volume between the expected response for an additive 
drug combination according to the Loewe additivity model and the actual measured response of the drug 
combination. It was defined that synergy scores S < -1 were indicative of antagonistic drug combinations, scores 
between -1 and 1 were additive and drug combinations yielding S > 1 were termed synergistic. However, synergy 
scores reduce the data obtained into one single value, leading to the loss of information. In this chapter, it was 
aimed at improving the amount of information obtained from one experiment. Thus, a dilution series of 13 
dilution steps was generated for each compound of a drug combination and the dilution series were mixed 
subsequently yielding a 13x13-dose-matrix. Besides the synergy score, curve-shift data were obtained from a 
dose-matrix assay as illustrated in figure 54. The horizontal data of a dose-matrix yielded the curve-shift of 
drug A supplemented with constant concentrations of drug B. The vertical data were considered as a curve-shift 
assay of drug B with different concentrations of drug A being added. The diagonals of the matrix were used to 
obtain information about curve-shifts of drug A and B when given simultaneously to the cells at varying fixed-
ratios where the ratio of each combination-curve was calculated according to eq. 5. 
 
 𝑟𝑎𝑡𝑖𝑜 =  
𝐶𝑑𝑟𝑢𝑔 𝐴
𝐶𝑑𝑟𝑢𝑔 𝐵
 Eq. 5 
 
In addition, the data of a curve-shift assay were used to calculate dose-reduction indices and combination 
indices according to eq. 2 and eq. 1, respectively. 
 
 
Figure 54: 6x6-dose-matrix assay set-up. A serial dilution with 6 dose-levels of drug A and B are mixed to yield a dose-matrix. A cell 
viability assay can be used to determine a synergy score from this dose-matrix assay. Furthermore, curve-shift data can be derived for 
serial-dilutions of drug B supplemented with a constant concentration of drug A and vice versa. In addition, curve-shifts of drug 
combinations of drug A plus drug B at a fixed-ratio can be derived from the diagonals of the dose-matrix. 
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Genedata Screener, which was used in the course of this work to calculate synergy scores, has no integrated 
solution for the calculation of the curve-shift assay data, DRIs or CIs.  
A R-based program was written that first fits the vertical, horizontal and diagonal data of the dose-matrix. This 
way full dose-response curves for the single agents and the combinations of drug A plus constant concentrations 
of drug B, and vice versa, were obtained as well as the drug combinations at a fixed-ratio between drug A and 
B. The DRCs were fitted using the logisitc fitting function LL.4 (Eq. 6) of the DRC package by inserting the viability 
of the cells f(x) for every dose x.154 This equation describes a 4-parameter logistic (4PL) curve and reads as 
follows: 
 
 𝑓(𝑥) =  𝐵𝑜𝑡𝑡𝑜𝑚 +
𝑇𝑜𝑝 − 𝐵𝑜𝑡𝑡𝑜𝑚
1 + 𝑒𝐻𝑖𝑙𝑙𝑆𝑙𝑜𝑝𝑒(log 𝑥−log 𝐼𝐶50)
 Eq. 6 
 
By fitting the cell-viability data, the parameters “Bottom”, “Top”, “HillSlope” and “IC50” are obtained that fully 
define the DRC at any given dose x. “Bottom” and “Top” describe the level of cell viability reached in saturation. 
“HillSlope” describes the slope of the curve and the “IC50” decribes the turning point of the curve. Another way 
to plot dose-response curves is based on the median effect equation (MEE) given in eq. 7.19  
 
 
𝑓𝑎
𝑓𝑢
= (
𝐷
𝐷𝑚
)
𝑚
 Eq. 7 
 
The effect level of a certain drug dose D is expressed as fraction of affected cells (fa) divided by the fraction of 
unaffected cells (fu), where the latter corresponds to the cell viability. The fraction of affected cells and 
unaffected cells adds up to one, representing the whole cell population (Eq. 8).  
  
 1 = 𝑓𝑎 + 𝑓𝑢 Eq. 8 
  
The parameter Dm corresponds to the IC50-value of the 4PL equation and m corresponds to the HillSlope of the 
4PL equation. Examples of DRCs using the 4-parameter logistic equation or the median effect equation are given 
in figure 55. 
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Figure 55: Examples of dose-response curves following 4-point logistic and median effect equation. A certain drug dose induces a certain 
cellular effect. The data pairs of drug dose and drug response can be used to fit a dose-response curve using the 4-point logistic equation 
or the median effect equation. Left: The DRC is defined by four parameters “Top”, “Bottom”, “HillSlope” and “IC50”. Right: The median 
effect equation is defined by the IC50 and the HillSlope. 
 
As a proof of concept experiment, MDA-MB-453 cells were treated for 6 d with αHER2-2 and AZD6738 in a 
13x13-dose-matrix format. The cell viability was determined using CellTiter-Glo reagent and luminescence was 
read using Envision reader. This experiment was performed twice and similar results were obtained. 
The validity of the fit data was checked by comparing the IC50-values obtained from fitting the data with the LL.4 
function and the IC50-values calculated by GeneData Screener software. Therefore, the mean of IC50-values of 
the two biological replicate experiments was plotted and fitted using a linear regression model in Microsoft 
Excel. The slope of the linear regression was m=0.9935 with a coefficient of determination R²=0.9812, indicating 
that IC50-values obtained through fitting with GeneData Screener or the LL.4 function of the DRC package are 
comparable (Appendix 3).  
The fitting results were stored in a table for the calculation of DRI. Next, the dose-reduction indices at the IC50-
value of the combination αHER2-2 plus AZD6738 were calculated and plotted against the amount of αHER2-2 or 
AZD6738 added to the respective other compound. A linear regression was performed. Representative graphs 
are displayed in figure 56.  
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Figure 56: DRI at IC50 of MDA-MB-453 cells treated with a combination of αHER2-2 and AZD6738. Left: The DRI of cells treated with serial 
dilutions of AZD6738 plus constant concentrations of αHER2-2 was plotted against the constant concentration of αHER2-2 added to the 
ATRi. Right: The DRI of combinations of αHER2-2 plus AZD6738 was plotted dependent on the concentration of AZD6738 that was added 
to the ADC. 
 
Slope and intercept of the linear regressions of two biological replicate experiments were averaged, yielding the 
linear equations eq. 9 for the DRI of the ADC αHER2-2 as a function of the amount of ATRi AZD6738 added and 
eq. 10 for the DRI of the ATRi AZD6738 depending on the amount of αHER2-2 added to the ATRi. Furthermore, 
combinations of αHER2-2 with ATRi 1 and BAY1895344 were studied on MDA-MB-453 cells and the DRIs at the 
IC50-value was plotted against the concentration of ADC or ATRi. The results of the linear regressions are 
summarized in table 15. The linear regression equations illustrated that the DRIs of the combinations were 
dependent on the amount of αHER2-2 or ATRi AZD6738, ATRi 1 and BAY1895344 added to the combination on 
MDA-MB-453. While the DRI of αHER2-2 was increased by m=0.0349/nM with growing concentration of 
AZD6738, the effect was 12-fold stronger if ATRi 1 was added (m=0.427/nM) or 90-fold stronger for the 
combination with BAY1895344 (m=3.13/nM). The same trend was observed considering the potentiation effects 
of the ATRi when adding constant concentrations of the ADC. The addition of αHER2-2 to AZD6738 led to an 
increase of m=75.2/nM with increasing ADC concentrations. Again, the addition of constant concentrations 
αHER2-2 to ATRi 1 led to stronger potentiation effects (4-fold, m=304/nM) and the effects of adding αHER2-2 to 
BAY1895344 were even more pronounced (8-fold regarding AZD6738, m=560/nM). 
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Table 15: Summary of equations of linear regressions for combination experiments of ATRi combined with αHER2-2 on MDA-MB-453 
cells at the half-maximum inhibitory concentration. The equations are depicted either as a function of the constant concentration of ATRi 
added or dependent on the constant concentration of αHER2-2 given to the cells. The parameters slope and y-axis intercept are the mean 
of N replicate experiments as stated in the table. The coeffcients of determination of the individual linear regressions are R²>.974.  
ADC ATRi Cell line Equation Eq. No. N 
αHER2-2 
AZD6738 
MDA-MB-453 
𝐷𝑅𝐼𝛼𝐻𝐸𝑅2−𝟐 =
0.0349
𝑛𝑀
∗ 𝐶𝐴𝑍𝐷6738 + 0.280 Eq. 9 
2 
𝐷𝑅𝐼𝐴𝑍𝐷6738 =
75.2
𝑛𝑀
∗ 𝐶𝛼𝐻𝐸𝑅2−𝟐 + 1.00 Eq. 10 
ATRi 1 
𝐷𝑅𝐼𝛼𝐻𝐸𝑅2−𝟐 =
0.427
𝑛𝑀
∗ 𝐶𝑀𝑒𝑟𝑐𝑘 331 − 0.124 Eq. 11 
2 
𝐷𝑅𝐼𝑀𝑒𝑟𝑐𝑘 331 =
304
𝑛𝑀
∗ 𝐶𝛼𝐻𝐸𝑅2−𝟐 + 1.02 Eq. 12 
BAY1895344 
𝐷𝑅𝐼𝛼𝐻𝐸𝑅2−𝟐 =
3.13
𝑛𝑀
∗ 𝐶𝐵𝐴𝑌1895344 − 1.08 Eq. 13 
1 
𝐷𝑅𝐼𝐵𝐴𝑌1895344 =
560
𝑛𝑀
∗ 𝐶𝛼𝐻𝐸𝑅2−𝟐 + 0.81 Eq. 14 
 
These calculations of the DRI for combinations of ATRi with αHER2-2 on MDA-MB-453 cells were performed for 
the IC50-values. In order to calculate the DRI at any given effect level it was necessary to calculate the dose 
needed to achieve a certain cellular response. Therefore, the MEE was solved for the dose D as shown in in eq. 
15. 
 
 𝐷 = 𝐷𝑚 ∗ (
1 − 𝑓𝑢
𝑓𝑢
)
1
𝑚
 Eq. 15 
 
Eq. 15 is defined by using the parameters obtained from fitting the cell viability data. Potentiation effects 
expressed as DRI can be calculated using eq. 2 as stated in materials and methods (chapter 4.18). This equation, 
however, is restricted to calculations using the dose at the IC50-value of mono- or combination therapy. A 
generalized equation is given in eq. 16, that allows the calculation of a DRI for every effect level for drug A 
combined with constant concentrations of drug B.  
 
 𝐷𝑅𝐼𝑑𝑟𝑢𝑔 𝐴 =
𝐷𝑑𝑟𝑢𝑔 𝐴
𝐷𝑑𝑟𝑢𝑔 𝐴+𝐶𝑑𝑟𝑢𝑔 𝐵
 Eq. 16 
 
Eq. 17 was yielded by inserting eq. 15 into eq. 2. This equation allowed the calculation of the DRI for a drug 
combination at every effect level. 
 
 𝐷𝑅𝐼𝑑𝑟𝑢𝑔 𝐴 =
𝐷𝑚𝑑𝑟𝑢𝑔 𝐴 ∗ (
1 − 𝑓𝑢
𝑓𝑢 )
1
𝑚𝑑𝑟𝑢𝑔 𝐴
𝐷𝑚𝑑𝑟𝑢𝑔 𝐴+𝐶𝑑𝑟𝑢𝑔 𝐵
∗ (
1 − 𝑓𝑢
𝑓𝑢 )
1
𝑚𝑑𝑟𝑢𝑔 𝐴+𝐶𝑑𝑟𝑢𝑔 𝐵
 Eq. 17 
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The fit results obtained from the cell viability assay for combinations of αHER2-2 and AZD6738 on MDA-MB-453 
were used to generate the DRI-surface displayed in figure 57. The DRI-surface was plotted dependent on the 
amount of drug at constant concentration added to serial dilutions of the respective other drug and on the effect 
level expressed as viability. The DRI of ATRi was calculated as a function of the amount of ADC added (Figure 57 
A1) In these combination experiments. Another, complementary set-up calculated the DRI of the ADC as a 
function of the constant concentration of ADC that was added to the cells (Figure 57 A2). The same calculations 
were performed for the addition of constant concentrations of ATRi to serial dilutions of the ADC. The DRI-
surfaces of AZD6738 plus constant concentrations of αHER2-2, and αHER2-2 combined with constant 
concentrations of AZD6738 were in line with the results of the DRI calculated at IC50 (Figure 56). Two trends 
were deduced from the calculations. Firstly, the DRI increased in these cases (Figure 57 A1 and B1) with 
increasing constant concentrations of the respective second drug. Secondly, the DRI depended on cell viability 
in a way that high cell viability correlated with strong potentiation effects. In contrast to that, the dose-reduction 
indices of αHER2-2 as a function of the constant concentration of αHER2-2 showed the highest values at low 
concentrations of αHER2-2 and low cell viabilities (Figure 57 A2). The same trend was found for the dependency 
of DRIs of AZD6738 on the concentration of AZD6738 added (Figure 57 B2).  
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Figure 57: DRI-surface of MDA-MB-453 cells treated with αHER2-2 and AZD6738. The DRI-surface was modeled using the DRC data 
obtained from a cell viability assay. These graphs are representative for two independent experiments. A1) Constant concentrations of 
αHER2-2 were added to serial dilutions of AZD6738 on MDA-MB-453. DRI of αHER2-2 was plotted as a function of the concentration of 
AZD6738. B1) Serial dilutions of αHER2-2 were supplemented with increasing constant concentrations of AZD6738 to treat MDA-MB-453 
cells. DRI of AZD6738 was plotted as a function of the concentration of αHER2-2. A2) Same data set as in A1, but DRI was calculated for 
the constant concentration of αHER2-2 that was given to the ATRi. B2) Same data set as in B1, but the DRI of AZD6738 was calculated for 
the constant concentration of AZD6738 that was added to the ADC αHER2-2. The surface is shaded in white to black, where white 
indicates low DRI and black indicates high DRI. 
 
The equation that defines the combination index for drug combinations (Eq. 1) was already introduced in the 
introduction. According to eq. 1, the CI can be calculated by dividing the doses of the individual drugs A and B in 
combination by the doses that are needed to achieve the same cellular effect when applying A or B as single 
agents. Subsequently, the sum of the fractions is formed to determine the CI. Another way to calculate the CI 
sums up the reciprocal DRI of drug A and B, which is expressed in eq. 18. 
 
 𝐶𝐼 =
𝐷𝐴
(𝐷𝑥)𝐴
+
𝐷𝐵
(𝐷𝑥)𝐵
=
1
𝐷𝑅𝐼𝑑𝑟𝑢𝑔 𝐴
+
1
𝐷𝑅𝐼𝑑𝑟𝑢𝑔 𝐵
 Eq. 18 
MDA-MB-453 MDA-MB-453
MDA-MB-453 MDA-MB-453
A1 B1
A2 B2
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Eq. 18 was used to generate a combination index surface that depends on viability of the cells as well as on the 
ratio between AZD6738 and αHER2-2. Figure 58 depicts the CI surface calculated using eq. 18 (left) and the 
CIcomp function implemented in the DRC package (right). The CI decreased at high effect levels or low cell 
viabilities. The ratio between the drugs strongly influenced the CI. Decreasing the ratio of AZD6738 to T-2 
decreased the CI simultaneously. 
 
 
Figure 58: Combination index surface of αHER2-2 combined with AZD6738 on MDA-MB-453 cells at a fixed-ratio for a range of effect 
levels. Left: CI surface derived from eq. 18. CI depends on viability and the ratio between the two drugs added to MDA-MB-453 cells. 
Right: CI surface calculated using the CIcomp function from DRC model. The CI depends on the effect level, which is the complement to 
cell viability, and the ratio between the compounds αHER2-2 and AZD6738. The surface is shaded in white to black, where white indicates 
low CI and black indicates high CI. The graphs are representative of two replicate experiments. 
 
Next, the CI was determined for the combination of αHER2-2 with AZD6738 on MDA-MB-453 at either constant 
concentration of the ADC or the ATRi for varying effect levels dependent on constant concentrations of ATRi or 
ADC added to the combination (Figure 59). The CI reached a minimum when T-2 was added at a constant 
concentration of 1.2 pM. In general, the CI decreased with increasing effect levels or decreasing cell viabilites, 
respectively. Although the CI increased with increasing constant concentrations of T-2 in the mixture, it 
remained smaller than one, indicating synergy. One exception is found at an effect level of 10% and a 
concentration of 0.6 pM ADC where the CI was 1.2, indicating antagonism. Similar results were obtained for the 
combination of αHER2-2 and AZD6738 dependent on the constant concentration of AZD6738 added to the cells. 
The minimal CI was reached when 9.8 nM of the ATRi were present. The combination was synergistic over the 
whole range of doses and effect levels except for the combinations of 625 nM AZD6738 with serial dilutions of 
αHER2-2 and at low effect levels when 2.4 nM ATRi were added to αHER2-2.  
MDA-MB-453 MDA-MB-453
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Figure 59: Combination index surface of αHER2-2 combined with AZD6738 on MDA-MB-453. The CI was determined as a function of the 
constant concentration of either αHER2-2 or AZD6738 added to the combination and of the cell viability. The surface is shaded in white 
to black, where white indicates low CI and black indicates high CI. The graphs are representative of two replicate experiments. 
 
In addition, the CI surfaces were modeled for the combination of αHER2-2 with ATRi 1 on MDA-MB-453 cells 
(Figure 60 A) and for the combination of αHER2-2 with BAY1895344 on MDA-MB-453 cells (Figure 60 B). When 
comparing the CI surfaces for αHER2-2 combined with either AZD6738, ATRi 1 or BAY1895344 on MDA-MB-453 
it became apparent, that the course of the CI surface of the ATRi combined with constant concentrations of ADC 
remained largely unaffected by the choice of the ATRi. The CIs of αHER2-2 plus BAY1895344 were the lowest, 
the CIs of αHER2-2 combined with ATRi 1 were nearly equally low and the CI values of the combination of αHER2-
2 with AZD6738 displayed the highest CI values over the range of tested concentrations. While the combination 
of αHER2-2 with varying constant concentrations of ATRi 1 had the minimum CI value at 9.8 nM ATR,i which is 
comparable to the combination of αHER2-2 with AZD6738, the minimum CI of αHER2-2 plus constant 
concentrations of BAY1895344 was 3.9 nM. The R-based script, that was written for the evaluation of the 13x13-
dose-matrices, is attached in appendix 20. 
. 
MDA-MB-453 MDA-MB-453
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Figure 60: Combination index surface of αHER2-2 combined with ATRi on MDA-MB-453. The CI was determined as a function of the 
constant concentration of either αHER2-2 or ATRi added to the combination and of the cell viability. The surface is shaded in white to 
black, where white indicates low CI and black indicates high CI. A) CI surface for αHER2-2 plus ATRi 1. The graphs are representative of 
two replicate experiments. B) CI surface of αHER2-2 combined with BAY1895344 on MDA-MB-453. The graphs are representative of one 
experiment. 
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5.8. In vivo Efficacy and Tolerability of αHER2-6 Combination with ATR Inhibitors AZD6738 and 
ATRi 1 
 
After it was sucessfully confirmed that duocarmycins also synergize with ATRi when conjugated to an antibody 
the combination was investigated in vivo to study efficacy and tolerability of the combination treatment. 10 days 
after subcutaneous injection of NCI-N87 cells into H2d Rag2 mice, animals were randomized and treated either 
with vehicle, with a single intravenous dose of 1.0 mg kg-1 αHER2-6 or with 50 mg kg-1 ATRi AZD6738 or ATRi 1, 
given once daily over 14 days per oral. The combination effects were studied by giving αHER2-6 combined with 
AZD6738 or αHER2-6 plus ATRi 1 at the same dosing and schedule as the single agents.  
The vehicle group was terminated on day 24, because the tumor volumes met the criterium for termination. The 
treatment with AZD6738 was not statistically different from the vehicle-treated group (P=.2). In case of the ATR 
Inhibitor ATRi 1, a transient tumor stasis was induced until day 8 but the tumor rapidly progressed to reach the 
endpoint. However, the tumor-growth inhibition was statistically significantly stronger compared to the vehicle 
group (P=.003). The administration of the single agent αHER2-6 led to transient tumor stasis until day 9 when 
the tumor progressed. ADC-treatment resulted in statistically significant reduction of tumor volume compared 
to the vehicle-receiving group (P=.0002) and the ATRi monotherapy groups treated with AZD6738 (P=9x10-9) and 
ATRi 1 (P=.006). 
The combination therapy groups αHER-6 plus AZD6738 or ATRi 1 however induced stastistically significantly 
stronger anti-tumoral effects than the vehicle-treated group (P=.00003 or P=.00002, respectively). The 
combination αHER-6 plus AZD6738 induced tumor stasis until day 66 when this group was terminated because 
three animals had skin lesions on the tumors. The treatment of mice with a combination of αHER-6 and ATRi 1 
led to tumor regression until day 63 when the tumors began to progress again. Remarkably, in the combination 
treatment group that received αHER-6 plus AZD6738, one mouse showed a complete response (Vtumor<20 mm3) 
which lasted until the group was terminated (day 66). In the group treated with αHER-6 plus ATRi 1 a total of 
three complete responses were observed. In one mouse, this effect was transient lasting around 90 days until 
the tumor progressed and in case of the other two mice, the animals showed tumor free survival until the end 
of the observation period (15 weeks). The data are displayed in figure 61 at the level of the treatment groups 
(Figure 61 A) and at the level of individual animals in the combination groups (Figure 61 B). 
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Figure 61: Therapeutic efficacy of αHER2-6 combined with the ATR inhibitors AZD6738 and ATRi 1 in H2d Rag2 mice bearing NCI-N87 
xenografts. A) Antitumor activity was assessed as change in tumor volume compared to vehicle, and the single agents αHER2-6, AZD6738 
and ATRi 1. Therefore mice (N=10 per group) were treated with 1.0 mg kg-1 αHER2-6 intravenously, 50 mg kg-1 AZD6738 or ATRi 1 per 
oral once daily for two weeks or a combination of αHER2-6 plus AZD6738 or αHER2-6 plus ATRi 1 at the same doses and schedules as the 
single agents beginning at day 0 as indicated by the arrow. The upper dotted line indicates an increase in tumor volume of 73%, while 
the lower dotted line indicates a decrease in tumor volume by 66% as compared to day 0. The range between the dotted lines indicates 
tumor stasis and below the lower line tumor regression. B) Tumor volume of the combination groups αHER2-6 plus AZD6738 or αHER2-
6 plus ATRi 1 at the level of individual animals. Treatment with αHER2-6 plus AZD6738 led to 1/10 cures, while the treatment with αHER2-
6 plus ATRi 1 led to 2/10 cures. 
 
The tolerability of the anti-cancer treatment was assessed considering the overall condition of the animal as well 
as body-weight changes of the mice (Figure 62). The body-weight of mice treated with the ADC αHER2-6 did not 
decrease and was comparable to the body-weight of the vehicle-treated group at all time points. However, mice 
treated with the ATRi AZD6738 and ATRi 1 lost weight compared to the vehicle group but body-weight loss was 
still below 5%. Mice receiving combination treatment with αHER2-6 and AZD6738 or ATRi 1 showed a body-
weight profile comparable to mice treated with the ATRi AZD6738 or ATRi 1 as single agents. 
It can be concluded that the ADC αHER2-6, the ATRi AZD6738 and ATRi 1 as well as the combination treatments 
were well tolerated. 
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Figure 62: Therapeutic tolerability of αHER2-6 combined with the ATR inhibitors AZD6738 and ATRi 1 in H2d Rag2 mice bearing NCI-N87-
xenografts.The body weight was assessed as a measure of tolerability of the combination treatment as well as the corresponding single 
agents αHER2-6, AZD6738 and ATRi 1. 
 
A B 
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5.9. Bleomycin A5-ADCs 
 
In preceeding chapters it was discovered that drugs of the duocarmycin family synergized with ATRi and that 
ATR knock-down cells were sensitized towards duocarmycin treatment. Furthermore, duocarmycins were 
coupled to antibodies and the resulting ADCs were studied in depth in combination with ATRi. It was proven, 
that the synergy observed with the combinations of small molecule duocarmycins could be translated to the 
ADC context. ATR belongs to the PIKK kinase family and is responsible for replication and DNA-damage response. 
DNA-PK and ATM are two other enzymes of the PIKK family that are both involved in DNA-damage response, 
specifically in the repair of double-strand breaks. It was hypothesized that synergistic drug combinations might 
be discovered for these members of the PIKK family. In this chapter double-strand break inducing Bleomycin A5-
based ADCs were generated and subsequently combined with DNA-PK inhibitors NU7441 and M3814. 
 
5.9.1. Generation of Bleomycin A5-Bearing ADCs 
 
Linker-drug 9 was synthesized (laboratory Dr. Carl Deutsch, department of ADCs and Targeted NBE Therapeutics, 
Merck KGaA), which carried the double-strand break inducer Bleomycin A5 (BA5). LD-9 consisted of several 
structural units. A triple-glycine motif for SrtA-mediated conjugation was introduced N-terminally, followed by 
a spacer. A valine-citrulline dipeptide coupled with a self-immolative PAB module ensured efficient release of 
the drug Bleomycin A5 (Figure 63). 
 
 
Figure 63: Bleomycin A5 linker-drug 9. The linker-drug can be structured into five units. Beginning N-terminally, a triple-glycine for SrtA 
conjugation is introduced, followed by a spacer. The dipeptide valine-citrulline paired with the self-immolative module PAB ensures 
efficient, traceless release of Bleomycin A5. 
 
LD-9 was conjugated to the LCs of the αHER2 and the αEGFR mAb (format A) via SrtA-mediated ligation. A DAR 
of 1.78 was achieved in both cases. Furthermore, LD-9 was conjugated to trastuzumab in the mAb format D, 
which allowed the conjugation of up to four drugs per mAb. The preparation yielded αHER2-9 with a DAR of 
3.38. The theoretical yield of the preparation of αHER2-9 with SrtA-site at HC and LC and the preparation of 
PAB
Valine-Citrulline
Triple-glycine
Bleomycin A5
spacer
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αEGFR-9 was exceeded (>100%). The yield of the generation of αHER2-9 with 1.78 drugs per mAb was excellent. 
The monomeric content was high with >99.0%. Table 16 gives an overview of the produced ADCs. 
 
Table 16: Overview of preparations of Bleomycin-A5 ADCs. The column “App.” contains the appendix number under which data such as 
HIC and SEC profile can be found. 
Target 
mAb 
format 
Linker-
drug 
Purification 
route 
Yield [µg] Yield [%] DAR Monomer [%] App. 
αHER2 A 9 A 2240 93.0 1.78 99.8 17 
αHER2 D 9 A 4430 116.0 3.38 99.2 16 
αEGFR A 9 A 5240 122.2 1.78 99.8 18 
αHEL A 9 A 1530 65.0 1.81 99.7 19 
 
5.9.2. Cytotoxicity of Bleomycin A5-Based ADCs 
 
Anti-proliferative effects of Bleomycin A5-ADC αEGFR-9 in mAb format A were studied on an EGFR-postive cell 
line panel. However, only on EGFR-positve cell lines MDA-MB-468 and A431 the effects of Cetuximab alone were 
exceeded (Figure 64). On MDA-MB-468, the potency of αEGFR-9 was 1.4±0.4 nM (N=6) and on A431 a potency 
of 5±1 nM (N=3) was reached. On EGFR-negative MCF7 cells, no effect was observed (N=1). In addition, on the 
EGFR-positive cell lines A549, Capan-2, MDA-MB-231 and SK-OV-3 no effect was observed up to 250 nM (N=1, 
each). The small molecule Bleomycin A5 was considerably less potent on MDA-MB-468 with an IC50-value of 
1973±387 nM (N=4). 
 
 
Figure 64: Representative dose-reduction curves of Bleomycin A5-ADC αEGFR-9 and αHEL-9 and mAb cetuximab on EGFR-positive cell 
lines MDA-MB-468, A431 and EGFR-negative cell line MCF7. 
 
The Bleomycin A5-ADC αHER2-9 was active on HCC-1954 cells with an IC50 value of 1.2±0.5 nM (N=3). At 250 nM, 
the highest concentration used in the assays, 42±4% of the cells were killed. In comparison to this, the small 
molecule Bleomycin A5 had an IC50-value of 567±21 nM (N=3). To exclude, that the effect is mediated by the 
αHER2 mAb itself, the mAb was tested on the cells. The αHER2 mAb alone killed 4±4% (N=3) of the cells at 
250 nM. On the negative cell line MDA-MB-468 αHER2-9 affected 7±4% (N=3) of the cells at C=250 nM. No 
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cytotoxic effect was observed up to 250 nM on BxPC3 and LNCaP cells when treated with αHER2-9. The 
potencies of Bleomycin A5-based ADCs are summarized in table 17. 
 
Table 17: Overview of cytotoxicity of Bleomycin A5-based ADCs. Isotype control ADC αHEL-9, αEGFR-9 and αHER2-9 as well as small 
molecule BA5 were studied on several cell lines. EGFR and HER2 levels are indicated by plus or minus sign for postive or negative cell 
lines, respectively. If no cytotoxic effect was observed up to 250 nM, it is indicated by “No Effect (N/E)”. Experiments were conducted in 
singlicates, except it is stated otherwise. 
   IC50 in nM 
 EGFR HER2 αHEL-9 αEGFR-9 αHER2-9 BA5 
A431 + N/E N/E 5±1 (N=3) - - 
A549 + N/E N/E N/E - - 
BxPC3 + N/E - - N/E - 
Capan-2 + N/E - N/E - - 
HCC-1954 + + - N/E 1.2±0.5 (N=3) 567±21 (N=3) 
LNCaP + N/E N/E - N/E - 
MCF7 - N/E N/E N/E - 4152 (N=1) 
MDA-MB-231 + N/E - N/E - - 
MDA-MB-468 + + N/E 1.4±0.4 (N=6) N/E 1973±387 (N=4) 
SK-OV-3 + + - N/E - - 
SK-BR-3 + + - - N/E - 
 
5.9.3. Synergistic Effects of Bleomycin A5-ADC Combinations with DDRi 
 
The Bleomycin A5-bearing ADC was active on MDA-MB-468 in the nanomolar range. As a next step, it was 
studied whether the Bleomycin A5-ADC synergizes with DDRi known to be involved in double-strand break 
repair. Therefore, αEGFR-9 was combined with the DNA-PKi NU7441 and M3814 on MDA-MB-468 in a dose-
matrix assay. As controls, the small molecule Bleomycin A5 and the antibody cetuximab were combined with 
the DDRi NU7441. After 6 d, the cell viability was read out as luminescence on an Envision reader. The data were 
analyzed via GeneData Screener and synergistic effects were expressed as synergy scores. All combinations 
exceeded the cutoff synergy score that indcated additivity. The small molecule Bleomycin A5 combined with 
NU7441 had a mean synergy sycore of 2.7, however, the values scattered strongly. The combination of 
cetuximab with NU7441 also exceeded the cutoff with S=1.8. The synergy of ADC αEGFR-9 combined with the 
DNA-PKi NU7441 (S=5.7) was stronger than the synergy between αEGFR-9 and M3814 (S=4.7). The synergy 
scores are summarized in figure 65. 
 
   113 
B
A
5

E
G
F
R
- 9

E
G
F
R
0
2
3
4
5
6
S
y
n
e
r
g
y
 S
c
o
r
e
N U 7 441
M 3 8 1 4
1
 
Figure 65: Synergy scores of αEGFR-9 when combined with DNA-PKi NU7441 or M3814 on EGFR-positive MDA-MB-468 cells. Control 
groups were combinations of cetuximab (C) or Bleomycin A5 combined with DNA-PKi NU7441. Individual data points are displayed as 
well as a black bar indicating the mean of the individual points. 
 
5.9.4. Potentiation Effects of Bleomycin A5-ADC Combined with NU7441 or KU-55933 
 
The ADC αEGFR-9 was added to MDA-MB-468 cells either alone or together with a constant concentration of 
the DNA-PKi NU7441. The DDRi was given at its respective MNED of 1.2 µM. The potency amounts to 
0.07±0.01 nM when 1.2 µM NU7441 and αEGFR-9 were added to MDA-MB-468 cells simultaneously. This is a 
significant (P=.0007) 19.3-fold potentiation of the ADC potency (IC50=1.4±0.4 nM). 
 
 
Figure 66: Dose-response curves of αEGFR-9 combined with constant doses of DNA-PKi NU7441 on MDA-MB-468. The combination of 
αEGFR-9 with 1.2 µM NU7441 led to a curve-shift of 19.3 as calculated from the mean of the mono- and combination treatment.  
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6. Discussion 
 
6.1. Screening for a Synergistic Drug Combination Partner for Duocarmycin 
 
A total of 17 DDRi were combined with DUBA on the two cancer cell lines HCC-1954 and MDA-MB-468. While 
most of the DDRi yielded only additive effects when combined with DUBA, some exceeded the cutoff for synergy 
barely. Two targets were identified whose inhibition led to strong synergistic anti-proliferative effects in 
combination with DUBA, namely ATR and CHK1. These enzymes play a major role in the replication stress 
response in the same pathway, where CHK1 is the downstream kinase of ATR. 
In order to prove the observed synergy between DUBA and the ATRi and CHK1i in the dose-matrix assay, the 
enzymes were downregulated by transfection of HCC-1954 cells with ATR and CHK1 siRNA. The potency of DUBA 
and DDM was substantially higher on ATR knock-down cells than on cells treated with non-targeting siRNA. 
However, only a minor potentiation was observed in case of CHK1 siRNA treated cells compared to control cells. 
One explanation for this might be that the CHK1i LY2603618 and AZD7762 have off-target effects on ATR. 
Although LY2603618 was described as a specific CHK1i based on a screening on 51 kinases, inhibitory effects 
regarding ATR were not studied.155 In case of the CHK1i AZD7762, it was tested for inhibitory effects on a total 
of 164 kinases, but again, ATR was not studied.156 Based on these reports it cannot be fully excluded, that the 
CHK1i have off-target effects on ATR. However, in case of CHK1 siRNA treatment, the knock-down efficiency was 
considerably lower compared to ATR knock-down, leading to residual CHK1 levels that might be sufficient for 
cell cycle regulation. This might also explain the differentially strong potentiation effects of ATR or CHK1 knock-
down versus control cells. 
Taken together, this work identified a synergistic drug combination of ATRi combined with the duocarmycin-
derivative DUBA. However, at this point it was not clear which influence the duocarmycin variant and also the 
type of the ATRi have on the synergistic cell killing effects. 
 
6.2. Impact of Duocarmycin Structure on Synergistic Effects 
 
During the screening procedure only one distinct molecule from the duocarmycin familiy was used, namely 
DUBA. In order to elucidate the influence of the structure of the duocarmycin on synergistic effects, a 
duocarmycin library was combined with the ATRi AZD6738 to treat HCC-1954 cells. Duocarmycins consist of two 
structural subunits – the binding and alkylating unit. It was aimed at identifying the distinct influence of these 
two structural subunits. The results are summarized in figure 67. Figure 67 A ranks compounds with a 
trimethoxyindole (TMI) binding moiety and five varying alkylating units. While the duocarmycins with bi- and 
tricyclic alkylating units had synergy scores in the same range when combined with AZD6738, the monocyclic 
variant synergized with the ATRi only weakly. Apparently, whether the achiral or chiral variants were combined 
with AZD6738 did not have a major impact on the synergy score for duocarmycins with the bi- and tricyclic 
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alkylating units. In figure 67 B and C, the duocarmycin variants from the CBI-series were ranked. Here, the 
alkylating unit was a CBI-unit or a methyl-CBI-unit. These duocarmycins comprised different binding units. 
Although small differences were observed for the combination of these compounds with the ATRi AZD6738 on 
HCC-1954, the differences were less distinct compared to the TMI-series, suggesting a larger impact of the 
alkylating unit on the synergistic effects than the binding unit.  
Members of the duocarmycin family have distinct properties that largely depend on their structure. These 
properties include stability, cytotoxicity and alkylation rate. It was reported that the choice of the alkylation unit 
as well as the binding unit influences the alkylation properties of the duocarmycin.157,158 In this report, no 
correlation between potency and synergy score for duocarmycins combined with ATRi was established. It is 
possible that the synergy between duocarmycins and ATRi depends on several factors such as the alkylation 
efficiency, the timing of the alkylation as well as the stabilization of DNA helix. 
 
 
Figure 67: Ranking of synergistic effects of a duocarmycin library combined with ATRi AZD6738 on HCC-1954 cells. A) Schematic 
representation of the influence of the alkylating unit on the synergy score upon keeping the binding unit constant. The binding unit was 
a trimethoxyindole moiety in all cases. B) Schematic representation of the influence of binding unit on synergy score. The alkylating unit 
was a CBI-unit, which was extended by three different binding units. C) Influence of binding unit on synergy score. Methyl-CBI unit as 
alkylating unit was extended by two distinct binding units. 
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6.3. ADC-Generation to Modulate the Therapeutic Window of Duocarmycin 
 
Adozelesin and Carzelesin, two molecules of the duocarmycin family, have been in clinical development for anti-
cancer therapy. However, both compounds failed because no therapeutic window could be established.75,159 
Duocarmycins were therefore conjugated to antibodies in order to increase the therapeutic window by 
mediating drug delivery to tumor cells specifically through the antibody portion. 
ADCs were conjugated using linker-drugs comprising the duocarmycins Duocarmycin DM, DUBA and 
Duocarmycin SA. The Duocarmycin DM linker-drug 1 was successfully conjugated using SrtA to the αHER2 
antibody, the αEGFR antibody as well as to an αHEL, αMET, a bispecific αMETxEGFR antibody and a glycoprotein 
binding antibody. No clear dependency of yield or physicochemical properties of the ADC on purification route 
or mAb format was found. In all cases the conjugation efficency was high, leading to ADCs with >75% of available 
conjugation sites covered, meaning that ADCs with two conjugation sites carried at least 1.5 drugs per antibody. 
The ADCs generally had high monomeric contents.  
The αHER2 mAb was used as model antibody to generate four additional ADCs comprising DUBA-based linker-
drugs 2, 3, 4 and 5. The conjugations of LD-2 and LD-3 were successful with yields as high as 97.8% and 81.1%, 
respectively and high DARs at low levels of aggregates <3%. However, the conjugation of LD-4 and LD-5 was 
considerably difficult. The analytical scale conjugation of LD-4 to the αHER2 mAb led to the precipitation of the 
reaction product so the conjugation of this linker-drug was not pursued any further. The analytical scale coupling 
of LD-5 to the αHER2 mAb was comparably slow. Even elongation of reaction time did not lead to a significant 
increase in conversion, hence, the ADC was not conjugated in preparative scale. The DUBA-ADC αHER2-6 and 
the DSA-ADC αEGFR-7 were kindly provided by the laboratory of Dr. Nicolas Rasche. 
The preparation of the clinically developed ADC SYD985 was performed according to literature upon conjugating 
the maleimide-containing LD-28 to reduced cysteines of the αHER2 mAb trastuzumab. The conjugation 
procedure led to the formation of a heterogeneous ADC mixture consisting of species with varying drug-loads 
including unconjugated mAb and also high molecular weight (HMW) species. Preparative HIC was applied to 
remove the high DAR and HWM species, finally yielding an ADC with a DAR of 2.8. However, the ADC SYD985 
was still a mixture comprising DAR=2 and DAR=4 species in a 2:1 ratio.82 In this work, the DUBA-based LD-2 which 
was closely related to the linker-drug of Synthon’s ADC SYD985 was used for ADC generation. The only difference 
between the two linkers was that LD-2 carried a triple-glycine tag N-terminally of the linker-drug in contrast to 
Synthon’s linker-drug bearing a maleimide (Figure 68). The oligo-glycine tag enabled site-specific conjugation of 
the linker-drug LD-2 to the genetically modified light chains of the αHER2 mAb via the enzyme Sortase A. This 
led to the formation of a homogenous ADC with a DAR of 1.85 and 97.4% monomeric content at a high yield of 
60.0%. Thus, site-specific drug conjugation might be beneficial for the generation of DUBA-based ADCs, because 
the drug product was considerably more homogeneous. 
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Figure 68: Chemical structures of LD-2 in comparison with the linker-drug of SYD985. The coupling strategy was changed from thiol 
coupling via maleimide as in the linker-drug of SYD985 to SrtA-mediated coupling via an oligo-glycine tag as in LD-2. 
 
After the successful conjugation of the ADCs, it was studied whether the cytotoxicity of the duocarmycins was 
retained in the ADC format. All the αHER2 ADCs (αHER2-1, αHER2-2, αHER2-3 and αHER2-6) were potent in the 
single-digit to subnanomolar range on HER2-positive cell lines reaching double-digit picomolar IC50-values in 
some cases. αHER2-1 comprised the drug Duocarmycin DM and the ADCs αHER2-2, αHER2-3 and αHER2-6 
carried DUBA as payload. The DUBA-ADCs differed in the linker-structure and conjugation technique. There was 
no clear connection between linker-drug and potency of the conjugate. In addition, the αHER2-duocarmycin 
ADCs were comparably cytotoxic as Kadcyla, except on Calu-3 cells, where Kadcyla was considerably less potent 
in the double-digit nanomolar range. As an isotype control, αHEL-1 was tested. This non-binding ADC was less 
toxic to the cells than the binding counterpart ADC αHER2-1, generally killing cells in the double- to triple-digit 
nanomolar range. Table 18 compares the results of the cell viability assays reported in this work for Kadcyla, and 
DUBA-based ADCs αHER2-2 and αHER2-6 with the cytotoxicity of SYD985 and Kadcyla reported by van der Lee 
et al.87 The IC50-values of Kadcyla reported in this work and in literature differed only to a minor extent although 
the linkers of αHER2-2 and αHER2-6 were not identical to the linker of SYD985. 
 
Table 18: Comparison between potencies of Kadcyla obtained from literature and determined in this work. 
 IC50-values reported in literature87 [nM] IC50-values reported in this work [nM] 
 SYD985 Kadcyla Kadcyla αHER2-2 αHER2-6 
SK-BR-3 0.046 0.11 0.2±0.1 0.16±0.05  
NCI-N87 0.16 0.30 0.08970±0.00003 0.18±0.01 0.3±0.4 
 
In order to evaluate whether the low potencies of the αHER2-duocarmycin ADCs were dependent on the target 
HER2 or if the cytotoxicity was target-independent, further ADCs based on other antibodies like the αEGFR mAb 
cetuximab and also αMET and a bispecific mAb directed against both EGFR and MET were studied regarding 
their anti-proliferative effects. 
SYD985
LD-2
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DDM-carrying αEGFR-1 and DSA-bearing αEGFR-7 as well as αMET-1 and the bispecific molecule αMETxEGFR-1 
were investigated on target-positive cells. Again, all ADCs were potent in the nano- to subnanomolar range on 
target-positive cells. The least potent ADC was αMETxEGFR-1 which was probably caused by the ADC carrying 
only ~0.9 drugs per mAb, while the cetuximab and αMET ADCs had a DAR>1.68.  
Besides studying the ADCs on target-positive cells, the ADCs were also tested for unspecific cell cytotoxicity on 
target negative cells. In case of αHER-ADCs, the IC50-values were in the double- to triple-digit nanomolar range. 
As a result, the ADCs were considerably less potent on HER2-negative MDA-MB-468 cells. Cetuximab-based 
ADCs showed similar results on EGFR-negative MCF7 cells with IC50-values in the single- to double-digit 
nanomolar range.  
During the drug development process it is important to assess the safety of a drug. A common measure for drug 
safety is the therapeutic index, which quantitatively correlates desired on-target pharmacological effects with 
off-target side-effects. Although, testing in animals or humans leads to a more accurate determination of the 
therapeutic index and also the safety of the drug, biochemical and in vitro methods can also be applied in early 
development to rank drug candidates. One such early estimation of the therapeutic index uses the on-target 
versus off-target selectivity of a drug.153  
Hence, the differential cytotoxic effects induced by ADCs towards target-negative versus target-positive cells 
was expressed in the form of a selectivity index (Eq. 4). The selectivity index is a measure of the selectivity of an 
ADC towards antigen-expressing cells. In general, a high selectivity index indicates a strong cell toxicity on 
antigen-positive cells uponbeing considerably less toxicity towards antigen-negative cells. The results presented 
in this work indicated that the Duocarmycin DM-bearing ADC αHER2-1 was approximately one order of 
magnitude more selective than the DUBA-based ADCs αHER2-2 and αHER2-3, which were almost equally 
selective. The DUBA-based ADCs were as selective as Kadcyla. The non-binding ADC anti-HEL-1 and the small 
molecules DDM and DUBA however did not show any selectivity towards HER2-expressing cells, as was 
expected.  
These results suggested a major impact of the duocarmycin variant conjugated to the mAb on the selectivity but 
only a minor influence of the linker regarding the selectivity of an ADC at least in the HER2-context. In addition, 
it was shown, that the cetuximab-based ADCs αEGFR-1 and αEGFR-7 were selective towards EGFR-expressing 
cells. However, Duocarmycin DM-bearing and DSA-carrying ADCs αEGFR-1 and αEGFR-7, respectively, were 
nearly equally selective towards EGFR-expressing cells. The small molecules DDM and DSA on these cell lines did 
not exert any selectivity for EGFR-positive cell lines, as expected. 
These results demonstrated very clearly that the cytotoxicity of the small molecule duocarmycins was retained 
in duocarmycin-bearing ADCs. In addition, the results suggested that the cytotoxicity was largely independent 
of the target antigen of the ADC. Furthermore, the ADCs specifically killed antigen-positive cells while antigen-
negative cells were affected only to a minor degree.  
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6.4. Synergistic Effects of Combinations of Duocarmycin-ADCs with ATRi 
 
After it was proven that ATRi AZD6738 synergized with duocarmycins independently of the structure of the 
duocarmycin, it was studied whether the synergy was also retained in the ADC format. The duocarmycin-bearing 
ADCs αHER2-1, αHER2-2 and αHER2-6 were applied together with AZD6738 to three cancer cell lines HCC-1954, 
NCI-N87 and MDA-MB-453. In all cases, the duocarmycin-carrying ADCs synergized comparably to the small 
molecule duocarmycin. On MDA-MB-453, the synergy of the ADC plus AZD6738 was higher than the synergy 
between DUBA and AZD6738. This observation might be explained as follows: 
The small molecule DUBA is highly efficacious on this cell line, while the ADC is only capable of affecting 70% of 
the cells. However, in combination the efficacy of the ADC is enhanced, leading to death of the entire cancer cell 
population. Since DUBA already affects all cells, the efficacy cannot be further increased, leading to a smaller 
synergy score (Figure 69). This indicated that the combination therapy might have the potential to increase the 
overall response of the cell population to the treatment. 
 
 
Figure 69: Cell viability of MDA-MB-453 after treatment with αHER2-2 or DUBA alone or in combination with constant doses of AZD6738. 
If MDA-MB-453 cells were treated with αHER2-2 alone, the cell viability was only reduced to 30%, while DUBA as single agents had 100% 
efficacy. In combination with AZD6738, the efficacy of αHER2-2 was enhanced leading to the death of an increased number of cells while 
the combination of DUBA with AZD6738 might only increase the potency. 
 
It was published by Wallez et al. that gemcitabine synergizes with the ATRi AZD6738.160 The synergistic effects 
of gemcitabine when combined with AZD6738 were reproduced on HCC-1954 cells. However, on NCI-N87 and 
MDA-MB-453 cells no or weak synergistic effects were observed, respectively, for the combination treatment. 
This indicated a strong dependency of gemcitabine-ATRi combinations on the cellular background. In another 
study by Thomas et al. a synthetic lethal screen with siRNA revealed that ATR depletion sensitized cells to TOP1 
poisons. Drug combinations of TOP1i irinotecan with ATRi VE-822 were investigated in vitro and in vivo. 
Synergistic anti-tumor effects were observed for the combination of irinotecan with VE-822. In this study, SN-
38, an active metabolite of irinotecan was combined with another ATRi AZD6738 as a benchmark. The synergistic 
effects of TOP1i combined with ATRi published by Thomas et al. were reproduced on HCC-1954 cells but not 
NCI-N87 and MDA-MB-453 cells. 
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As negative controls, a microtubule-targeting agent (MTA), MMAE, and the MTA-carrying ADC Kadcyla were 
studied. On HCC-1954 cells, both drugs had weak synergistic effects when combined with the ATRi AZD6738, 
which is in line with the observation that ciliobrevin D had weak synergistic effects in the screening when 
combined with AZD6738 on HCC-1954 cells. However, on NCI-N87 and MDA-MB-453 cells no synergy between 
Kadcyla and the ATRi AZD6738 were observed. Interestingly, the positive controls Gemcitabine, SN-38 as well as 
DUBA and the DUBA-ADC αHER2-2 had nearly identical synergy scores when combined with AZD6738. By 
treating EGFR-positive cells with combinations of αEGFR-1 or αEGFR-7 and the ATRi AZD6738 it was proven that 
the synergistic effects of duocarmycins with ATRi were not exclusive for HER2-targeting ADCs but could also be 
translated to ADCs targeting different antigens and thus potentially other indications.  
A total of seven ATRi were investigated in this study to eludidate the effect of the ATRi on the combination 
effects. The ATRi were ranked according to their ability to inhibit the phosphorylation and thus activation of 
CHK1 after HT29 cells were stressed by treatment with hydroxyurea. The results allowed the establishment of a 
correlation between synergy scores and the potency of CHK1 phosphorylation inhibtion. Ultimately, it was 
observed that, the more potent the ATRi in terms of CHK1 phosphorylation inhibition, the higher the synergy 
score when combined with DUBA or DUBA-ADCs.  
By comparing the synergy scores of small molecule duocarmycins with ATR on several cell lines, the sensitivity 
of different cell lines toward combined treatment could be estimated. MCF7 and A549 cells e.g. responded 
comparably weak to the drug combination, while the same combination led to 2-3 fold higher synergy scores on 
HCC-1954 and MDA-MB-468 cells. These data suggested a strong dependency on the cellular background. A 
review by Forment and O’Connor described several genes that rendered cells resistant or sensitive for treatment 
with ATR inhibitors.94 Increased sensitivity or resistance toward ATR inhibition might account for the differences 
between the cell lines. 
The synergistic effects between duocarmycins and duocarmycin-ADCs combined with ATRi were elucidated 
using a curve-shift assay system. The potentiation effects were reproduced on nine HER2-positive cell lines using 
a combination of αHER2-1 with AZD6738 or VE-822. However, the extent of the potentiation effects varied 
strongly which is not surprising given the different synergy scores of the small molecules combined with the 
ATRi on several cell lines. Besides, a strong dependency of the potentiation effects on the choice of ATRi 
AZD6738, VE-822, ATRi 1 or BAY73 in the combination with αHER2-1 was observed on HCC-1954. Again, the 
potentiation effects were dependent on the potency of the ATRi to inhibit CHK1 phosphorylation. Furthermore, 
also the duocarmycin variant had an influence on the potentiation effects if ATRi were added. DUBA-variants 
displayed greater potentiation effects than DDM-based ADCs combined with ATRi. Additionally, the potency of 
a glycoprotein binding ADC combined with the ATRi AZD6738 and VE-822 was potentiated. All in all, the results 
of the curve-shift assay underpinned the results obtained from the dose-matrix assays.  
The dose-reduction effects were used to study whether the combination treatment of duocarmycin-ADC with 
ATRi might lead to a beneficial therapeutic window compared to monotherapy. The combination of αHER2-1 
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with AZD6738 or VE-822 led to an increased selectivity index over monotherapy on around half of the cell lines. 
Lehár et al.22 reported that synergistic drug combinations tended to be more selective towards diseased tissues 
compared to the single agents. The fact that only on half of the cell lines combination treatment posed a 
selectivity benefit over monotherapy might be explained in part by the crosstalk between HER2 and ATR. HER2 
inhibition and also knock-down leads to the inhibtion of ATR activation and abrogation of G2/M checkpoint 
following treatment of cells with IR.138 This suggests that HER2-negative cancer cell lines might be particularly 
sensitive to ATR inhibition and thus combination treatment. Furthermore, the HER2-negative cell line MDA-MB-
468 responded comparably strong to combined treatment with ATRi and duocarmycin. MDA-MB-468 cells are 
mutated in the PTEN gene leading to loss of function of the enzyme.161 PTEN plays an important role in 
replication fork recovery and checkpoint response after cells were stressed with replication inhibitors.162 In 
addition, PTEN dephosphorylates MCM2 upon replication stress and thereby restricts the progression of the 
fork.163 Hence, PTEN loss of function might lead to formation of long stretches of ssDNA due to uncoupling of 
helicase and DNA polymerases which might result in depletion of RPA pools. Besides, fork stabilization is 
impaired in PTEN loss cells, whereby fork collapse and subsequent formation of DSBs might be promoted. Thus, 
the selectivity index might be underestimated.  
Overall, these results demonstrated the translatability of the combination effects of small molecule 
duocarmycins to the ADC format. Furthermore, the synergistic effects of gemcitabine, SN-38 and DUBA or DUBA-
ADCs with ATRi were in good comparison on HCC-1954 cells. Thirdly, synergistic effects of duocarmycin-ADCs 
with ATRi can be observed independently of the cancer indication, although the extent of the synergistic effects 
strongly depended on the molecular background of the cancer cell. Fourthly, more potent ATRi led to stronger 
synergistic anti-cancer effects when given simultaneously with duocarmycin-ADCs. 
 
6.5. Therapeutic Relevance of the Synergistic Combination of Duocarmycin-ADCs with ATR Inhibitors 
 
Combination therapy brings along several benefits over single agent therapy such as increased efficacy or equal 
efficacy at lower doses. Through the administration of lower doses, side effects might be reduced and in 
addition, the development of resistance might be slowed down.19 
Several ATRi such as AZ20, AZD6738 or VE-822 are in clinical evaluation as combination therapy combined with 
radiotherapy, or chemotherapy agents like TOP1i topotecan or cisplatin.164 VE-822 combined with irinotecan 
was studied in a subcutanous COLO205 mouse xenograft model. While VE-822 had no anti-tumor effect as single 
agent, irinotecan led to tumor growth delay. The combination of VE-822 with irinotecan had substantially 
stronger anti-tumor effects, inducing transient tumor shrinkage. The combined treatment resulted in no 
additional body-weight loss over irinotecan alone.165 In a phase I dose-escalation study, VE-822 was combined 
with topotecan. Although partial responses and stable diseases were observed, one patient suffered from dose-
limiting grade 4 thrombocytopenia. Furthermore, grade 3 and 4 adverse events were observed such as 
neutropenia, anemia and leukopenia.166 These dose-limiting toxicities and grade 3 and 4 adverse events 
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observed in the clinical setting might be circumvented by targeted delivery of the cytotoxic drug to the tumor 
using an ADC, because exposure of healthy tissue would be minimized. The effects of the ADC might be 
enhanced by the addition of chemotherapeutic drugs. 
Several combinations of ADCs with small molecules or antibodies have been published (Table 19). The antitumor 
effects of the MMAE-bearing ADC SGN-35 when combined with ABVD (doxorubicin, bleomycin, vinblastine, 
dacarbazine) or Gemcitabine were assessed in xenograft mouse models. The combination groups had 9/9 or 5/5 
durable tumor regressions for SGN-35 plus ABVC or gemcitabine, respectively. No significant body-weight loss 
and no morbidity was observed in the combination groups.167 The approved ADC Kadcyla was studied in 
combination with several chemotherapeutic agents such as lapatinib, docetaxel, gemcitabine, carboplatin, 5-
fluorouracil etc. The combination groups showed stronger tumor regression compared to single agents and in 
case of Kadcyla plus lapatinib or 5-fluorouracil it was proven that the combination acted synergistically. Besides 
microtubule-targeting ADCs, also DNA-targeting ADCs were investigated for potential use in combination 
therapy. The calicheamicin-ADCs Mylotarg and inotuzumab ozagamicin were or are currently evaluated in 
clinical studies in combination with chemotherapy. Inotuzumab ozagamicin is studied in combination with 
rituximab or standard chemotherapy regimens R-CVP (Rituximab, cyclophosphamide, vincristine, prednisolone) 
and R-GDP (rituximab, gemcitabine, dexamethasone, cisplatin). While mylotarg plus chemotherapy did not yield 
a clinical benefit as first-line treatment over chemotherapy alone for patients with relapsed ALL, rituximab plus 
inotuzumab ozagamicin is currently evaluated in an open-label phase III study for relapsed or refractory B-cell 
NHL.168  
Furthermore, the SN-38 ADC IMMU-132 was intensively studied in combination therapy. Since SN-38 is substrate 
for ABC transporters, overexpression of these transporters is a mechanism of resistance development against 
IMMU-132. SN-38-resistant cell lines were established and treated with IMMU-132 or IMMU-132 plus ABCG2 
inhibitor YHO-13351. The combination resensitized SN-38-resistant cells for IMMU-132 in vitro and in vivo.169 
The ADC IMMU-132 plus PARP inhibitor olaparib was the first published combination of an ADC plus DNA-
damage response inhibitor. The combination was evaluated for anti-cancer treatment and proved to 
synergistically inhibit cancer cell proliferation in vitro. Subsequently the results were translated to an in vivo 
xenograft model in mice. Since it was known that topoismerase I inhibition is synthetic lethal with PARP1 
inhibition in BRCA1/2-deficient cells, the combination was studied in BRCA1/2-deficient and BRCA1/2 wildtype 
cells. The ADC alone as well as olaparib had only minor anti-tumor effects. The combination of IMMU-132 plus 
olaparib however led to a tumor remission in BRCA1/2-deficient xenograft models and provided a survival 
benefit of treated mice in BRCA1/2-wildtype xenograft mice. No severe side-effects were observed as assessed 
by body-weight change. Toxicity studies revealed that the combination of the ADC with olaparib decreased 
platelet, lymphocyte and neutrophil count stronger than the single agents. However, the counts were still in the 
tolerated range.170 In addition, the monoalkylating anti-CD33 ADC IMGN779 was combined in preclinical studies 
with cytarabine yielding additive anti-tumor effects171 but also with several PARP inhibitors which led to 
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synergistic anti-proliferative effects.172,173 So far, two DNA-damaging ADCs, IMMU-132 and IMGN779, were 
combined with PARPi and synergistic anti-tumor effects were observed. 
In this work, a synergistic combination of a DNA-targeting ADC plus DNA-damage response inhibitor was 
discovered. Therefore, an in vivo xenograft model was established to prove the therapeutic relevance of the 
αHER2-duocarmycin-ATRi combination. Rag 2 mice bearing subcutaneous NCI-N87 tumors were treated with 
αHER2-6, and two ATRi AZD6738 and ATRi 1 either alone or in combination. While the ATRi AZD6738 had no 
significant effect on tumor growth, ATRi 1 given as single agent delayed tumor growth. Although a low dose of 
ADC was chosen to better resolve combination effects, the ADC had tumor growth inhibiting effects after initial 
tumor stasis. The combination of αHER2-6 with AZD6738 led to durable tumor stasis where one mouse 
experienced tumor free survival and αHER2-6 combined with ATRi 1 induced tumor regressifon with two mice 
showing tumor free survival until the endpoint was reached. The antitumor effects of ATRi 1 plus αHER2-6 were 
stronger compared to AZD6738 combined with αHER2-6 which reflects the finding that ATRi 1 synergized 
stronger with duocarmycin-ADCs than AZD6738 on the cellular level. This gives rise to the assumption that the 
combination treatment can be optimized in vitro to yield improved efficacy in vivo. However, so far a 
quantitative assessment of the combination effects is missing. Fu et al. described a detailed method for the 
quantification of in vivo combination effects. Therefore, it is necessary to determine a dose-response 
relationship for the individual compounds as well as the combination at e.g. a fixed ratio of doses. The dose-
response data can be fitted using the median-effect equation and a combination index can be calculated as a 
proof of synergy.174 
In addition to the efficacy data, the xenograft model revealed that the mice in the combination groups did not 
suffer body-weight loss, suggesting that the therapy was well tolerated. This is of particular importance because 
it is often suggested, that synergistic drug combination do also lead to synergistic side effects,22 which was not 
the case for combination treatment with αHER2-6 and the ATRi AZD6738 and ATRi 1 in this study. 
The DUBA-based αHER2-6 ADC used in this study was closely related to the phase III clinically evaluated ADC 
SYD985,90 which was studied in monotherapy only so far. In a phase I expanded cohorts study, SYD985 led to 
grade 3 and 4 adverse events such as neutropenia and conjunctivitis.89 Besides duocarmycin-ADC SYD985 also 
ATRi are currently under clinical development. The ATRi VE-822 was studied in a phase I dose-escalation study 
and no toxicity was observed up to a dose level of 480 mg/m².175 On the contrary, patients treated with the ATRi 
AZD6738 had grade 3 and 4 toxicities such as thrombocytopenia, pancytopenia, elevated amylase, 
photosensitivity, mucositis, anemia when treated with 240 mg/m² BD for 21 of a 28 day cycle and 5 days on, 2 
days off. At a dose level of 160 mg/m² only anaemia was observed with the same scheduling.176 The findings 
reported in this work provide the rationale for the clinical evaluation of SYD985 in combination with ATRi. The 
combination of ATRi with targeted delivery of duocarmycin mediated by an ADC might boost anti-tumor effects. 
This would give room for lowering the doses and hence combination therapy might lead to less adverse events, 
especially since the toxicity profiles do not overlap for SYD985 and the ATRi AZD6738 or VE-822. 
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Table 19: Summary of ADC combination therapies. 
ADC Combination  
Identifyer Target Payload MoA Drug MoA Source 
Besponsa CD22 Calicheamicin DSB R-CVP/R-GDP/R MTA/DTA 168 
Mylotarg CD33 Calicheamicin DSB Chemotherapy CD20 168 
SGN-35 CD30 MMAE MTA ABVD/Gemcitabine MTA/DTA 167 
Kadcyla HER2 DM1 MTA Chemotherapy  177 
IMMU-132 TROP2 SN-38 TOP1i YHO13351 ABCG2 169 
IMMU-132 TROP2 SN-38 TOP1i Olaparib PARPi 170 
IMGN779 CD33  Alkylation Cytarabine Antimetabolite 171 
IMGN779 CD33  Alkylation  PARPi 172,173 
 
6.6. Mechanism of ATR-Mediated Sensitization for Duocarmyin Treatment 
 
As already lined out, the combined treatment with duocarmycin-ADCs and ATR inhibitors might lead to improved 
efficacy of anti-cancer treament. Therefore, profound knowledge of the underlying mechanism of action of the 
synergy between duocarmycin and ATRi is important because it facilitates the selection of patients based on e.g. 
biomarkers with potentially high response rates and also to anticipate resistance mechanisms. Thus, a 
mechanism of action for the syneristic cytotoxicity between duocarmycins and ATRi will be proposed in this 
chaper which might serve as a basis for detailed mechanistic studies. 
The repair of Duocarmycin-induced DNA-damage is not fully unraveled yet. It was reported, that the 
duocarmycin variant CC-1065 was not recognized by the nucleotide excision repair apparatus, propably due to 
the thermodynamic stabilization effects on double-stranded DNA.145 However, CHO cells deficient in 
components of the NER were more sensitive to treatment with duocarmycin-derivative AS-I-145 than their NER 
proficient counterparts.147 Treatment of HCT116 cells with adozelesin led to increased expression of p53 and 
stabilization by phosphorylation at serine S15. As a result, p21 was transcribed which led to G2 arrest after 
adozelesin treatment with low doses. High doses of adozelesin however arrested cells in S phase and at the 
same time p21 levels were decreased. A consequence of adozelesin-treatment was that cells entered 
apoptosis.178 Liu et al. studied the cellular responses upon duocarmycin treatment. Cells treated with adozelesin 
showed phosphorylation of ssDNA-binding protein RPA and also histone H2AX, which was supressed by addition 
of aphidicholin prior to adozelesin treatment. The cells formed RPA and γ-H2AX foci which colocalized. By 
incubating the cells with BUdR, a fluorescent nucleotide analogon, cells were labeled that were actively 
synthesizing DNA. Cells actively incorporating BUdR were also positive for RPA foci formation upon adozelesin 
treatment. In another experiment, cells were arrested by overnight treatment with aphidicholin. While arrested 
cells showed not RPA foci formation, released cells did. Taken together these data suggest that adozelesin-
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alkylation lesions were S phase specific and relied on active fork progression.148 Furthermore, the 
phosphorylation of DNA-damage marker γ-H2AX was mediated by ATR. This was proven by overexpression of a 
kinase dead mutant of ATR and subsequent treatment of kinase dead ATR and ATR wildtype cells with HU, UV 
or IR. It was observed that γ-H2AX foci formation was largely suppressed in ATR kinase dead cells.179 Besides, 
adozelesin treatment of HeLa cells induced CHK1 phosphorylation.180 
The synergy between duocarmycins and ATRi can best be described as anti-counteractive synergy. In case of 
anti-counteractive synergistic drug combinations a drug induces a cellular response that would decrease its 
efficacy and a second drug is added that suppresses the cellular response to the first drug.28 Literature data 
suggest that duocarmycin might induce ATR phosphorylation. ATR activity however can be suppressed by adding 
an ATR inhibitor. This leads, as demonstrated in this work, to an increased response to duocarmycin-ATRi 
combination treatment compared to the single agents. 
Based on the cellular response discussed in this chapter and the functions of ATR upon replication stress and 
DNA damage, a mechanism of synergy between duocarmycin and ATR inhibitors is proposed as depicted in figure 
70. When cells enter S phase and start replication of the genome, the DNA polymerase eventually collides with 
a duocarmycin-lesion. The MCM2-7 replicative helicase and DNA-polymerase become uncoupled whereby 
stretches of ssDNA are formed. These are protected against nucleolytic restriction by coating the ssDNA with 
RPA. The 9-1-1 complex binds to ssDNA-dsDNA junctions, and TOPBP1, ETAA1 and ATRIP are recruited, 
ultimatively leading to the activation of ATR. ATR in turn has several functions that include the induction of cell 
cycle arrest by activation of p53, WEE1 and CHK1. ATR also regulates the activity of SMARCAL1 translocase which 
is required for fork maintenance and fork restart.181 Through SMARCAL1 inactivation, the stalled replication fork 
is protected from fork remodeling which otherwise would result in restriction by SLX4/MUS81 endonucleases. 
In addtion, ATR downstream kinase CHK1 inhibits CDC45, which is required for the initiation of a bidirectional 
replication fork, to suppress the firing of not-yet fired late origins. This process limits the use of RPA as does the 
slowing-down of helicase movement by Claspin-TIPIN-Timeless complex. Through the ATR-mediated response, 
the cell cycle progression is slowed down, the replication fork is protected, the firing of late origins is prevented 
and finally the RPA level is kept at an acceptable level. In contrast to that, in the absence of functional ATR, forks 
are no longer protected against SLX4/MUS81-mediated degradation. More importantly, cell cycle checkpoints 
are abrogated and late origins fired. DNA synthesis occurs at multiple sites whereby ssDNA is formed excessively. 
The ssDNA stretches are coated by RPA until RPA-levels fall below a certain level. A sudden pan-nuclear 
appearance of DNA double-strand breaks at replicons is associated with the depletion of RPA and this finally 
leads to the so called “replication catastrophe”.92  
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Figure 70: Proposal of mechanism of synergy between duocarmycin and ATR inhibitors. Duocarmycin poses a replication fork barrier, 
leading to the inhibition of the DNA-polymerase. As a result, DNA-polymerase and MCM2-7 helicase might be uncoupled leading the 
formation of ssDNA, which is coated by RPA. In order to keep RPA levels above a threshold level, the Claspin-TIPIN-Timeless complex 
blocks the movement of the helicase. RPA-coated ssDNA is recognized by the 9-1-1 complex. Subsequently, TOPBP1, ETAA1 and ATRIP 
are recruited. The latte activates ATR which mediates fork-protective actions and also cell cycle regulation via p53 and CHK1. By inhibition 
of SMARCAL1, the stalled replication fork is protected from fork remodeling and subsequent nucleolytic restriction. Through these 
mechanisms, correct replication of the genome is mediated. In the absence of ATR, SRF might be nucleolytically cleaved, and also cell 
cycle is not slowed down to assure correct genome duplication and maintain RPA levels. The result is the replication catastrophe if the 
cell tries to replicate despite the DNA-damage which is accompanied by fork collapse and DSBs. 
 
In a head-to-head comparison by Liu et al., it was found that Adozelesin treatment led to the same cellular 
response as camptothecin treatment148 indicating that the cells cannot discriminate between a replication block 
induced by duocarmycin-derivative adozelesin or TOP1 poison camptothecin. The combination of camptothecin 
with ATRi was studied in detail by Jossé et al. Camptothecin treatment induced cell cycle arrest and at the same 
time the firing of late origins in S phase. Furthermore, chain elongation was inhibited which was associated with 
a slower fork progression. The addition of the ATRi VE-821 however abrogated cell cycle checkpoint, led to firing 
of late origins during S phase and increased fork velocity when compared to camptothecin-treated cells alone. 
Furthermore, camptothecin treatment induced CHK1, CHK2 and H2AX phosphorylation.165 Adozelesin treatment 
was also reported to induce CHK1 and H2AX phosphorylation.180 The finding, that cellular response to adozelesin 
and camptothecin treatment was comparable, might in part explain why the combinations of DUBA or SN-38 
with AZD6738 led to equal synergy scores on HCC-1954 cells.  
Sensitivity of cancer cell lines toward combined treatment with duocarmycin or duocarmycin-ADC and ATRi and 
mutational status of respective cell lines is summarized in table 20. p53-wildtype cell lines were not sensitive to 
the combination treatment with duocarmycin and ATRi. At the same time, p53-mutated cell lines were 
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frequently sensitive toward combination treatment. p53-binding protein 1 (p53BP1) is important for p53 
function. It was shown, that p21 expression was impaired in p53-wildtype but p53BP1-deficient cells182, propably 
contributing to the sensitivity of MDA-MB-453 cells to duocarmycin-ATRi combination treatment. MDA-MB-468 
were also sensitive toward combination treatment, which might be mediated by its PTEN loss of function 
mutation as discussed earlier. Sensitivity was reduced for p53-mutated cell lines that simultaneously carried an 
ARID1A mutation. ARID1A is a protein involved in the modification of chromatin structure by sliding or ejecting 
nucleosomes from DNA leading to the modulation of replication, transcription and DNA-repair.183 Williamson et 
al. reported a synthetic lethality relationship between ARID1A-deficiency and ATR inhibition. Treatment of cells 
deficient in ARID1A with ATRi VE-822 led to increased levels of apoptosis, DNA-damage and also fragmentation 
of chromosomes when compared to ARID1A-proficient cells.183 Hence, ARID1A-deficient cells are already 
sensitive to ATR inhibitor treatment. Appearently, combination treatment with duocarmycin and ATRi does not 
bring along an additional benefit over ATR inhibitor treatment alone. 
 
Table 20: Summary of sensitivity of cell lines studied in this work and mutational status. Sensitivity was classified on A549, HCC-1954, 
MCF-7, MDA-MB-453, MDA-MB-468 and NCI-N87 cells after treatment with small molecule duocarmycins DUBA, Duocarmycin DM or 
Duocarmycin SA and ATRi AZD6738 as follows: Synergy score > 3 was termed sensitive (“+”) and synergy score < 3 was termined non-
sensitive (“-“). Senstivity toward treatment of BT-474, Calu-3, JIMT-1, MDA-MB-361, SK-BR-3 and SK-OV-3 cells with αHER2-1 and 
constant doses of AZD6738 was classified as follows: DRI > 3 was termed sensitive (“+”), DRI < 3 was termed insensitive (“-”). The DRI 
data were extracted from figure 47. Mutational status of genes in the headline were extracted from the ancer Cell Line Encyclopedia 
(CCLE) database. It was marked with “mut“ if the proteins were mutated. Tolerated mutations were denoted with “mut (tol)”. TP53 and 
PTEN status of MDA-MB-468 cell line was extracted from literature.184 p21 has another gene symbol CDKN1A. 
Cell line Sensitivity ARID1A ATR ATM p21 PTEN p53 p53BP1 
A549 -  mut      
BT-474 +      mut  
Calu-3 -    mut  mut  
HCC1954 +      mut  
JIMT-1 - mut     mut  
MCF7 -        
MDA-MB-361 - mut     mut  
MDA-MB-453 +       mut 
MDA-MB-468 +     mut   
NCI-N87 +      mut  
SK-BR-3 -      mut (tol)  
SK-OV-3 - mut  mut     
 
However, the proposed mechanism is solely based on the finding, that duocarmycins synergized with ATR and 
CHK1 inhibitors leading to improved tumor cell killing and data from literature. This allows only to speculate 
about the mechanism of synergy between duocarmycin and ATRi. In the outlook section, methods are described 
that allow the refinement of the proposed mechanism. 
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6.7. DNA-PK Inhibition for ADC Combination Therapy 
 
After it was discovered that duocarmycin-ADCs synergize with inhibitors of ATR, a member of the PIKK enzyme 
family, the question arose whether the concept might be translated to other members of the PIKK family. 
Therefore, Bleomycin A5-based ADCs were generated by conjugation to the αHER2 mAb, αEGFR mAb cetuximab 
and isotype control αHEL. The conjugation of BA5 to these antibodies had good to excellent yields. Since yields 
greater than 100% were observed, it might be hypothesized that BA5 absorbs in the same range as the antibody 
and this way influenced the measurement of the concentration. In all cases, more than 80% of the available 
conjugation sites were covered. The monomeric content was greater than 99% in all cases. The ADCs were 
studied on several cell lines subsequently. While the HER2-targeting ADC αHER2-9 (DAR=1.78) was active on 
HCC-1954 cells in the nanomolar range, no cytotoxicity was observed on LNCaP and BxPC3 cells. αEGFR-9 was 
studied on the cell lines A549, Capan-2, MDA-MB-231 and SK-OV-3, A431, MDA-MB-468 and EGFR-negative cell 
line MCF7. The ADC was exceeding the effects of the mAb alone only on A431 and MDA-MB-468 cells. The 
treatment of HCC-1954 cells with αHER2-9 or MDA-MB-468 cells with αEGFR-9 led to a substantial increase in 
potency of the small molecule drug Bleomycin A5 of approximately 470 and 1400, respectively.  
Another ADC was described in literature that used a Bleomycin-derivative as payload.185 The ADC was based on 
the antibody BR96 that targets Lewis Y antigen which was associated with colon, breast, ovary and lung 
carcinomas but not normal tissues. Tallysomycin S10b, the already mentioned Bleomycin analogue, was 
conjugated to BR96 and cancer cells were treated with the conjugate. The ADC was potent in the single- to 
double-digit nanomolar range. An non-targeting Tallysomycin S10b-ADC was considerably less potent, and 
Tallysomycin S10b alone was 13-875-fold less potent than the corresponding ADC.185 The potencies of the 
Bleomycin A5-ADCs αHER2-9 and αEGFR-9 were in the same range as that described in literature, and also an 
increased potency was observed for the conjugates compared to the drug alone. However, it was surprising that 
the conjugates αHER2-9 and αEGFR-9 were inactive in the vast majority of cell lines studied. This might be 
explained by differences in the cellular uptake and subsequent trafficking between the antibodies cetuximab 
and BR96. Furthermore, the synthesis of the linker-drug containing Tallysomycin S10b reported in literture 
involved the complexation of the drug with copper(II)-ions. The synthesis of LD-9, however, was performed 
without the complexation step. Thus, the formation of a complex of ADC with bivalent cations prior to treatment 
of cells with the ADCs might be of importance for unfolding the cytotoxic activity. 
Nevertheless, synergistic effects were studied on MDA-MB-468 cells. Therefore αEGFR-9 was combined with 
two DNA-PKi in a dose-matrix assay. The combination of αEGFR-9 with the DNA-PKi NU7441 and M3814 was 
synergistic on MDA-MB-468 cells. A control experiment was conducted wherein the small molecule 
Bleomycin A5 and the antibody cetuximab were combined with DNA-PKi NU7441. The synergy score of BA5 plus 
NU7441 was around two-fold lower than αEGFR-9 plus NU7441. Interestingly, the antibody cetuximab also 
weakly synergized with NU7441 (S=1.8). A role of the surface receptor EGFR in DNA repair has been described 
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by Dittmacher et al.186 EGFR is translocated to the nucleus upon irradation. As a result, EGFR forms a complex 
with DNA-PK, which led to an increased DNA-PK activity. DNA-PK activity was again suppressed by addition of 
cetuximab.186 Apparently, simultaneous inhibition of DNA-PK by cetuximab and NU7441 led to synergistic 
shutdown of DNA-PK-mediated DNA-damage repair. The synergy between the bleomycin A5-ADC and the DNA-
PKi NU7441 translated also in 19.3-fold potentiation of ADC potency as determined using the MNED-curve-shift 
assay.  
Bleomycin-ADC have not been clinically evaluated. However, several ADCs with double-strand break inducing 
payloads are clinically studied. The company Pfizer has a strong pipeline of calicheamicin-based ADCs. 
PF-06647263, inotuzumab ozogamicin, gemtuzumab ozogamicin are currently in clinical development in all 
clinical phases.119 Inotuzumab ozogamicin, gemtuzumab ozogamicin are clinically studied when combined with 
standard chemotherapy168, however not with targeted chemotherapy agents such as DNA-PK inhibitors. It was 
demonstrated by Bouquet et al. that calicheamicin induced DNA-PK and ATM phosphorylation in HeLa cells187 
underpinning the potential benefit of combining calicheamicin-ADCs with DDRi on a cellular level. Furthermore, 
IMMU-110, a doxorubicin-carrying ADC, is currently evaluated in a phase II clinical study. The data reported in 
this study pose a rationale for the further evaluation of combinations of double-strand inducing ADCs with DNA-
PK inhibitors. 
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7. Outlook 
 
7.1. Biomarker Identification and Refinement of Proposed Mechanism of Synergy 
 
In regard of a therapeutic application of combinations of duocarmycin-ADCs with ATRi, it would be essential to 
identify a biomarker to increase the response toward treatment. A biomarker is important to select patient 
populations that are in particular reponsive regarding combination therapy. Biomarker identification and 
refinement of the proposed mechanism of synergy between duocarmycin and ATRi go hand in hand. The efforts 
put into biomarker identification might also improve the mechanistic understanding of the synergy between 
duocarmycins and ATR inhibitors, because key enzymes might potentially be identified that in- or decreased 
sensitivity toward the combination of the drugs.  
Therefore two approaches might be followed. First, the combination might be studied on a large cancer cell 
panel. Bioinformatic data bases contain information about mRNA levels, that correspond to protein expression, 
and also mutations of specific genes. A correlation between high or low synergy scores and mutation or 
expression levels of specific genes might be established. Secondly, genes known to mediate sensitivity or 
resistance toward ATRi treatment as published by e.g. Forment and O’Connor94 might be downregulated using 
siRNA knock-down. The knockdown cells would be treated with a combination of duocarmycin and ATRi and 
synergy scores would be determined, possibly revealing key enzymes that are involved in the response to 
duocarmycin plus ATRi treatment. 
Additional insight into the model might be gained by studying expression levels and phosphorylation status of 
the kinases and phosphatases mentioned in the model after treatment of cells with duocarmycin or duocarmycin 
plus ATRi by western blotting. This might help to elucidate the signalling pathways that are activated upon 
stressing the cells with the drugs. Additionally, compensatory mechanisms might be identified that support cells 
in surviving the cellular stress induced by treatment with ATRi and duocarmycins.  
In this work, replication catastrophe was assumed to be the main reason for cell death upon combined 
treatment of cells with duocarmycin and ATR inhibitors. To test whether this hypothesis was correct, replication 
catastrophe can be assessed by quantification of DNA-damage and RPA1 as well as RPA2 levels on chromatin 
after pre-extraction according to Toledo et al.92 
One promising starting point for biomarker studies might be p53. This was already indicated by a correlation 
between sensitivity of the cells towards combination treatment and p53 status. Furthermore, Hall et al. reported 
increased sensitivity of A549 p53-knockdown cells toward combined treatment with VE-822 and DNA-damaging 
drugs cisplatin, etoposide, gemcitabine, oxaliplatin and irinotecan compared to p53-wildtype cells.188 Although 
duocarmycin was not included in the study by Hall et al., the work published by Liu et al.148 strongly suggests 
that the cellular response to duocarmycin and irinotecan treatment are similar. 
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This underpins the possible role of p53 in sensitivity to duocarmycin and ATRi treatment. To prove the 
hypothesis, that p53-mutations render cells sensitive toward combination treatment with duocarmycin and 
ATRi, p53-knock-out cells might be generated to compare their sensitivity toward the treatment with isogenic 
p53-proficient cells in cell viability assays and ideally in a xenograft model. 
 
7.2. Improvement of Anti-Tumor Effects of Duocarmycin-ADCs Combined with ATR Inhibitors 
 
It was demonstrated in the NCI-N87 xenograft model that the combination of the DUBA-ADC αHER2-6 with ATR 
inhibitors led to improved anti-tumor effects compared to the drugs as single agents. However, there is still 
room for improving the outcome of further xenograft studies. The combination effects might largely depend on 
the constant supply with both drugs, especially because ADCs often cannot penetrate the tumor leading to the 
saturation of the tumor surface only.189 Therefore, the dosing and scheduling poses an important optimization 
parameter. A study by Elgersma et al. suggested that multiple administration of SYD985 has an improved anti-
tumor efficacy compared to a single administration at the very same dose.82 Therefore, a repeated 
administration of the ADC e.g. might not only improve anti-tumor effects of the single agent but also of the 
combination. In addition, the good tolerability of the ADC allows the administration of a higher ADC dose in 
further experiments to increase the exposure of the tumor to the drug. 
Besides the optimization of the dosing and scheduling, the model cell line potentially has a great influence on 
the tumor killing effects of the combination in vivo. In this work it was shown that for example the synergy score 
of αHER2-6 combined with ATRi AZD6738 is 3-times higher on MDA-MB-453 cells than on NCI-N87 cells which 
might also translate into stronger anti-tumor effects.  
Furthermore, it was reported by Ubink et al. that a certain carbamate in the structure of the linker-drug is subject 
to proteolytic cleavage by carboxylesterase 1c (ces1c), which is a protease found in the sera of rodents.190 The 
ces1c-mediated cleavage impacts the pharmacokinetic properties of the ADC and by this means limits tumor-
specific delivery of duocarmycin to the tumor. In order to overcome this issue, either the linker-drug might be 
modified or a ces1c-knock-out mouse model might be established that would also allow for a more precise 
prediction a the clinical dose.190  
All in all, although the combination results reported in this work are encouraging, potential for improvement 
was identified which might be evaluated in upcoming studies. 
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8. Appendix 
 
Appendix 1: Cell lines and corresponding cell culturing medium. 
Cell line Medium 
BT-474 Ham’s F12, 2 mM L-Glutamine, 10 µg/mL insulin, 10% FBS 
Calu-3 DMEM, 10% FBS 
HCC-1954 RPMI-1640, 2 mM L-Glutamine, 1 mM Na-pyruvate, 10% FBS 
Hela Silencix ATR 
DMEM, 2 mM L-Glutamine, 1 mM Na-pyruvate, 4.5 g/L Glucose, 125 µg/mL Hygromycin B, 
10% FBS 
Hela Silencix control 
DMEM, 2 mM L-Glutamine, 1 mM Na-pyruvate, 4.5 g/L Glucose, 125 µg/mL Hygromycin B, 
10% FBS 
HT-29 DMEM high glucose, GlutaMax w/o phenol red, 1 mM Na-pyruvate 
JIMT-1 DMEM, 10% FBS 
MDA-MB-361 DMEM, 10% FBS 
MDA-MB-453 DMEM, 2 mM L-Glutamine, 1 mM Na-pyruvate, 10% FBS 
NCI-N87 RPMI-1640, 2 mM L-Glutamine, 1 mM Na-pyruvate, 10 mM HEPES, 4.5 g/L glucose, 10% FBS 
SK-BR-3 DMEM, 2 mM L-Glutamine, 1 mM Na-pyruvate, 10% FBS 
SK-OV-3 DMEM, 2 mM L-Glutamine, 1 mM Na-pyruvate, 10% FBS 
MDA-MB-468 RPMI-1640, 2 mM L-Glutamine, 1 mM Na-pyruvate, 10% FBS 
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Appendix 2: Overview of cell line origin and quality controls. The quality controls were performed by the department Molecular 
Biology, Merck KGaA. 
Cell line Origin 
Accession 
number 
Mycoplasma 
(qPCR) 
Cross-contamination 
(nested PCR) 
STR Sterility (last test) 
BT-474 ATCC HTB-20 negative negative yes Yes (04.05.2017) 
Calu-3 ATCC HTB-55 negative negative  Yes (08.08.2016) 
HCC-1954 ATCC CRL-2338 negative negative yes Yes (14.11.2017) 
Hela Silencix 
ATR 
Tebu-bio 
laboratories 
 negative negative yes Yes (24.02.2012) 
Hela Silencix 
control 
Tebu-bio 
laboratories 
 negative negative yes Yes (24.02.2012) 
JIMT-1 DSMZ ACC589 negative negative yes Yes (06.09.2012) 
MDA-MB-361 ATCC HTB-27 negative negative yes Yes (17.01.2013) 
MDA-MB-453 DSMZ ACC65 negative negative yes Yes (18.04.2013) 
NCI-N87 ATCC CRL-5822 negative negative yes Yes (19.02.2017) 
SK-BR-3 ATCC HTB-30 negative negative yes Yes (09.03.2017) 
SK-OV-3 ATCC HTB-77 negative negative yes Yes (05.03.2013) 
MDA-MB-468 ATCC HTB-132 negative negative yes Yes (14.02.2016) 
 
 
 
Appendix 3: Plot of IC50-values obtained from own code using LL.4 function of the DRC package against the IC50-values obtained from 
GeneData Screener software. A linear regression was performed and the equation as well as coefficient of determination are displayed 
in the graph. 
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Appendix 4: Analytical data for the preparation of αHER2-1. A) HIC profile of the ADC at 280 nm. B) SEC chromatogram at 214 nm.  
 
 
Appendix 5: Analytical data for the preparation of αHER2-1. A) HIC profile of the ADC at 214 nm. B) SEC chromatogram at 280 nm.  
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Appendix 6: Analytical data for the preparation of αHER2-1. A) HIC profile of the ADC at 214 nm. B) SEC chromatogram at 280 nm. 
Red: αHER2-1; Blue: αHER2 mAb.  
 
 
Appendix 7: Analytical data for the preparation of αEGFR-1. A) HIC profile of the ADC at 280 nm. B) SEC chromatogram at 214 nm.  
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Appendix 8: Analytical data for the preparation of αMET-1. SEC profile of the ADC at 214 nm. HIC profile was not transferred. The 
integrals were evaluated online and only the DAR was noted.  
 
 
Appendix 9: Analytical data for the preparation of αMETxEGFR-1. A) HIC profile of the ADC at 280 nm. B) SEC chromatogram at 214 nm.  
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Appendix 10: Analytical data for the preparation of αMETxEGFR-1. A) HIC profile of the ADC at 280 nm. B) SEC chromatogram at 214 
nm.  
 
 
Appendix 11: Analytical data for the preparation of αHEL-1. A) HIC profile of the ADC at 280 nm. B) SEC chromatogram at 280 nm.  
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Appendix 12: Analytical data for the preparation of αHER2-2. A) HIC profile of the ADC at 280 nm. B) SEC chromatogram at 214 nm.  
 
 
Appendix 13: Analytical data for the preparation of αHER2-3. A) HIC profile of the ADC at 280 nm. B) SEC chromatogram at 214 nm.  
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Appendix 14: Analytical data for the analytical scale reaction to generate αHER2-5. A) HIC profile of the ADC at 280 nm.  
 
 
Appendix 15: Analytical data for the preparation of glycoprotein binding ADC GPB-1. A) HIC profile of the ADC at 280 nm. B) SEC 
chromatogram at 214 nm.  
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Appendix 16: Analytical data for the generation of αHER2-9 with a DAR of 3.38. Top: Analytical HIC profile measured at a detector 
wavelength of 280 nm. Bottom. Analytical SEC profile measured at a detector wavelength of 214 nm. 
 
 
 
Appendix 17: Analytical data for the generation of αHER2-9 with a DAR of 1.78. Top: Analytical HIC profile measured at a detector 
wavelength of 280 nm. Bottom. Analytical SEC profile measured at a detector wavelength of 214 nm. 
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Appendix 18: Analytical data for the generation of αEGFR-9 with a DAR of 1.78. Top: Analytical HIC profile measured at a detector 
wavelength of 280 nm. Bottom. Analytical SEC profile measured at a detector wavelength of 214 nm. 
 
 
 
Appendix 19: Analytical data for the generation of αHEL-9 with a DAR of 1.81. Top: Analytical HIC profile measured at a detector 
wavelength of 280 nm. Bottom. Analytical SEC profile measured at a detector wavelength of 214 nm. 
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Appendix 20: R-based code for the calculations performed in chapter 5.7. Comment characters were used to structure the code as well 
to comment on the functions that will be fulfilled by the subsequent section. 
 
########################################################################## 
# load required packages 
########################################################################## 
require(drc) 
library(drc) 
require(Matrix) 
require(plot3D) 
require(spatial) 
require(rgl) 
require(colorRamps) 
########################################################################## 
# annotations 
########################################################################## 
 
#name horizontally diluted drug 
drug_h <- "BAY1895344" 
#define starting concentration of horizontally diluted drug in nM 
c0_conc_h=500 
 
#name vertically diluted drug 
drug_v <- "αHER2-2" 
#define starting concentration of vertically diluted drug in nM 
c0_conc_v=2.5 
 
cell_line <- "MDA-MB-453" 
exp_no <- "MRK00303" 
#create working directory 
setwd("Q:/Marcel/PhD/!R/") 
dir.create(paste(exp_no,cell_line,drug_v,drug_h)) 
setwd(paste(exp_no,cell_line,drug_v,drug_h)) 
 
########################################################################### data import 
########################################################################## 
 
full_data <- read.csv(file.choose(), header=F, skip=154, nrows=17, sep=";")  
#normalization 
 Appendix  12 
full_data_truncated <- full_data[3:16, 3:16] 
#dim(full_data_truncated) 
full_data_truncated_norm <- full_data_truncated/full_data_truncated[14,14] 
 
#adjustment for evaluation of the vertically applied drug (drug_v) 
drug_vert_extract <- full_data_truncated_norm[c(1:13),1:14] 
#adjustment for evaluation of the horizontally applied drug (drug_h) 
drug_hori_extract_t <- t(full_data_truncated_norm[c(1:14),1:13]) 
 
########################################################################## 
# serial dilutions 
########################################################################## 
 
#this part decribes the serial dilution of the drug that is serial diluted horizontally 
#define number of dilution steps 
N=12 
#generate serial dilution 
conc_h <- rep(NA, N) 
for(i in 0:N){ 
 conc_h[i+1] <- c0_conc_h/2^i 
log_conc_h=(log(conc_h)) 
} 
#this part decribes the serial dilution of the drug that is serial diluted vertically 
#define number of dilution steps 
N=12 
#generate serial dilution 
conc_v <- rep(NA, N) 
for(i in 0:N){ 
 conc_v[i+1] <- c0_conc_v/2^i 
} 
log_conc_v=(log(conc_v)) 
v1 <- c(numeric(14)) 
for(p in 0:13){ 
 p <- p+1 
 if(p<14){ 
  v1[p] <- conc_h[p]  
 } 
 else{ 
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  v1[p] <- 0 
}} 
conc_h_names <- as.matrix(v1) 
v2 <- c(numeric(14)) 
for(p in 0:13){ 
 p <- p+1 
 if(p<14){ 
  v2[p] <- conc_v[p]  
 } else{ 
  v2[p] <- 0 
 }} 
conc_v_names <- as.matrix(v2) 
 
########################################################################## 
# extract data and fit them 
########################################################################## 
 
#define matrix from which the diagonals shall be extracted 
m <- as.matrix(drug_vert_extract) 
#use the mid diagonal of the matrix to get the dimension of the matrix 
con <- length(diag(m)) 
#define a matrix in which the diagonals are written column by column 
m_diags <- matrix(0,con,2*con-1) 
#loop runs through every column and every row and extracts the columns 
j <- 0 
for(l in 1:(2*con-1)){ 
 j <- j+1 
 i <- 1 
  for(n in 1:con){ 
  if(n+l>=con+1) { 
    
   if(i+j<(2*con+1)){ 
    m_diags[n,l] <- m[i,i+j-(con)]  
   }} 
  i <- i+1 
 }} 
diagonal_data <- data.frame(m_diags) 
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# fits of single agents 
j <- 14 
fit_vert <- drm(full_data_truncated_norm[1:nrow(full_data_truncated_norm)-1,j]~conc_v, 
fct=LL.4(fixed=c(NA,NA,NA,NA),names=c("HillSlope", "Bottom", "Top", "IC50"))) 
fit_hori <- drm(as.numeric(full_data_truncated_norm[j,1:nrow(full_data_truncated_norm)-1])~conc_h, 
fct=LL.4(fixed=c(NA,NA,NA,NA),names=c("HillSlope", "Bottom", "Top", "IC50"))) 
 
# generate fit table for vertical drug 
# for loop from j=2 to j=14 to skip first probably buggy line 
fits_vert <- matrix(0,ncol=4,nrow=nrow(full_data_truncated_norm)) 
for(j in 2:14){ 
 fits_vert[j,1:4] <- as.numeric(coef(drm(full_data_truncated_norm[1:nrow(full_data_truncated_norm)-1,j]~conc_v, 
fct=LL.4(fixed=c(NA,NA,NA,NA),names=c("HillSlope", "Bottom", "Top", "IC50"))))) 
} 
fits_vert <- cbind(fits_vert,conc_h_names) 
colnames(fits_vert) <- c("HillSlope", "Bottom", "Top", "IC50",paste("concentration of",drug_h)) 
fits_vert <- subset(fits_vert, fits_vert[,3]>0.8) 
# HillSlope smoothing 
#mean_HillSlope_vert <- mean(fits_vert[,1]) 
#fits_vert[,1] <- mean_HillSlope_vert  
 
# generate fit table for horizontal drug 
# for loop from j=2 to j=14 to skip first probably buggy line 
fits_hori <- matrix(0,ncol=4,nrow=ncol(full_data_truncated_norm)) 
for(j in 2:14){ 
 fits_hori[j,1:4] <- as.numeric(coef(drm(as.numeric(full_data_truncated_norm[j,1:nrow(full_data_truncated_norm)-
1])~conc_h, fct=LL.4(fixed=c(NA,NA,NA,NA),names=c("HillSlope", "Bottom", "Top", "IC50"))))) 
} 
fits_hori <- cbind(fits_hori,conc_v_names) 
colnames(fits_hori) <- c("HillSlope", "Bottom", "Top", "IC50",paste("concentration of",drug_v)) 
fits_hori <- subset(fits_hori, fits_hori[,3]>0.8) 
 
# calculate ratios between vertically and horizontally diluted drugs 
ratio <- c(numeric(ncol(diagonal_data))) 
if(c0_conc_v > c0_conc_h){ 
 for(j in 1:ncol(diagonal_data)){ 
 if(j <= 13){ 
  ratio[j] <- conc_h[14-j]/conc_v[1]  
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 }else{ 
  ratio[j] <- conc_h[1]/conc_v[j-12] 
}}}else{ 
 for(j in 1:ncol(diagonal_data)){ 
  if(j <= 13){ 
   ratio[j] <- conc_v[14-j]/conc_h[1]  
  }else{ 
   ratio[j] <- conc_v[1]/conc_h[j-12] 
}}} 
# define effect levels that are interesting 
n_effect_levels <- seq(5,95,1) 
# create empty matrices 
CI_sum <- matrix(0, ncol=ncol(diagonal_data),nrow=length(n_effect_levels)) 
fits_diag <- matrix(0,ncol=4,nrow=ncol(diagonal_data)) 
# generate fit table for diagonal data 
# if-else is used to exclude data that not enough data to yield a DRC 
for(j in 1:ncol(diagonal_data)){ 
 xy_matrix <- subset(data.frame(conc_v,diagonal_data[,j]), data.frame(conc_h,diagonal_data[,j])[,2]!=0) 
 if(nrow(xy_matrix) > 5){ 
  fit_diag <- drm(xy_matrix[,2]~xy_matrix[,1],fct=LL.4(fixed=c(NA,NA,NA,NA),names=c("HillSlope", "Bottom", "Top", 
"IC50"))) 
  CI_sum[,j] <- as.numeric(CIcomp(ratio[j], list(fit_diag,fit_hori,fit_vert), c(n_effect_levels))[,1]) 
  fits_diag[j,1:4] <- as.numeric(coef(drm(xy_matrix[,2]~xy_matrix[,1], fct=LL.4(fixed=c(NA,NA,NA,NA),names=c("HillSlope", 
"Bottom", "Top", "IC50"))))) 
 }else{ 
  fits_diag[j,1:4] <- c(numeric(4))  
 }} 
fits_diag <- cbind(fits_diag,ratio) 
colnames(fits_diag) <- c("HillSlope", "Bottom", "Top", "IC50","Ratio") 
 
########################################################################## 
# global functions 
##########################################################################MEE_drug_v_solve <- 
function(y){ 
 return(fits_vert[nrow(fits_vert),4]*((1-y)/y)^(1/fits_vert[nrow(fits_vert),1]))  
} 
MEE_drug_h_solve <- function(y){ 
 return(fits_hori[nrow(fits_hori),4]*((1-y)/y)^(1/fits_hori[nrow(fits_hori),1])) 
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} 
MEE_fits_vert_solve <- function(y){ 
 return(fits_vert[j,4]*((1-y)/y)^(1/fits_vert[j,1])) 
} 
MEE_fits_hori_solve <- function(y){ 
 return(fits_hori[j,4]*((1-y)/y)^(1/fits_hori[j,1])) 
} 
MEE_fits_diag_solve <- function(y){ 
 return(fits_diag[j,4]*((1-y)/y)^(1/fits_diag[j,1])) 
} 
DRI_vert_drug_v_MEE <- function(y){ 
 return(MEE_drug_v_solve(y)/MEE_fits_vert_solve(y)) 
} 
DRI_vert_drug_h_MEE <- function(y){ 
 return(MEE_drug_h_solve(y)/fits_vert[j,5]) 
} 
DRI_hori_drug_v_MEE <- function(y){ 
 return(MEE_drug_v_solve(y)/fits_hori[j,5]) 
} 
DRI_hori_drug_h_MEE <- function(y){ 
 return(MEE_drug_h_solve(y)/MEE_fits_hori_solve(y)) 
} 
CI_vert_MEE <- function(y){ 
 return(1/DRI_vert_drug_h_MEE(y)+1/DRI_vert_drug_v_MEE(y)) 
} 
CI_hori_MEE <- function(y){ 
 return(1/DRI_hori_drug_h_MEE(y)+1/DRI_hori_drug_v_MEE(y)) 
} 
get_const_conc_h <- function(j){ 
 return(as.numeric(fits_vert[nrow(fits_vert)-j,5])) 
} 
get_const_conc_v <- function(j){ 
 return(as.numeric(fits_hori[nrow(fits_hori)-j,5])) 
} 
CI_diag_MEE <- function(y){ 
 return(MEE_fits_diag_solve(y)/MEE_drug_v_solve(y)+(MEE_fits_diag_solve(y)*fits_diag[j,5])/MEE_drug_h_solve(y)) 
} 
DRI_diag_drug_v_MEE <- function(y){ 
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 return(MEE_drug_v_solve(y)/MEE_fits_diag_solve(y)) 
} 
DRI_diag_drug_h_MEE <- function(y){ 
 return(MEE_drug_h_solve(y)/(MEE_fits_diag_solve(y)*fits_diag[j,5])) 
} 
########################################################################## 
# plot CI dependent on fu and amount of horizontal drug added 
########################################################################## 
y=seq(.1,.9,.1) 
j <- seq(1,nrow(fits_vert)-1,1) 
CI_table_vert <- matrix(0,nrow=length(j),ncol=length(y)) 
for(j in 1:length(j)){ 
 CI_table_vert[j,] <- CI_vert_MEE(y) 
} 
j <- seq(1,nrow(fits_vert)-1,1) 
png(filename =paste("3D_CI for different concentrations of",drug_h,".png") , 
  width = 1000, height = 1000, units = "px", pointsize = 18, 
  bg = "white", res = NA, family = "", restoreConsole = TRUE, 
  type = c("windows", "cairo", "cairo-png")) 
persp3D(x=log10(get_const_conc_h(j)),y=y,z=CI_table_vert, ticktype="detailed" 
    ,xlab=paste("log of concentration",drug_h,"[nM]"),ylab="Viability [%]",zlab="Combination index",main=paste(cell_line) 
    ,expand=0.5, col=ramp.col(c("white","black")), border="black", nticks=9) 
dev.off() 
########################################################################## 
# plot DRI for both drugs dependent on fu and amount of horizontal drug added 
########################################################################## 
j <- seq(1,nrow(fits_vert)-1,1) 
DRI_table_vert_drug_v <- matrix(0,nrow=length(j),ncol=length(y)) 
for(j in 1:length(j)){ 
 DRI_table_vert_drug_v[j,] <- DRI_vert_drug_v_MEE(y) 
} 
j <- seq(1,nrow(fits_vert)-1,1) 
 
png(filename =paste("3D_DRI",drug_v,"for const. conc. of",drug_h,".png") , 
  width = 1000, height = 1000, units = "px", pointsize = 18, 
  bg = "white", res = NA, family = "", restoreConsole = TRUE, 
  type = c("windows", "cairo", "cairo-png")) 
persp3D(x=log10(get_const_conc_h(length(j)+1-j)),y=y,z=DRI_table_vert_drug_v, ticktype="detailed" 
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    ,xlab=paste("log of concentration",drug_h,"[nM]"),ylab="Viability [%]",zlab=paste("Dose-reduction index 
of",drug_v),main=paste(cell_line) 
    ,expand=0.5, col=ramp.col(c("white","black")), border="black", nticks=9) 
dev.off() 
###################################### 
DRI_table_vert_drug_h <- matrix(0,nrow=length(j),ncol=length(y)) 
for(j in 1:length(j)){ 
 DRI_table_vert_drug_h[j,] <- DRI_vert_drug_h_MEE(y) 
} 
j <- seq(1,nrow(fits_vert)-1,1) 
 
png(filename =paste("3D_DRI",drug_h,"for const. conc. of",drug_h,".png") , 
  width = 1000, height = 1000, units = "px", pointsize = 18, 
  bg = "white", res = NA, family = "", restoreConsole = TRUE, 
  type = c("windows", "cairo", "cairo-png")) 
persp3D(x=log10(get_const_conc_h(length(j)+1-j)),y=y,z=DRI_table_vert_drug_h, ticktype="detailed" 
    ,xlab=paste("log of concentration",drug_h,"[nM]"),ylab="Viability [%]",zlab=paste("Dose-reduction index 
of",drug_h),main=paste(cell_line) 
    ,expand=0.5, col=ramp.col(c("white","black")), border="black", nticks=9) 
dev.off() 
########################################################################## 
# plot CI dependent on fu and amount of vertical drug added 
########################################################################## 
y=seq(.1,.9,.1) 
j <- seq(1,nrow(fits_hori)-1,1) 
CI_table_hori <- matrix(0,nrow=length(j),ncol=length(y)) 
for(j in 1:length(j)){ 
 CI_table_hori[j,] <- CI_hori_MEE(y) 
} 
j <- seq(1,nrow(fits_hori)-1,1) 
png(filename =paste("3D_CI for different concentrations of",drug_v,".png") , 
  width = 1000, height = 1000, units = "px", pointsize = 18, 
  bg = "white", res = NA, family = "", restoreConsole = TRUE, 
  type = c("windows", "cairo", "cairo-png")) 
persp3D(x=log10(get_const_conc_v(j)),y=y,z=CI_table_hori, ticktype="detailed" 
    ,xlab=paste("log of concentration",drug_v,"[nM]"),ylab="Viability [%]",zlab="Combination index",main=paste(cell_line) 
    ,expand=0.5, col=ramp.col(c("white","black")), border="black", nticks=9) 
dev.off() 
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########################################################################### plot DRI of both drugs 
dependent on fu and amount of vertical drug added 
########################################################################## 
j <- seq(1,nrow(fits_hori)-1,1) 
DRI_table_hori_drug_v <- matrix(0,nrow=length(j),ncol=length(y)) 
for(j in 1:length(j)){ 
 DRI_table_hori_drug_v[j,] <- DRI_hori_drug_v_MEE(y) 
} 
j <- seq(1,nrow(fits_hori)-1,1) 
png(filename =paste("3D_DRI",drug_v,"for const. conc. of",drug_v,".png") , 
  width = 1000, height = 1000, units = "px", pointsize = 18, 
  bg = "white", res = NA, family = "", restoreConsole = TRUE, 
  type = c("windows", "cairo", "cairo-png")) 
persp3D(x=log10(get_const_conc_v(length(j)+1-j)),y=y,z=DRI_table_hori_drug_v, ticktype="detailed" 
    ,xlab=paste("log of concentration",drug_v,"[nM]"),ylab="Viability",zlab=paste("Dose-reduction index 
of",drug_v),main=paste(cell_line) 
    ,expand=0.5, col=ramp.col(c("white","black")), border="black", nticks=9) 
dev.off() 
###################################### 
j <- seq(1,nrow(fits_hori)-1,1) 
DRI_table_hori_drug_h <- matrix(0,nrow=length(j),ncol=length(y)) 
for(j in 1:length(j)){ 
 DRI_table_hori_drug_h[j,] <- DRI_hori_drug_h_MEE(y) 
} 
j <- seq(1,nrow(fits_hori)-1,1) 
png(filename =paste("3D_DRI",drug_h,"for const. conc. of",drug_v,".png") , 
  width = 1000, height = 1000, units = "px", pointsize = 18, 
  bg = "white", res = NA, family = "", restoreConsole = TRUE, 
  type = c("windows", "cairo", "cairo-png")) 
persp3D(x=log10(get_const_conc_v(length(j)+1-j)),y=y,z=DRI_table_hori_drug_h, ticktype="detailed" 
    ,xlab=paste("log of concentration",drug_v,"[nM]"),ylab="Viability [%]",zlab=paste("Dose-reduction index 
of",drug_h),main=paste(cell_line) 
    ,expand=0.5, col=ramp.col(c("white","black")), border="black", nticks=9) 
dev.off() 
########################################################################## 
# Plot CI for diagonal data 
##########################################################################y=seq(.1,.9,.1) 
a <- 6 
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e <- 15 
j <- seq(1,nrow(fits_diag),1) 
CI_table_diag <- matrix(0,nrow=length(j),ncol=length(y)) 
for(j in 1:length(j)){ 
 CI_table_diag[j,] <- CI_diag_MEE(y) 
} 
j <- seq(1,nrow(fits_diag),1) 
png(filename = "CI_for_fixed_ratio_my_functions.png", 
  width = 1000, height = 1000, units = "px", pointsize = 18, 
  bg = "white", res = NA, family = "", restoreConsole = TRUE, 
  type = c("windows", "cairo", "cairo-png")) 
persp3D(x=fits_diag[a:e,5],y=y,z=CI_table_diag[a:e,], ticktype="detailed" 
    ,xlab=paste("Ratio",drug_h,"to",drug_v),ylab="Viability",zlab="Combination index",main=paste(cell_line) 
    ,phi=10,inttype=2, r=2, theta=310 
    ,expand=0.75, nticks=10, col=ramp.col(c("white","black")), border="black" 
    ,facets=T,colkey = list(side = 1, length = 0.5, dist=-0.05, cex.clab=0.7, width=0.6) 
    ,cex.main=1.2,cex.lab=1.2) 
dev.off() 
 
########################################################################## 
# calculate CI values of data directly from plate 
########################################################################## 
 
CI_plate <- matrix(0, ncol=ncol(full_data_truncated_norm), nrow=nrow(full_data_truncated_norm)) 
for(j in 1:ncol(full_data_truncated_norm)){ 
 for(i in 1:nrow(full_data_truncated_norm)){ 
  CI_plate[i,j] <- 
conc_h[i]/MEE_drug_h_solve(full_data_truncated_norm[i,j])+conc_v[j]/MEE_drug_v_solve(full_data_truncated_norm[i,j]
) 
 }} 
colnames(CI_plate) <- conc_v_names 
rownames(CI_plate) <- conc_h_names 
 
########################################################################## 
# write that stuff 
##########################################################################png(filename = 
"CI_for_fixed_ratio_CIcomp_function.png", 
  width = 1000, height = 1000, units = "px", pointsize = 18, 
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  bg = "white", res = NA, family = "", restoreConsole = TRUE, 
  type = c("windows", "cairo", "cairo-png")) 
a <- 6 
e <- 15 
persp3D(x=n_effect_levels,y=ratio[a:e],z=CI_sum[,a:e], ticktype="detailed" 
    ,phi=10, inttype=2, r=2, xlab="Effect level [%]" 
    ,ylab=paste("Ratio",drug_h,"to",drug_v), zlab="Combination Index", main=paste(cell_line) 
    ,expand=0.75, nticks=10, col=ramp.col(c("white","black")), border="black" 
    ,colkey = list(side = 1, length = 0.5, dist=-0.05, cex.clab=0.7, width=0.6), facets=T 
    ,cex.main=1.2,cex.lab=1.2) 
dev.off() 
 
# export fitting results 
write.csv(fits_diag, file=paste(exp_no,cell_line,drug_h,drug_v,"diagonals fitted.txt")) 
write.csv(fits_vert, file=paste(exp_no,cell_line,drug_h,drug_v,"vertical data fitted.txt")) 
write.csv(fits_hori, file=paste(exp_no,cell_line,drug_h,drug_v,"horizontal data fitted.txt")) 
 
write.csv(CI_plate, file=paste(exp_no,cell_line,drug_h,drug_v,"horizontal data fitted.txt")) 
# DRI of drug h when adding constant concentrations of drug v @ IC50 
# fit the data using linear model 
png(filename =paste("DRI",drug_h,"at constant concentrations of",drug_v,"at IC50.png"), 
  width = 1000, height = 1000, units = "px", pointsize = 18, 
  bg = "white", res = NA, family = "", restoreConsole = TRUE, 
  type = c("windows", "cairo", "cairo-png")) 
filtered_fits_hori <- subset(fits_hori, fits_hori[,3]>0.7) 
plot(filtered_fits_hori[nrow(filtered_fits_hori),4]/filtered_fits_hori[,4]~filtered_fits_hori[,5], log="" 
   ,xlab=paste("Concentration of",drug_v,"[nM]"),ylab="Dose-reduction index at IC50", main=paste(cell_line), 
cex.main=1.5, cex.lab=1.5) 
fit_DRI_hori_at_IC50 <- lm(filtered_fits_hori[nrow(filtered_fits_hori),4]/filtered_fits_hori[,4]~filtered_fits_hori[,5]) 
lines(filtered_fits_hori[,5],predict(fit_DRI_hori_at_IC50)) 
legend("topleft",inset=.05, horiz=T, bty="n", 
    c(paste("Y=",round(summary(fit_DRI_hori_at_IC50)$coefficients[2,1],digits=4), 
        "*X+",round(summary(fit_DRI_hori_at_IC50)$coefficients[1,1],digits=4), 
        "\nR²=",round(summary(fit_DRI_hori_at_IC50)$r.squared,digits=4)))) 
dev.off() 
 
# DRI of drug v when adding constant concentrations of drug h @ IC50 
# fit the data using linear model 
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png(filename =paste("DRI",drug_v,"at constant concentrations of",drug_h,"at IC50.png"), 
  width = 1000, height = 1000, units = "px", pointsize = 18, 
  bg = "white", res = NA, family = "", restoreConsole = TRUE, 
  type = c("windows", "cairo", "cairo-png")) 
filtered_fits_vert <- subset(fits_vert, fits_vert[,3]>0.7) 
plot(filtered_fits_vert[nrow(filtered_fits_vert),4]/filtered_fits_vert[,4]~filtered_fits_vert[,5], log="" 
   ,xlab=paste("Concentration of",drug_h,"[nM]"), 
   ylab="Dose-reduction index at IC50", main=paste(cell_line), cex.main=1.5, cex.lab=1.5) 
fit_DRI_vert_at_IC50 <- lm(filtered_fits_vert[nrow(filtered_fits_vert),4]/filtered_fits_vert[,4]~filtered_fits_vert[,5]) 
lines(filtered_fits_vert[,5],predict(fit_DRI_vert_at_IC50)) 
legend("topleft",inset=.05, horiz=T, bty="n", 
    c(paste("Y=",round(summary(fit_DRI_vert_at_IC50)$coefficients[2,1],digits=4), 
     "*X+",round(summary(fit_DRI_vert_at_IC50)$coefficients[1,1],digits=4), 
     "\nR²=",round(summary(fit_DRI_vert_at_IC50)$r.squared,digits=4)))) 
dev.off() 
 
rm(list = ls()) 
gc() 
setwd("Q:/Marcel/PhD/!R/") 
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ATR Ataxia telangiectasia and Rad3 related 
ATRIP Ataxia telangiectasia and Rad3 related-interacting protein 
AU Alkylating unit 
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CaCl2 Calcium chloride 
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CCLE Cancer Cell Line Encyclopedia 
CEA carcinoembryonic antigen 
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CHK1 Checkpoint kinase 1 
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D Dose 
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DDM Duocarmycin DM 
DDR DNA-damage response 
DDRi DNA-damage response inhibitor 
Dm IC50 
DMEM Dulbecco's Modified Eagle's Medium 
DNA Deoxyribonucleic acid 
DNA-PK DNA-dependent protein kinase 
DRC Dose-response curve 
DRI Dose-reduction index 
DSA  Duocarmycin SA 
DSB Double-strand break 
DTA DNA-targeting agent 
DTT Dithiothreitol 
Dx Dose of a drug in combination to achieve the same effect as if given as single agent 
EGFR Epidermal Growth Factor Receptor 
eq. Equivalents 
eq. equation 
eSrtA Evolved Sortase A 
ETAA1 Ewing's tumor-associated antigen 1 
fa Fraction affected 
Fab Fragment antigen binding 
Fc Fragment crystalline 
FCS Fetal calf serum 
FDA Food and Drug Administration 
fu Fraction unaffected 
g Gravitational constant 
G1 Growth phase 1  
G2 Growth phase 2 
h Hour 
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HSA Human serum albumin 
HC Heavy chain 
HCl Hydrochloride 
HEL Hen Egg Lysozyme 
HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) 
HER2 human epidermal growth factor receptor 2 
HIC Hydrophobic interaction chromatography 
HMW High molecular weight 
HRR Homologous recombination repair 
Hus1 Checkpoint protein HUS1 
i Inhibitor 
IBD indilino-benzodiazepine 
IC50 Half-maximum inhibitory effect 
IgG Immunoglobulin G 
IPTG Isopropyl-β-D-thiogalactopyranosid 
iv intravenous 
k kilo 
kg Kilogram 
L Liter 
LC Light chain 
LD Linker-drug 
LDS Laureate dodecyl sulfate 
Lys Lysine 
m Milli 
M molar 
mAb Monoclonal antibody 
mCRC Metastatic colorectal cancer 
MEE Median-effect equation 
MET Mesenchymal-epithelial transition 
mg Milligram 
MGB Minor-groove binder 
min Minutes 
mM Millimolar 
MMAE Monomethyl auristatin E 
MMAF Monomethyl auristatin F 
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MMR Mismatch repair 
MNED Maximum non-efficacious dose 
MRN MRN-complex consisting of MRE11, Rad50 and Nibrin 
MTA Microtubule-targeting agents 
MTD Maximum tolerated dose 
MTH1 MutT homologue 1 
mut Mutated 
n  Nano 
N Number, in the context of this work often number of individual experiments 
N.A. Not available 
N/E No effect 
Na2HPO4 Disodium hydrogen phosphate 
NaCl Sodium chloride 
NaH2PO4 Sodium dihydrogen phosphate 
NER Nucleotide excision repair 
NFR Nucleosome free region 
NHEJ Non-homologous end joining 
NHL Non-hodgkin lymphoma 
nm Nanometer 
NMR Nuclear magnetic resonance 
OD600 Optical density at a wavelength of 600 nm 
ORC Origin recognition complex 
p  Pico 
P P value for statistical analysis 
p53BP1 p53 binding protein 1 
PAB para-aminobenzyl moiety 
PAGE Poly amide gel electrophoresis 
PBD dimer Pyrrolobenzodiazepine dimer 
PD-1 Programmed cell death protein 1 
PD-L1 Programmed death ligand 1 
PI3K Phosphoinositide 3-kinase 
PIKK Phosphatidylinositol 3-kinase-related kinase 
Pre-RC Pre replication complex 
qd Quaque die, latin for every day 
qPCR Quantitative polymerase chain reaction 
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Rad1 DNA-damage protein Rad1 
Rad51 Recombinase Rad51 
Rad9 DNA-damage protein Rad9 
rcf Relative centrifugal force 
R-CVP Rituximab, cyclophosphamide, vincristine, prednisolone 
rer. nat. rerum naturalium 
R-GDP rituximab, gemcitabine, dexamethasone, cisplatin 
RNA Ribonucleic acid 
RPA Replication protein A 
Rpm Rounds per minute 
rpm Rounds per minute 
RPMI-1640 Roswell Park Memorial Institute 
RT Room temperature 
RTK Receptor tyrosine kinase 
S Synergy score 
sd Single dose 
SDS Sodium dodecyl sulfate 
SEC Size-exclusion chromatography 
SEED Strand exchange engineered domain 
Ser Serine 
SI Selectivity index 
siRNA Small interfering RNA 
SMCC succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate 
SN-38 Active metabolite of irinotecan, topoisomerase I inhibitor 
SOC Super Optimal Broth 
SRF Stalled replication fork 
SrtA Sortase A 
SSB Single strand break 
T Temperature 
TMI Trimethody indole 
tol Tolerated 
TOP1 Topoisomerase 1 
TOP2 Topoisomerase 2 
TOPBP1 DNA topoisomerase 2-binding protein 1 
Tris Tris(hydroxymethyl)-aminomethan 
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V Volt 
val Valine 
VH Variable domain of the heavy chain 
VL Variable domain of the light chain 
XLF XRCC1-like factor 
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